200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 162011-90-7
162011-90-7 | 2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-
CAS No: 162011-90-7 Catalog No: AG001SMS MDL No:MFCD00935806
Product Description
Catalog Number:
AG001SMS
Chemical Name:
2(5H)-Furanone, 4-[4-(methylsulfonyl)phenyl]-3-phenyl-
CAS Number:
162011-90-7
Molecular Formula:
C17H14O4S
Molecular Weight:
314.3557
MDL Number:
MFCD00935806
IUPAC Name:
3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one
InChI:
InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
InChI Key:
RZJQGNCSTQAWON-UHFFFAOYSA-N
SMILES:
O=C1OCC(=C1c1ccccc1)c1ccc(cc1)S(=O)(=O)C
UNII:
0QTW8Z7MCR
Properties
Complexity:
556
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
314.061g/mol
Formal Charge:
0
Heavy Atom Count:
22
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
314.355g/mol
Monoisotopic Mass:
314.061g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
68.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
2.3
Literature
| Title | Journal |
|---|---|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| MAPK pathway activation by chronic lead-exposure increases vascular reactivity through oxidative stress/cyclooxygenase-2-dependent pathways. | Toxicology and applied pharmacology 20150301 |
| Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways. | Toxicology and applied pharmacology 20130415 |
| Cyclo-oxygenase (COX) inhibitors for preventing preterm labour. | The Cochrane database of systematic reviews 20121017 |
| Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study. | Alimentary pharmacology & therapeutics 20121001 |
| Reactivity of nonsteroidal anti-inflammatory drugs with peroxidase: a classification of nonsteroidal anti-inflammatory drugs. | The Journal of pharmacy and pharmacology 20121001 |
| Phospholipase A₂ activities in skin physiology and pathology. | European journal of pharmacology 20120915 |
| In with the new: the determinants of prescribing innovation by general practitioners in Ireland. | The European journal of health economics : HEPAC : health economics in prevention and care 20120801 |
| Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. | European heart journal 20120801 |
| Prostaglandin E2 EP3 receptor regulates cyclooxygenase-2 expression in the kidney. | American journal of physiology. Renal physiology 20120801 |
| MyD88 signaling promotes both mucosal homeostatic and fibrotic responses during Salmonella-induced colitis. | American journal of physiology. Gastrointestinal and liver physiology 20120801 |
| Cardiovascular properties of a nitric oxide releasing rofecoxib analogue: beneficial anti-hypertensive activity and enhanced recovery in an ischemic reperfusion injury model. | ChemMedChem 20120801 |
| Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. | American heart journal 20120801 |
| Two centuries of assessing drug risks. | The New England journal of medicine 20120719 |
| Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition. | American journal of physiology. Renal physiology 20120715 |
| Determination of non-steroidal anti-inflammatory drugs and their metabolites in milk by liquid chromatography-tandem mass spectrometry. | Analytical and bioanalytical chemistry 20120701 |
| Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20120701 |
| A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. | Rheumatology international 20120601 |
| Do drug warnings and market withdrawals have an impact on the number of calls to teratogen information services? | Pharmacopsychiatry 20120601 |
| Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. | Angiogenesis 20120601 |
| Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. | Journal of pediatric surgery 20120601 |
| Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. | World journal of gastroenterology 20120514 |
| Vascular COX-2 modulates blood pressure and thrombosis in mice. | Science translational medicine 20120502 |
| Risk of gastrointestinal events in patients with rheumatoid arthritis after withdrawal of rofecoxib. | The Journal of rheumatology 20120501 |
| Italian guidelines for primary headaches: 2012 revised version. | The journal of headache and pain 20120501 |
| Concordance with guideline recommendations: previous and more recent nonsteroidal anti-inflammatory drug prescriptions in Quebec, Canada. | Pharmacoepidemiology and drug safety 20120401 |
| Advertising of prescription-only medicines to the public: does evidence of benefit counterbalance harm? | Annual review of public health 20120401 |
| Automatic filtering and substantiation of drug safety signals. | PLoS computational biology 20120401 |
| The imperative to share clinical study reports: recommendations from the Tamiflu experience. | PLoS medicine 20120401 |
| Interaction between selective cyclooxygenase inhibitors and capsaicin-sensitive afferent sensory nerves in pathogenesis of stress-induced gastric lesions. Role of oxidative stress. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20120401 |
| Cox-2 inhibitors and the risk of cardiovascular thrombotic events. | Irish medical journal 20120401 |
| Role of basic science in the development of new medicines: examples from the eicosanoid field. | The Journal of biological chemistry 20120323 |
| Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold. | Journal of medicinal chemistry 20120308 |
| IL-10 production in non-small cell lung carcinoma patients is regulated by ERK, P38 and COX-2. | Journal of cellular and molecular medicine 20120301 |
| Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120301 |
| Risk management of biosimilars in oncology: each medicine is a work in progress. | Targeted oncology 20120301 |
| Synthesis, evaluation and docking studies on 3-alkoxy-4-methanesulfonamido acetophenone derivatives as non ulcerogenic anti-inflammatory agents. | European journal of medicinal chemistry 20120301 |
| TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. | Gut 20120201 |
| A novel nitro-oxy substituted analogue of rofecoxib reduces human colon cancer cell growth. | Molecular and cellular biochemistry 20120201 |
| In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. | Purinergic signalling 20120201 |
| Synthesis, pharmacological evaluation and docking studies of N-(benzo[d]thiazol-2-yl)-2-(piperazin-1-yl)acetamide analogs as COX-2 inhibitors. | Bioorganic & medicinal chemistry letters 20120115 |
| Rofecoxib analogues possessing a nitric oxide donor sulfohydroxamic acid (SO2NHOH) cyclooxygenase-2 pharmacophore: synthesis, molecular modeling, and biological evaluation as anti-inflammatory agents. | ChemMedChem 20120102 |
| Neuromodulatory role of endogenous interleukin-1β in acute seizures: possible contribution of cyclooxygenase-2. | Neurobiology of disease 20120101 |
| Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. | The Journal of steroid biochemistry and molecular biology 20120101 |
| Reduction of post-surgical pericardial adhesions using a pig model. | Heart, lung & circulation 20120101 |
| A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. | Current medical research and opinion 20120101 |
| Effects of combination therapy with celecoxib and doxycycline on neointimal hyperplasia and inflammatory biomarkers in coronary artery disease patients treated with bare metal stents. | Yonsei medical journal 20120101 |
| Comparison of CD63 Upregulation Induced by NSAIDs on Basophils and Monocytes in Patients with NSAID Hypersensitivity. | Journal of allergy 20120101 |
| Aspirin: pharmacology and clinical applications. | Thrombosis 20120101 |
| Beneficial effect of ultra-low-dose aspirin in platelet activity alterations and haemorrhage observed in experimental portal hypertension. | Thrombosis 20120101 |
| A systematic review and meta-analysis of efficacy, cost-effectiveness, and safety of selected complementary and alternative medicine for neck and low-back pain. | Evidence-based complementary and alternative medicine : eCAM 20120101 |
| Stretching of the back improves gait, mechanical sensitivity and connective tissue inflammation in a rodent model. | PloS one 20120101 |
| Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. | PLoS pathogens 20120101 |
| Enhancement of Antinociception by Co-administrations of Nefopam, Morphine, and Nimesulide in a Rat Model of Neuropathic Pain. | The Korean journal of pain 20120101 |
| Challenges to physician-patient communication about medication use: a window into the skeptical patient's world. | Patient preference and adherence 20120101 |
| Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. | TheScientificWorldJournal 20120101 |
| Autocrine prostaglandin E2 signaling promotes tumor cell survival and proliferation in childhood neuroblastoma. | PloS one 20120101 |
| Modelling of mouse experimental colitis by global property screens: a holistic approach to assess drug effects in inflammatory bowel disease. | PloS one 20120101 |
| Challenging medical ghostwriting in US courts. | PLoS medicine 20120101 |
| Massage therapy for osteoarthritis of the knee: a randomized dose-finding trial. | PloS one 20120101 |
| Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. | BMJ open 20120101 |
| Anti-arthritic effects of magnolol in human interleukin 1β-stimulated fibroblast-like synoviocytes and in a rat arthritis model. | PloS one 20120101 |
| Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. | Journal of neuroinflammation 20120101 |
| Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care. | BMC family practice 20120101 |
| Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. | Journal of neuroinflammation 20120101 |
| Prostaglandins in cancer cell adhesion, migration, and invasion. | International journal of cell biology 20120101 |
| Fraud in anaesthetic research and publication. | Indian journal of anaesthesia 20120101 |
| Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. | Frontiers in psychology 20120101 |
| Selected papers from the 14th Annual Bio-Ontologies Special Interest Group Meeting. | Journal of biomedical semantics 20120101 |
| Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. | Journal of biomedical semantics 20120101 |
| Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. | TheScientificWorldJournal 20120101 |
| Combination Drug Therapy for Pain following Chronic Spinal Cord Injury. | Pain research and treatment 20120101 |
| A review: inflammatory process in Alzheimer's disease, role of cytokines. | TheScientificWorldJournal 20120101 |
| COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. | International journal of medical sciences 20120101 |
| Neuroprotection and neurodegeneration in Alzheimer's disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention with aerobic exercise in african americans. | International journal of Alzheimer's disease 20120101 |
| Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. | The open rheumatology journal 20120101 |
| Antineuropathic and antinociceptive drugs combination in patients with chronic low back pain: a systematic review. | Pain research and treatment 20120101 |
| Drug management of visceral pain: concepts from basic research. | Pain research and treatment 20120101 |
| Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database. | The open rheumatology journal 20120101 |
| Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? | TheScientificWorldJournal 20120101 |
| Of money and trust in medical care redux. | Mens sana monographs 20120101 |
| Criminals in the Citadel and Deceit all along the Watchtower: Irresponsibility, Fraud, and Complicity in the Search for Scientific Truth. | Mens sana monographs 20120101 |
| The Prostaglandin F Synthase Activity of the Human Aldose Reductase AKR1B1 Brings New Lenses to Look at Pathologic Conditions. | Frontiers in pharmacology 20120101 |
| PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials. | PPAR research 20120101 |
| Effect of peppermint oil on serum lipid peroxidation and hepatic enzymes after immobility stress in mice. | The open biochemistry journal 20120101 |
| Inhibition of ion channels and heart beat in Drosophila by selective COX-2 inhibitor SC-791. | PloS one 20120101 |
| Metallothionein colon crypt immuno-positivity as a rapid in vivo essay for drug efficacy studies. | In vivo (Athens, Greece) 20120101 |
| Drug-induced Sweet's syndrome by aceclofenac. | Cutaneous and ocular toxicology 20111201 |
| Stroke risk and NSAIDs: a systematic review of observational studies. | Pharmacoepidemiology and drug safety 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Roles of serotonergic and adrenergic receptors in the antinociception of selective cyclooxygenase-2 inhibitor in the rat spinal cord. | The Korean journal of pain 20111201 |
| Merck pays $1bn penalty in relation to promotion of rofecoxib. | BMJ (Clinical research ed.) 20111128 |
| Design, synthesis and biological evaluation of benzo[1.3.2]dithiazolium ylide 1,1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors. | Bioorganic & medicinal chemistry 20111101 |
| Rofecoxib and clinically significant upper and lower gastrointestinal events revisited based on documents from recent litigation. | The American journal of the medical sciences 20111101 |
| Rofecoxib and clinically significant gastrointestinal events. | The American journal of the medical sciences 20111101 |
| Residual vectors for Alzheimer disease diagnosis and prognostication. | Brain and behavior 20111101 |
| Synthesis of unsymmetrical 3,4-diaryl-3-pyrrolin-2-ones utilizing pyrrole Weinreb amides. | The Journal of organic chemistry 20111021 |
| Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20111018 |
| Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. | Chemical reviews 20111012 |
| The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 gene. | British journal of clinical pharmacology 20111001 |
| Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. | Pediatric nephrology (Berlin, Germany) 20111001 |
| Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. | Carcinogenesis 20111001 |
| Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials. | Alimentary pharmacology & therapeutics 20111001 |
| Biological perspectives: update on newer antipsychotic drugs: are they evidence based? | Perspectives in psychiatric care 20111001 |
| Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit. | British journal of pharmacology 20110901 |
| Managing risk in developing transplant immunosuppressive agents: the new regulatory environment. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20110901 |
| Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety. | Drug safety 20110901 |
| Safety of new medicines in young children. | Archives of disease in childhood 20110901 |
| Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. | PLoS medicine 20110901 |
| Why drug safety should not take a back seat to efficacy. | PLoS medicine 20110901 |
| Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors. | Cancer research and treatment : official journal of Korean Cancer Association 20110901 |
| The effect of epidural administration of dexamethasone on postoperative pain: a randomized controlled study in radical subtotal gastrectomy. | Korean journal of anesthesiology 20110901 |
| Bioactive sulfoximines: syntheses and properties of Vioxx analogs. | Bioorganic & medicinal chemistry letters 20110815 |
| Acetyl salicylic acid treatment in neonatal Bartter syndrome--a commentary letter. | Pediatric nephrology (Berlin, Germany) 20110801 |
| Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles. | PLoS medicine 20110801 |
| Nitric Oxide (NO) and Cyclooxygenase-2 (COX-2) Cross-Talk in Co-Cultures of Tumor Spheroids with Normal Cells. | Cancer microenvironment : official journal of the International Cancer Microenvironment Society 20110801 |
| Proceedings of the One Day Symposium on 'Safety and Risk Assessment Approaches for Materials of Herbal Origin' Organized by Unilever Research India, along with Ayurvedic Drug Manufacturers Association, and Indian Drug Manufacturers Association, at Bangalore, on 3 September, 2010. | Toxicology international 20110801 |
| High-throughput analysis of standardized pharmacokinetic studies in the rat using sample pooling and UPLC-MS/MS. | Journal of pharmaceutical and biomedical analysis 20110715 |
| HB-EGF induces cardiomyocyte hypertrophy via an ERK5-MEF2A-COX2 signaling pathway. | Cellular signalling 20110701 |
| Defects in mouse nephrogenesis induced by selective and non-selective cyclooxygenase-2 inhibitors. | British journal of pharmacology 20110701 |
| A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: synthesis, biological evaluation and nitric oxide release studies. | Bioorganic & medicinal chemistry letters 20110701 |
| Clinical toxicology and drug regulation: a United Kingdom perspective. | Clinical toxicology (Philadelphia, Pa.) 20110701 |
| Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. | British journal of cancer 20110607 |
| All-cause mortality of elderly Australian veterans using COX-2 selective or non-selective NSAIDs: a longitudinal study. | British journal of clinical pharmacology 20110601 |
| COX-2 is not required for the development of murine chronic pancreatitis. | American journal of physiology. Gastrointestinal and liver physiology 20110601 |
| Profiling the regulatory lipids: another systemic way to unveil the biological mystery. | Current opinion in lipidology 20110601 |
| Synthesis and biological evaluation of loxoprofen derivatives. | Bioorganic & medicinal chemistry 20110601 |
| Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. | PLoS genetics 20110601 |
| Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers. | Current HIV research 20110601 |
| Sorbitan ester niosomes for topical delivery of rofecoxib. | Indian journal of experimental biology 20110601 |
| Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center. | Anticancer research 20110601 |
| Tamsulosin Monotherapy versus Combination Therapy with Antibiotics or Anti-Inflammatory Agents in the Treatment of Chronic Pelvic Pain Syndrome. | International neurourology journal 20110601 |
| Assessing the benefit: risk ratio of a drug--randomized and naturalistic evidence. | Dialogues in clinical neuroscience 20110601 |
| Kainic Acid-induced neurotoxicity: targeting glial responses and glia-derived cytokines. | Current neuropharmacology 20110601 |
| Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat. | Brain research bulletin 20110530 |
| Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase. | Journal of medicinal chemistry 20110526 |
| The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. | Annals of the rheumatic diseases 20110501 |
| Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review. | PLoS medicine 20110501 |
| Is pharmacogenomics a reality? Challenges and oppurtunities for India. | Indian journal of human genetics 20110501 |
| Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. | Journal of medicinal chemistry 20110428 |
| [A woman with unilateral headache]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20110408 |
| High-dose ketorolac affects adult spinal fusion: a meta-analysis of the effect of perioperative nonsteroidal anti-inflammatory drugs on spinal fusion. | Spine 20110401 |
| Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG). | The journal of headache and pain 20110401 |
| Regulatory mechanism of duodenal bicarbonate secretion: Roles of endogenous prostaglandins and nitric oxide. | Pharmacology & therapeutics 20110401 |
| Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. | PLoS medicine 20110401 |
| Exploring the mechanisms of renoprotection against progressive glomerulosclerosis. | Proceedings of the Japan Academy. Series B, Physical and biological sciences 20110311 |
| Climate change, nuclear economics, and conflicts of interest. | Science and engineering ethics 20110301 |
| Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles. | PLoS medicine 20110301 |
| Inflammation in depression: is adiposity a cause? | Dialogues in clinical neuroscience 20110301 |
| [Antitumor effects of sulindac in ovarian cell cultures]. | Ginekologia polska 20110301 |
| Analysis of Relationship between Levofloxacin and Corrected QT Prolongation Using a Clinical Data Warehouse. | Healthcare informatics research 20110301 |
| Cannabinoid system and cyclooxygenases inhibitors. | Journal of medicine and life 20110215 |
| Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. | Breast (Edinburgh, Scotland) 20110201 |
| Exogenous estrogen does not attenuate the association between rofecoxib and myocardial infarction in perimenopausal women. | Journal of cardiovascular pharmacology 20110201 |
| Use of nonsteroidal antiinflammatory drugs: is there a change in patient risk profile after withdrawal of rofecoxib? | The Journal of rheumatology 20110201 |
| Prophylactic, prandial rofecoxib treatment lacks efficacy against acute PTZ-induced seizure generation and kindling acquisition. | Epilepsia 20110201 |
| Present state and future perspectives of using pluripotent stem cells in toxicology research. | Archives of toxicology 20110201 |
| Hemicrania continua changed to chronic paroxysmal hemicrania after treatment with cyclooxygenase-2 inhibitor. | Headache 20110201 |
| A double-blind, randomized, multicentric, placebo-controlled clinical trial of antarth, a phytomedicine, in the treatment of osteoarthritis. | Indian journal of pharmacology 20110201 |
| Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). | Archives of medical science : AMS 20110201 |
| Health-Beneficial Phenolic Aldehyde in Antigonon leptopus Tea. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Meta-analysis of the related nutritional supplements dimethyl sulfoxide and methylsulfonylmethane in the treatment of osteoarthritis of the knee. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Anti-Arthritic Activity of Bartogenic Acid Isolated from Fruits of Barringtonia racemosa Roxb. (Lecythidaceae). | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| A systematic review on the effectiveness of pharmacological interventions for chronic non-specific low-back pain. | European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20110101 |
| Kainic acid-induced neurodegenerative model: potentials and limitations. | Journal of biomedicine & biotechnology 20110101 |
| Renal function during rofecoxib therapy in patients with metastatic cancer: retrospective analysis of a prospective phase II trial. | BMC research notes 20110101 |
| Salvianolic Acid B, a potential chemopreventive agent, for head and neck squamous cell cancer. | Journal of oncology 20110101 |
| Aspirin-exacerbated respiratory disease: evaluation and management. | Allergy, asthma & immunology research 20110101 |
| Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. | BMJ (Clinical research ed.) 20110101 |
| Investigator experiences with financial conflicts of interest in clinical trials. | Trials 20110101 |
| Immunomodulation of Autoimmune Arthritis by Herbal CAM. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. | Parkinson's disease 20110101 |
| Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome. | Cardiovascular revascularization medicine : including molecular interventions 20110101 |
| Animal products, diseases and drugs: a plea for better integration between agricultural sciences, human nutrition and human pharmacology. | Lipids in health and disease 20110101 |
| Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. | Journal of biomedicine & biotechnology 20110101 |
| The effect of Cox-2 specific inhibition on direct fracture healing in the rabbit tibia. | Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20110101 |
| Knowledge of ghostwriting and financial conflicts-of-interest reduces the perceived credibility of biomedical research. | BMC research notes 20110101 |
| Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. | PloS one 20110101 |
| Common fragile site tumor suppressor genes and corresponding mouse models of cancer. | Journal of biomedicine & biotechnology 20110101 |
| NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. | PloS one 20110101 |
| The quality of registration of clinical trials. | PloS one 20110101 |
| EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. | Journal of experimental & clinical cancer research : CR 20110101 |
| Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. | Molecular cancer 20110101 |
| IL-1β stimulates COX-2 dependent PGE₂ synthesis and CGRP release in rat trigeminal ganglia cells. | PloS one 20110101 |
| Parkinson's disease and systemic inflammation. | Parkinson's disease 20110101 |
| Common secondary causes of resistant hypertension and rational for treatment. | International journal of hypertension 20110101 |
| Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. | Journal of neuroinflammation 20110101 |
| Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. | Arthritis research & therapy 20110101 |
| Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics? | BMC neurology 20110101 |
| Role of the kidneys in resistant hypertension. | International journal of hypertension 20110101 |
| Temporal profiles of age-dependent changes in cytokine mRNA expression and glial cell activation after status epilepticus in postnatal rat hippocampus. | Journal of neuroinflammation 20110101 |
| Clinical trials update: Tertiary prevention of colorectal cancer. | Journal of carcinogenesis 20110101 |
| Methotrexate in atherogenesis and cholesterol metabolism. | Cholesterol 20110101 |
| Etoricoxibium picrate. | Acta crystallographica. Section E, Structure reports online 20110101 |
| Lipoxins, the novel mediators of gastroprotection and gastric adaptation to ulcerogenic action of aspirin. | Current pharmaceutical design 20110101 |
| Identification of peripheral inflammatory markers between normal control and Alzheimer's disease. | BMC neurology 20110101 |
| Prostaglandin E(2) binding peptide screened by phage displaying: a new therapeutic strategy in rheumatoid arthritis. | Lipids in health and disease 20110101 |
| Cattle bile aggravates diclofenac sodium-induced small intestinal injury in mice. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Rheumatoid arthritis-associated polymorphisms are not protective against Alzheimer's disease. | Molecular neurodegeneration 20110101 |
| Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process. | BMC public health 20110101 |
| Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. | International journal of medical sciences 20110101 |
| Thrombosis is reduced by inhibition of COX-1, but unaffected by inhibition of COX-2, in an acute model of platelet activation in the mouse. | PloS one 20110101 |
| Fluorescence Spectrometric Determination of Drugs Containing α-Methylene Sulfone/Sulfonamide Functional Groups Using N-Methylnicotinamide Chloride as a Fluorogenic Agent. | International journal of analytical chemistry 20110101 |
| Prostacyclin: an inflammatory paradox. | Frontiers in pharmacology 20110101 |
| One universal common endpoint in mouse models of amyotrophic lateral sclerosis. | PloS one 20110101 |
| The emerging use of aromatase inhibitors for endometriosis treatment. | Reproductive biology and endocrinology : RB&E 20110101 |
| Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study. | BMC complementary and alternative medicine 20110101 |
| Perspective: Chemoprevention of colorectal neoplasia: Translating scientific promise into clinical practice. | Journal of carcinogenesis 20110101 |
| The quest for targeted delivery in colon cancer: mucoadhesive valdecoxib microspheres. | International journal of nanomedicine 20110101 |
| Cause for concern in the use of non-steroidal anti-inflammatory medications in the community--a population-based study. | BMC family practice 20110101 |
| Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. | Clinical interventions in aging 20110101 |
| Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease. | Drug, healthcare and patient safety 20110101 |
| COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs. | Current medicinal chemistry 20110101 |
| Cancer cachexia: mechanisms and clinical implications. | Gastroenterology research and practice 20110101 |
| Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant. | Mediators of inflammation 20110101 |
| Medical research: Is everything all right? | Journal of anaesthesiology, clinical pharmacology 20110101 |
| Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis. | Journal of toxicology 20110101 |
| Characterization of chromosomal instability in murine colitis-associated colorectal cancer. | PloS one 20110101 |
| Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. | Journal of pain research 20110101 |
| Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. | Arthritis research & therapy 20110101 |
| Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. | BMC cancer 20110101 |
| Effect of a Herbal-Leucine mix on the IL-1β-induced cartilage degradation and inflammatory gene expression in human chondrocytes. | BMC complementary and alternative medicine 20110101 |
| WNT5A signaling contributes to Aβ-induced neuroinflammation and neurotoxicity. | PloS one 20110101 |
| Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. | PloS one 20110101 |
| Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam. | PloS one 20110101 |
| Pharmacogenomic technologies: a necessary 'luxury' for better global public health? | Globalization and health 20110101 |
| Innate inflammation and cancer: Is it time for cancer prevention? | F1000 medicine reports 20110101 |
| Design, synthesis and biological evaluation of new 5,5-diarylhydantoin derivatives as selective cyclooxygenase-2 inhibitors. | Scientia pharmaceutica 20110101 |
| Synthesis of Diarylpyrazoles Containing a Phenylsulphone or Carbonitrile Moiety and their Chalcones as Possible Anti-Inflammatory Agents. | Scientia pharmaceutica 20110101 |
| Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. | Journal of neuroinflammation 20110101 |
| Should benefit-risk assessment have its own drug 'label'? | Drug, healthcare and patient safety 20110101 |
| 5-α reductase inhibitors and prostate cancer prevention: where do we turn now? | BMC medicine 20110101 |
| Pathobiology and chemoprevention of bladder cancer. | Journal of oncology 20110101 |
| Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. | Arthritis research & therapy 20110101 |
| Skeletal muscle protein metabolism in the elderly: Interventions to counteract the 'anabolic resistance' of ageing. | Nutrition & metabolism 20110101 |
| Spectrophotometric determination of tizanidine and orphenadrine via ion pair complex formation using eosin Y. | Chemistry Central journal 20110101 |
| Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. | BMJ (Clinical research ed.) 20110101 |
| Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. | PloS one 20110101 |
| Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. | BMJ (Clinical research ed.) 20110101 |
| Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. | PloS one 20110101 |
| Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. | PloS one 20110101 |
| Effects of collagen-induced rheumatoid arthritis on amyloidosis and microvascular pathology in APP/PS1 mice. | BMC neuroscience 20110101 |
| Inhibition of HERG potassium channels by celecoxib and its mechanism. | PloS one 20110101 |
| Lumiracoxib for acute postoperative dental pain: a systematic review of randomized clinical trials. | Sao Paulo medical journal = Revista paulista de medicina 20110101 |
| Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini Review. | ISRN pharmacology 20110101 |
| Assessment and treatment of abuse risk in opioid prescribing for chronic pain. | Pain research and treatment 20110101 |
| Why we need easy access to all data from all clinical trials and how to accomplish it. | Trials 20110101 |
| An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect? | BMC public health 20110101 |
| Virtual screening of 2,3-disubstituted-4(3H)-quinazolinones possessing benzenesulfonamide moiety for COX-2 inhibitor. | Bioinformation 20110101 |
| Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. | BMC health services research 20110101 |
| Prevalence and risk factors of gastrointestinal disorders in patients with rheumatoid arthritis: results from a population-based survey in olmsted county, Minnesota. | Gastroenterology research and practice 20110101 |
| Assessment of endothelial function by brachial artery flow mediated dilatation in microvascular disease. | Cardiovascular ultrasound 20110101 |
| Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. | Clinical & developmental immunology 20110101 |
| The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. | Trials 20110101 |
| Prevention of preterm labour: 2011 update on tocolysis. | Journal of pregnancy 20110101 |
| Fast disintegrating tablets: Opportunity in drug delivery system. | Journal of advanced pharmaceutical technology & research 20110101 |
| Observational therapeutics: Scope, challenges, and organization. | Journal of Ayurveda and integrative medicine 20110101 |
| Aspirin, salicylates and cancer: report of a meeting at the Royal Society of Medicine, London, 23 November 2010. | Ecancermedicalscience 20110101 |
| Systematic review of herbals as potential anti-inflammatory agents: Recent advances, current clinical status and future perspectives. | Pharmacognosy reviews 20110101 |
| Chronic inflammation in cancer development. | Frontiers in immunology 20110101 |
| Pseudoseptic arthritis: a case series and review of the literature. | Case reports in infectious diseases 20110101 |
| Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. | Frontiers in oncology 20110101 |
| Therapeutic targeting of cancer stem cells. | Frontiers in oncology 20110101 |
| Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. | Journal of the National Cancer Institute 20101215 |
| Persistence of cardiovascular risk after rofecoxib discontinuation. | Archives of internal medicine 20101213 |
| Modular therapy approach in metastatic castration-refractory prostate cancer. | World journal of urology 20101201 |
| Selective COX-2 inhibition affects fatty acids, but not COX mRNA expression in patients with FAP. | Familial cancer 20101201 |
| Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels: effects on cardiac action potentials. | Journal of molecular and cellular cardiology 20101201 |
| Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1. | Bioorganic & medicinal chemistry letters 20101201 |
| Accelerated fracture healing in mice lacking the 5-lipoxygenase gene. | Acta orthopaedica 20101201 |
| Effects of cyclooxygenase-2 inhibitor and adenosine triphosphate-sensitive potassium channel opener in syngeneic mouse islet transplantation. | Transplantation proceedings 20101201 |
| Increased expression of cyclooxygenase-2 is associated with the progression to cirrhosis. | The Korean journal of internal medicine 20101201 |
| Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet. | International journal of emergency medicine 20101201 |
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | Healthcare informatics research 20101201 |
| Coxibs: a significant therapeutic opportunity. | Acta bio-medica : Atenei Parmensis 20101201 |
| Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. | Expert opinion on drug safety 20101101 |
| A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. | Pharmacoepidemiology and drug safety 20101101 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Using non-steroidal anti-inflammatory drugs in the treatment of depression. | Psychiatria Danubina 20101101 |
| VICTOR spoiled? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020 |
| Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101020 |
| Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies. | Protoplasma 20101001 |
| Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. | PLoS medicine 20101001 |
| Editors, publishers, impact factors, and reprint income. | PLoS medicine 20101001 |
| Cyclooxygenase-2 expression and its association with thyroid lesions. | Archives of medical science : AMS 20101001 |
| Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells. | British journal of cancer 20100928 |
| Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. | Journal of medicinal chemistry 20100923 |
| Prophylactic etoricoxib is effective in preventing Yom Kippur headache: a placebo-controlled double-blind and randomized trial of prophylaxis for ritual fasting headache. | Headache 20100901 |
| Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone. | Clinical and experimental pharmacology & physiology 20100901 |
| Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis. | Annals of the rheumatic diseases 20100901 |
| cPLA2 is protective against COX inhibitor-induced intestinal damage. | Toxicological sciences : an official journal of the Society of Toxicology 20100901 |
| Synthesis, biological evaluation, and docking studies of novel heterocyclic diaryl compounds as selective COX-2 inhibitors. | Bioorganic & medicinal chemistry 20100901 |
| Identifying early prescribers of cycloxygenase-2 inhibitors (COX-2s) in Nova Scotia, Canada: Considerations for targeted academic detailing. | Research in social & administrative pharmacy : RSAP 20100901 |
| Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation. | Journal of clinical biochemistry and nutrition 20100901 |
| The haunting of medical journals: how ghostwriting sold 'HRT'. | PLoS medicine 20100901 |
| The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe & Dohme (Aust) Pty Ltd (2010) 184 FCR 1. | Journal of law and medicine 20100901 |
| A systematic review on the effectiveness of complementary and alternative medicine for chronic non-specific low-back pain. | European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20100801 |
| Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? | Current hypertension reports 20100801 |
| A retrospective analysis of VIOXX in Australia: using clinical trial data and linked administrative health data to predict patient groups at risk of an adverse drug event. | Australian and New Zealand journal of public health 20100801 |
| International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction. | Pharmacoepidemiology and drug safety 20100801 |
| Treatment strategies for osteoarthritis patients with pain and hypertension. | Therapeutic advances in musculoskeletal disease 20100801 |
| Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. | Journal of molecular and cellular cardiology 20100701 |
| Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. | Circulation. Cardiovascular quality and outcomes 20100701 |
| Analgesic use and the risk for progression of chronic kidney disease. | Pharmacoepidemiology and drug safety 20100701 |
| Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. | Pharmacoepidemiology and drug safety 20100701 |
| Cardiovascular safety of celecoxib on top of dual antiplatelet therapy. | Korean circulation journal 20100701 |
| Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. | Korean circulation journal 20100701 |
| Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy. | Anti-cancer agents in medicinal chemistry 20100701 |
| Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. | British journal of cancer 20100629 |
| Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain. | Bioorganic & medicinal chemistry letters 20100615 |
| Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study. | European journal of clinical pharmacology 20100601 |
| Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. | Arthritis and rheumatism 20100601 |
| Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. | Diabetes care 20100601 |
| Effects of nonsteroidal anti-inflammatory drugs on flexor tendon adhesion. | The Journal of hand surgery 20100601 |
| Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. | PLoS medicine 20100601 |
| Revised STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA): extending the CONSORT statement. | Acupuncture in medicine : journal of the British Medical Acupuncture Society 20100601 |
| Patient benefit-risk in arthritis--a rheumatologist's perspective. | Rheumatology (Oxford, England) 20100501 |
| Identifying and assessing benefit-risk in primary care--a family physician's perspective. | Rheumatology (Oxford, England) 20100501 |
| A review of the gastrointestinal safety data--a gastroenterologist's perspective. | Rheumatology (Oxford, England) 20100501 |
| Nitrooxymethyl-substituted analogues of rofecoxib: synthesis and pharmacological characterization. | Chemistry & biodiversity 20100501 |
| The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. | International journal of clinical practice 20100501 |
| Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. | British journal of cancer 20100427 |
| Celecoxib activates PI-3K/Akt and mitochondrial redox signaling to enhance heme oxygenase-1-mediated anti-inflammatory activity in vascular endothelium. | Free radical biology & medicine 20100415 |
| Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. | Clinica chimica acta; international journal of clinical chemistry 20100402 |
| Can L(+)-lactate be used as a marker of experimentally induced inflammation in rats? | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20100401 |
| Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. | Anesthesia and analgesia 20100401 |
| Unbalanced reporting of benefits and harms in abstracts on rofecoxib. | European journal of clinical pharmacology 20100401 |
| The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. | Korean journal of urology 20100401 |
| Roles of arrest-defective protein 1(225) and hypoxia-inducible factor 1alpha in tumor growth and metastasis. | Journal of the National Cancer Institute 20100317 |
| The discovery of 4-{1-[({2,5-dimethyl-4-[4-(trifluoromethyl)benzyl]-3-thienyl}carbonyl)amino]cyclopropyl}benzoic acid (MK-2894), a potent and selective prostaglandin E2 subtype 4 receptor antagonist. | Journal of medicinal chemistry 20100311 |
| Impact of biomarker development on drug safety assessment. | Toxicology and applied pharmacology 20100301 |
| Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats. | Neurotoxicology 20100301 |
| Risk factors of drug interaction between warfarin and nonsteroidal anti-inflammatory drugs in practical setting. | Journal of Korean medical science 20100301 |
| Hospitalizations for gastrointestinal and cardiovascular events in the CADEUS cohort of traditional or Coxib NSAID users. | British journal of clinical pharmacology 20100301 |
| Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. | Health technology assessment (Winchester, England) 20100301 |
| Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration. | Current neuropharmacology 20100301 |
| Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. | British journal of cancer 20100216 |
| Chemopreventive actions by enterolactone and 13 VIOXX-related lactone derivatives in H295R human adrenocortical carcinoma cells. | Toxicology letters 20100215 |
| Proteomic analysis in NSAIDs-treated primary cardiomyocytes. | Journal of proteomics 20100210 |
| Effects of selective Cox-2 inhibitor, rofecoxib, alone or combination with furosemide on renal functions and renal Cox-2 expression in rats. | Clinical and experimental nephrology 20100201 |
| Improvement in neurogenic detrusor overactivity by peripheral C fiber's suppression with cyclooxygenase inhibitors. | The Journal of urology 20100201 |
| Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study. | Naunyn-Schmiedeberg's archives of pharmacology 20100201 |
| Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress. | Neuroscience bulletin 20100201 |
| Ghostwriting at elite academic medical centers in the United States. | PLoS medicine 20100201 |
| Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. | Journal of digestive diseases 20100201 |
| Naproxen aggravates doxorubicin-induced cardiomyopathy in rats. | Indian journal of pharmacology 20100201 |
| Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as anti-inflammatory and analgesic agents. Synthesis and in vitro and in vivo biological evaluation. | Journal of medicinal chemistry 20100128 |
| Drug safety: are we making progress?: comment on 'pooled analysis of rofecoxib placebo-controlled clinical trial data'. | Archives of internal medicine 20100125 |
| COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. | British journal of cancer 20100119 |
| Microsomal prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumour growth, invasion and metastasis. | The Biochemical journal 20100115 |
| Prevention of urinary bladder cancer in the FHIT knock-out mouse with Rofecoxib, a Cox-2 inhibitor. | Urologic oncology 20100101 |
| Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma. | PPAR research 20100101 |
| Maternal consumption of polyphenol-rich foods in late pregnancy and fetal ductus arteriosus flow dynamics. | Journal of perinatology : official journal of the California Perinatal Association 20100101 |
| Water mediated construction of trisubstituted pyrazoles/isoxazoles library using ketene dithioacetals. | Journal of combinatorial chemistry 20100101 |
| Mechanisms of Kv2.1 channel inhibition by celecoxib--modification of gating and channel block. | British journal of pharmacology 20100101 |
| Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia. | Journal of neuroinflammation 20100101 |
| Effectiveness of diclofenac versus acetaminophen in primary care patients with knee osteoarthritis: [NTR1485], DIPA-trial: design of a randomized clinical trial. | BMC musculoskeletal disorders 20100101 |
| Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. | BMJ (Clinical research ed.) 20100101 |
| Water displacement leg volumetry in clinical studies--a discussion of error sources. | BMC medical research methodology 20100101 |
| What rheumatologists in the United States think of complementary and alternative medicine: results of a national survey. | BMC complementary and alternative medicine 20100101 |
| Retraction. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. | The Journal of arthroplasty 20100101 |
| Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. | Molecular cancer 20100101 |
| Progress in COX-2 inhibitors: a journey so far. | Current medicinal chemistry 20100101 |
| Nonsteroidal Anti-Inflammatory Drugs: A survey of practices and concerns of pediatric medical and surgical specialists and a summary of available safety data. | Pediatric rheumatology online journal 20100101 |
| Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. | Breast cancer research : BCR 20100101 |
| Evidence and consensus-based German guidelines for the management of analgesia, sedation and delirium in intensive care--short version. | German medical science : GMS e-journal 20100101 |
| Reduced uptake of the proliferation-seeking radiotracer technetium-99m-labelled pentavalent dimercaptosuccinic acid in a 47-year-old woman with severe breast epithelial hyperplasia taking ibuprofen: a case report. | Journal of medical case reports 20100101 |
| Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. | BMJ (Clinical research ed.) 20100101 |
| The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. | International journal of cell biology 20100101 |
| Citability of original research and reviews in journals and their sponsored supplements. | PloS one 20100101 |
| 'We noticed that suddenly the country has become full of MRI'. Policy makers' views on diffusion and use of health technologies in Iran. | Health research policy and systems 20100101 |
| Traumeel S for pain relief following hallux valgus surgery: a randomized controlled trial. | BMC clinical pharmacology 20100101 |
| Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander? | Alzheimer's research & therapy 20100101 |
| Reporting bias in medical research - a narrative review. | Trials 20100101 |
| Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. | Therapeutics and clinical risk management 20100101 |
| Effect of St. John's Wort (Hypericum perforatum) treatment on restraint stress-induced behavioral and biochemical alteration in mice. | BMC complementary and alternative medicine 20100101 |
| Legislation for trial registration and data transparency. | Trials 20100101 |
| Etoricoxib--preemptive and postoperative analgesia (EPPA) in patients with laparotomy or thoracotomy--design and protocols. | Trials 20100101 |
| Design of group IIA secreted/synovial phospholipase A(2) inhibitors: an oxadiazolone derivative suppresses chondrocyte prostaglandin E(2) secretion. | PloS one 20100101 |
| Presenilin/gamma-Secretase and Inflammation. | Frontiers in aging neuroscience 20100101 |
| Characterization of indomethacin release from polyethylene glycol tablet fabricated with mold technique. | Indian journal of pharmaceutical sciences 20100101 |
| Single dose oral lumiracoxib for postoperative pain in adults. | The Cochrane database of systematic reviews 20100101 |
| RNAi-based strategies for cyclooxygenase-2 inhibition in cancer. | Journal of biomedicine & biotechnology 20100101 |
| Vane's blood-bathed organ technique adapted to examine the endothelial effects of cardiovascular drugs in vivo. | Pharmacological reports : PR 20100101 |
| Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004. | BMC health services research 20100101 |
| Role of COX-2 in cough reflex sensitivity to inhaled capsaicin in patients with sinobronchial syndrome. | Cough (London, England) 20100101 |
| [The relation between publication bias and clinical trials funding]. | Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 20100101 |
| Clinical pharmacology and vascular risk. | The open neurology journal 20100101 |
| Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? | Frontiers in aging neuroscience 20100101 |
| Neurodegenerative diseases: exercising toward neurogenesis and neuroregeneration. | Frontiers in aging neuroscience 20100101 |
| Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. | International journal of Alzheimer's disease 20100101 |
| PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study. | PPAR research 20100101 |
| Are guidelines needed for the diagnosis and management of incipient Alzheimer's disease and mild cognitive impairment? | International journal of Alzheimer's disease 20100101 |
| The anti-vaccination movement and resistance to allergen-immunotherapy: a guide for clinical allergists. | Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20100101 |
| Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. | PloS one 20100101 |
| Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3. | Drug metabolism and pharmacokinetics 20100101 |
| NSAIDs may protect against age-related brain atrophy. | Frontiers in aging neuroscience 20100101 |
| Evidence at a glance: error matrix approach for overviewing available evidence. | BMC medical research methodology 20100101 |
| Ibuprofen with or without an antiemetic for acute migraine headaches in adults. | The Cochrane database of systematic reviews 20100101 |
| Using effective subnetworks to predict selected properties of gene networks. | PloS one 20100101 |
| Development and evaluation of a common data model enabling active drug safety surveillance using disparate healthcare databases. | Journal of the American Medical Informatics Association : JAMIA 20100101 |
| Development of a combined system for identification and classification of adverse drug reactions: Alerts Based on ADR Causality and Severity (ABACUS). | Journal of the American Medical Informatics Association : JAMIA 20100101 |
| Comparing etoricoxib and celecoxib for preemptive analgesia for acute postoperative pain in patients undergoing arthroscopic anterior cruciate ligament reconstruction: a randomized controlled trial. | BMC musculoskeletal disorders 20100101 |
| Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database. | BMC musculoskeletal disorders 20100101 |
| Relationship between Fecal Content of Fatty Acids and Cyclooxygenase mRNA Expression and Fatty Acid Composition in Duodenal Biopsies, Serum Lipoproteins, and Dietary Fat in Colectomized Familial Adenomatous Polyposis Patients. | Journal of nutrition and metabolism 20100101 |
| Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. | International journal of medical sciences 20100101 |
| Prostaglandins in action indispensable roles of cyclooxygenase-1 and -2 in endothelium-dependent contractions. | Advances in pharmacology (San Diego, Calif.) 20100101 |
| Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors. | Chiropractic & osteopathy 20100101 |
| Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review. | BMC neurology 20100101 |
| Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. | Journal of neuroinflammation 20100101 |
| Enhancement of antinociception by coadministration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in naïve mice and murine models of LPS-induced thermal hyperalgesia and monoarthritis. | BMC musculoskeletal disorders 20100101 |
| The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. | BMC medicine 20100101 |
| Changes in Physical Activity Involvement and Attitude to Physical Activity in a 16-Year Follow-Up Study among the Elderly. | Journal of aging research 20100101 |
| Existing data sources for clinical epidemiology: Aarhus University Prescription Database. | Clinical epidemiology 20100101 |
| Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo. | International journal of molecular sciences 20100101 |
| Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. | Alzheimer's research & therapy 20100101 |
| Classical peer review: an empty gun. | Breast cancer research : BCR 20100101 |
| Pharmacophore elucidation and molecular docking studies on 5-phenyl-1-(3-pyridyl)-1h-1,2,4-triazole-3-carboxylic acid derivatives as COX-2 inhibitors. | Scientia pharmaceutica 20100101 |
| Intravenous ibuprofen: the first injectable product for the treatment of pain and fever. | Journal of pain research 20100101 |
| Acute pain management in children. | Journal of pain research 20100101 |
| Musculoskeletal pain: prescription of NSAID and weak opioid by primary health care physicians in Sweden 2004-2008 - a retrospective patient record review. | Journal of pain research 20100101 |
| Investigational pharmacology for low back pain. | Journal of pain research 20100101 |
| Natural anti-inflammatory agents for pain relief. | Surgical neurology international 20100101 |
| Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine. | Mens sana monographs 20100101 |
| COX-2 Inhibition by Use of Rofecoxib or High Dose Aspirin Enhances ADP-Induced Platelet Aggregation in Fresh Blood. | The open cardiovascular medicine journal 20100101 |
| The endothelium and its role in regulating vascular tone. | The open cardiovascular medicine journal 20100101 |
| An overview of clinical research for anesthesiologists. | Journal of anaesthesiology, clinical pharmacology 20100101 |
| 'Protective premedication': a comparative study of acetaminophen, gabapentin and combination of acetaminophen with gabapentin for post-operative analgesia. | Journal of anaesthesiology, clinical pharmacology 20100101 |
| Colon delivery of budesonide using solid dispersion in dextran for the treatment and secondary prevention of ulcerative colitis in rat. | International journal of preventive medicine 20100101 |
| Preparation and characterization of solid dispersions of carvedilol with PVP K30. | Research in pharmaceutical sciences 20100101 |
| Neoliberalism, conflict of interest, and the governance of health research in Canada. | Open medicine : a peer-reviewed, independent, open-access journal 20100101 |
| Governance of conflicts of interest in postmarketing surveillance research and the Canadian Drug Safety and Effectiveness Network. | Open medicine : a peer-reviewed, independent, open-access journal 20100101 |
| New and improved strategies for the treatment of gout. | International journal of nephrology and renovascular disease 20100101 |
| Antiepileptic drugs and suicidality. | Drug, healthcare and patient safety 20100101 |
| Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes. | Frontiers in pharmacology 20100101 |
| Clinical aspects of acute post-operative pain management & its assessment. | Journal of advanced pharmaceutical technology & research 20100101 |
| The homeopathic preparation Nervoheel N can offer an alternative to lorazepam therapy for mild nervous disorders. | Evidence-based complementary and alternative medicine : eCAM 20091201 |
| Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats. | Pharmacology, biochemistry, and behavior 20091201 |
| NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. | Pharmacoepidemiology and drug safety 20091201 |
| Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. | Journal of hypertension 20091201 |
| Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. | Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 20091201 |
| Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. | Neuroscience bulletin 20091201 |
| Roles of NADPH oxidase in occurrence of gastric damage and expression of cyclooxygenase-2 during ischemia/reperfusion in rat stomachs. | Journal of pharmacological sciences 20091201 |
| Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. | Pharmacotherapy 20091201 |
| A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example. | PLoS medicine 20091201 |
| Direct-to-consumer advertising of prescription medicines: a counter argument. | Future medicinal chemistry 20091201 |
| Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. | Archives of internal medicine 20091123 |
| Bringing the FDA's Information to Market. | Archives of internal medicine 20091123 |
| A conditional sequential sampling procedure for drug safety surveillance. | Statistics in medicine 20091110 |
| Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. | Molecular pharmacology 20091101 |
| Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. | Pharmacoepidemiology and drug safety 20091101 |
| An ion channel hypothesis to explain divergent cardiovascular safety of cyclooxygenase-2 inhibitors: the answer to a hotly debated puzzle? | Molecular pharmacology 20091101 |
| Endothelial cell signalling supports pancreatic beta cell function in the rat. | Diabetologia 20091101 |
| The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. | Pharmacoepidemiology and drug safety 20091101 |
| Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan. | Clinical therapeutics 20091101 |
| Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain. | Journal of medicinal chemistry 20091008 |
| Parecoxib has non-significant long-term effects on bone healing in rats when administered for a short period after fracture. | Archives of orthopaedic and trauma surgery 20091001 |
| A prospective, randomized, comparative trial of a COX-2 selective nonsteroidal anti-inflammatory drug versus placebo in inguinal herniorrhaphy patients. | Hernia : the journal of hernias and abdominal wall surgery 20091001 |
| Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers. | Gastroenterology 20091001 |
| Selective and non-selective non-steroidal anti-inflammatory drugs and the risk of acute kidney injury. | Pharmacoepidemiology and drug safety 20091001 |
| Resorcylidene aminoguanidine induces antithrombotic action that is not dependent on its antiglycation activity. | Vascular pharmacology 20091001 |
| Cellular membranes function as a storage compartment for celecoxib. | Journal of molecular medicine (Berlin, Germany) 20091001 |
| Precaution, cyclooxygenase inhibition, and cardiovascular risk. | Trends in pharmacological sciences 20091001 |
| Beyond debacle and debate: developing solutions in drug safety. | Nature reviews. Drug discovery 20091001 |
| Public access to genome-wide data: five views on balancing research with privacy and protection. | PLoS genetics 20091001 |
| A comparison of the effects of ibuprofen and rofecoxib on rabbit fibula osteotomy healing. | Acta orthopaedica 20091001 |
| Cyclooxygenase inhibitors repress vascular hyaluronan-synthesis in murine atherosclerosis and neointimal thickening. | Journal of cellular and molecular medicine 20090901 |
| Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease. | The Journal of pharmacology and experimental therapeutics 20090901 |
| Principles of modular tumor therapy. | Cancer microenvironment : official journal of the International Cancer Microenvironment Society 20090901 |
| Cyclooxygenase 2 modulates killing of cytotoxic T lymphocytes by colon cancer cells. | Journal of clinical biochemistry and nutrition 20090901 |
| Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. | Journal of clinical biochemistry and nutrition 20090901 |
| Acute toxicity of cyclooxygenase-2 inhibitor rofecoxib as a radiosensitizer for concurrent chemoradiation in the treatment of uterine cervical cancer. | Journal of gynecologic oncology 20090901 |
| The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders--relation to drug treatment. | Dialogues in clinical neuroscience 20090901 |
| Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis. | PLoS medicine 20090901 |
| Ghostwriting: the dirty little secret of medical publishing that just got bigger. | PLoS medicine 20090901 |
| Effect of various antiepileptic drugs in a pentylenetetrazol-induced seizure model in mice. | Methods and findings in experimental and clinical pharmacology 20090901 |
| The role of adenosine in Alzheimer's disease. | Current neuropharmacology 20090901 |
| Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer. | British journal of cancer 20090804 |
| Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled clinical study. | Clinical rheumatology 20090801 |
| Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry letters 20090801 |
| Involvement of lipids in dimethoate-induced inhibition of testosterone biosynthesis in rat interstitial cells. | Lipids 20090801 |
| An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease. | Expert opinion on investigational drugs 20090801 |
| Protective mechanisms of NO preconditioning against NO-induced apoptosis in H9c2 cells: role of PKC and COX-2. | Free radical research 20090801 |
| Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. | Inflammopharmacology 20090801 |
| Rofecoxib increased risk of CV events in patients with history of colorectal adenomas > or = 1 year after stopping treatment. | Evidence-based medicine 20090801 |
| Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. | Current Alzheimer research 20090801 |
| Treatment of mild cognitive impairment (MCI). | Current Alzheimer research 20090801 |
| Precautionary harm disclosure in clinical trials. | The American journal of bioethics : AJOB 20090801 |
| A systematic review on the effectiveness of willow bark for musculoskeletal pain. | Phytotherapy research : PTR 20090701 |
| Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice: role of sigma-1 receptors. | Psychopharmacology 20090701 |
| Prostaglandin E(2) synthase inhibition as a therapeutic target. | Expert opinion on therapeutic targets 20090701 |
| Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. | PLoS computational biology 20090701 |
| Cardiovascular safety of celecoxib in acute myocardial infarction patients: a nested case-control study. | Heart international 20090630 |
| Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs. | Investigational new drugs 20090601 |
| Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. | The Journal of rheumatology 20090601 |
| Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. | Current medical research and opinion 20090601 |
| Mechanism-based treatments for Alzheimer's disease. | Dialogues in clinical neuroscience 20090601 |
| The effects of cardiovascular risk factors on cognitive compromise. | Dialogues in clinical neuroscience 20090601 |
| Merck defends Vioxx in court, as publisher apologises for fake journal. | BMJ (Clinical research ed.) 20090511 |
| The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. | Annals of the rheumatic diseases 20090501 |
| Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors. | European journal of pain (London, England) 20090501 |
| Synthesis and biological evaluation of 4,5-diphenyloxazolone derivatives on route towards selective COX-2 inhibitors. | European journal of medicinal chemistry 20090501 |
| Perceived barriers to paracetamol (acetaminophen) prescribing, especially following rofecoxib withdrawal from the market. | Clinical rheumatology 20090501 |
| Fact or fiction: the need for independent pharmaceutical policy research. | Journal of general internal medicine 20090501 |
| Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. | Current atherosclerosis reports 20090501 |
| No more free drug samples? | PLoS medicine 20090501 |
| Effect of excessive cholesterol and lipopolysaccharide on cerebellar neuronal cells in in vitro and protective role of anti-inflammatory drugs. | Indian journal of experimental biology 20090501 |
| Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. | Circulation. Cardiovascular quality and outcomes 20090501 |
| Merck disguised 'marketing publication' as medical journal to help promote Vioxx, court hears. | BMJ (Clinical research ed.) 20090428 |
| Induction of cell cycle arrest in human MCF-7 breast cancer cells by cis-stilbene derivatives related to VIOXX. | Toxicology letters 20090425 |
| Court hears how drug giant Merck tried to 'neutralise' and 'discredit' doctors critical of Vioxx. | BMJ (Clinical research ed.) 20090406 |
| Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20090401 |
| Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. | Annals of the rheumatic diseases 20090401 |
| The role of an independent and interdisciplinary assessment of research studies with human subjects in Europe and worldwide. | Legal medicine (Tokyo, Japan) 20090401 |
| Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. | Inflammopharmacology 20090401 |
| [A cyclooxygenase-2 selective inhibitor worsens respiratory function and enhances mast cell activity in ovalbumin-sensitized mice]. | Archivos de bronconeumologia 20090401 |
| Demographics of toxic exposures presenting to three public hospital emergency departments in Singapore 2001-2003. | International journal of emergency medicine 20090401 |
| Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors? | Polskie Archiwum Medycyny Wewnetrznej 20090401 |
| A role for cyclooxygenase-1 in beta-amyloid-induced neuroinflammation. | Aging 20090401 |
| Clinical epidemiology: Archived answers. | Nature 20090319 |
| PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells. | European journal of pharmacology 20090315 |
| Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. | Annals of the rheumatic diseases 20090301 |
| Periganglionic inflammation elicits a distally radiating pain hypersensitivity by promoting COX-2 induction in the dorsal root ganglion. | Pain 20090301 |
| Evaluation and management of post-shock wave lithotripsy pain with third-generation lithotriptors using rofecoxib. | Journal of endourology 20090301 |
| Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. | Clinics (Sao Paulo, Brazil) 20090301 |
| [Changes in nitric oxide, prostaglandins and myeloperoxidase activity in acrolein-induced cystitis in rats]. | Investigacion clinica 20090301 |
| Curcumin potentiates the anti-inflammatory activity of cyclooxygenase inhibitors in the cotton pellet granuloma pouch model. | Methods and findings in experimental and clinical pharmacology 20090301 |
| Celecoxib does not appear to affect prosthesis fixation in total knee replacement: A randomized study using radiostereometry in 50 patients. | Acta orthopaedica 20090226 |
| Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. | Clinical pharmacology and therapeutics 20090201 |
| Altered monocyte cyclo-oxygenase response in non-obese diabetic mice. | Clinical and experimental immunology 20090201 |
| COX-1 vs. COX-2 as a determinant of basal tone in the internal anal sphincter. | American journal of physiology. Gastrointestinal and liver physiology 20090201 |
| What should be done to tackle ghostwriting in the medical literature? | PLoS medicine 20090201 |
| Inflammatory and oxidative stress markers in experimental crystalopathy: their modification by photostimulation. | Photomedicine and laser surgery 20090201 |
| Diagnostic delay and suboptimal management in a referral population with hemicrania continua. | Headache 20090201 |
| An unbiased scientific record should be everyone's agenda. | PLoS medicine 20090201 |
| Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. | Aging 20090201 |
| Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. | Archives of internal medicine 20090126 |
| Synthesis and evaluation of dithiolethiones as novel cyclooxygenase inhibitors. | Bioorganic & medicinal chemistry letters 20090115 |
| Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. | Arthritis and rheumatism 20090115 |
| A 4-week randomized study of acetaminophen extended-release vs rofecoxib in knee osteoarthritis. | Osteoarthritis and cartilage 20090101 |
| Protective effect of latex of Calotropis procera in Freund's Complete Adjuvant induced monoarthritis. | Phytotherapy research : PTR 20090101 |
| A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild-to-moderate osteoarthritis. | Osteopathic medicine and primary care 20090101 |
| Is new drug prescribing in primary care specialist induced? | BMC health services research 20090101 |
| Are animal models predictive for humans? | Philosophy, ethics, and humanities in medicine : PEHM 20090101 |
| Overstating the evidence: double counting in meta-analysis and related problems. | BMC medical research methodology 20090101 |
| Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. | Journal of neuroinflammation 20090101 |
| Delayed neonatal closure of the ductus arteriosus following early in utero exposure to indomethacin in the rat. | Neonatology 20090101 |
| Developments in the clinical understanding of osteoarthritis. | Arthritis research & therapy 20090101 |
| Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. | BMC clinical pharmacology 20090101 |
| Identification of novel cyclooxygenase-2-dependent genes in Helicobacter pylori infection in vivo. | Molecular cancer 20090101 |
| Anti-inflammatory and antiarthritic effects of piperine in human interleukin 1beta-stimulated fibroblast-like synoviocytes and in rat arthritis models. | Arthritis research & therapy 20090101 |
| Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship. | PloS one 20090101 |
| Prophylaxis of heterotopic ossification - an updated review. | Journal of orthopaedic surgery and research 20090101 |
| Experimental study of COX-2 selective and traditional non-steroidal anti-inflammatory drugs in total hip replacement. | The Journal of international medical research 20090101 |
| Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. | Drug safety 20090101 |
| Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells. | Arthritis research & therapy 20090101 |
| Design, analysis, and presentation of crossover trials. | Trials 20090101 |
| Data mining in pharmacovigilance--detecting the unexpected: the role of index of suspicion of the reporter. | Drug safety 20090101 |
| Regular use of traditional analgesics predicts major coronary events: A cohort study. | Therapeutics and clinical risk management 20090101 |
| Challenging issues in molecular-targeted therapy. | Therapeutics and clinical risk management 20090101 |
| Treatment and chemoprevention of NSAID-associated gastrointestinal complications. | Therapeutics and clinical risk management 20090101 |
| Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? | The open neurology journal 20090101 |
| The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. | Journal of orthopaedic surgery and research 20090101 |
| Sequential Combination Therapy Leading to Sustained Remission in a Patient with SAPHO Syndrome. | The open rheumatology journal 20090101 |
| Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale. | PloS one 20090101 |
| Making trials matter: pragmatic and explanatory trials and the problem of applicability. | Trials 20090101 |
| Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. | Arthritis research & therapy 20090101 |
| Discrepancy among observational studies: example of naproxen-associated adverse events. | The open rheumatology journal 20090101 |
| Eggshell membrane: a possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies. | Clinical interventions in aging 20090101 |
| Proneoplastic effects of PGE2 mediated by EP4 receptor in colorectal cancer. | BMC cancer 20090101 |
| Barrett's esophagus: where do we stand? | Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association 20090101 |
| Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. | BMJ (Clinical research ed.) 20090101 |
| Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1. | PPAR research 20090101 |
| Ability to generate patient registries among practices with and without electronic health records. | Journal of medical Internet research 20090101 |
| Genome-wide mRNA expression analysis of hepatic adaptation to high-fat diets reveals switch from an inflammatory to steatotic transcriptional program. | PloS one 20090101 |
| Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy. | PloS one 20090101 |
| Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. | Molecular cancer 20090101 |
| Health-state utilities in a prisoner population: a cross-sectional survey. | Health and quality of life outcomes 20090101 |
| Interactions between herbal medicines and prescribed drugs: an updated systematic review. | Drugs 20090101 |
| Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice. | BMC neuroscience 20090101 |
| Public perceptions of the pharmaceutical industry and drug safety: implications for the pharmacovigilance professional and the culture of safety. | Drug safety 20090101 |
| Potential prescription patterns and errors in elderly adult patients attending public primary health care centers in Mexico City. | Clinical interventions in aging 20090101 |
| Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. | Current medicinal chemistry 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| Single dose oral rofecoxib for acute postoperative pain in adults. | The Cochrane database of systematic reviews 20090101 |
| Familial adenomatous polyposis. | Orphanet journal of rare diseases 20090101 |
| Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes. | BMC cancer 20090101 |
| Microstructure and mineral composition of dystrophic calcification associated with the idiopathic inflammatory myopathies. | Arthritis research & therapy 20090101 |
| Does neuroinflammation fan the flame in neurodegenerative diseases? | Molecular neurodegeneration 20090101 |
| Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. | Open medicine : a peer-reviewed, independent, open-access journal 20090101 |
| Celecoxib in arthritis: relative risk management profile and implications for patients. | Therapeutics and clinical risk management 20090101 |
| Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. | PloS one 20090101 |
| Drug-induced hematologic syndromes. | Advances in hematology 20090101 |
| Effects of dietary supplementation of high-dose folic acid on biomarkers of methylating reaction in vitamin B(12)-deficient rats. | Nutrition research and practice 20090101 |
| Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. | Journal of ophthalmology 20090101 |
| Solid Dispersion Matrix Tablet Comprising Indomethacin-PEG-HPMC Fabricated with Fusion and Mold Technique. | Indian journal of pharmaceutical sciences 20090101 |
| Recent advances in peptic ulcer bleeding. | F1000 medicine reports 20090101 |
| Mild cognitive impairment: The dilemma. | Indian journal of psychiatry 20090101 |
| Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. | Drug, healthcare and patient safety 20090101 |
| The obligatory role of COX-2 expression for induction of HO-1 in ischemic preconditioned rat brain. | Biochemical and biophysical research communications 20081226 |
| COX-2 selective inhibitors in the treatment of osteoarthritis. | Seminars in arthritis and rheumatism 20081201 |
| 2,3,5-Substituted tetrahydrofurans: COX-2 inhibitory activities of 5-hydroxymethyl-/carboxyl-2,3-diaryl-tetrahydro-furan-3-ols. | European journal of medicinal chemistry 20081201 |
| The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic COX-2 selective inhibitor. | Journal of cardiovascular pharmacology and therapeutics 20081201 |
| Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. | The American journal of medicine 20081201 |
| Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension. | American journal of Alzheimer's disease and other dementias 20081201 |
| Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. | Cardiovascular & hematological disorders drug targets 20081201 |
| Acute myocardial infarction after treatment of thrombocytopenia in a young woman with systemic lupus erythematosus. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20081201 |
| Systems biology: a therapeutic target for tumor therapy. | Cancer microenvironment : official journal of the International Cancer Microenvironment Society 20081201 |
| Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. | Alimentary pharmacology & therapeutics 20081115 |
| Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. | Lancet (London, England) 20081115 |
| Selective COX-2 inhibitors: where do we go from here? | Lancet (London, England) 20081115 |
| COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20081101 |
| Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. | European journal of heart failure 20081101 |
| Effect of Vioxx on adipose tissue development in mice with genetically determined obesity. | Thrombosis and haemostasis 20081101 |
| Former pharma pitchman: beware of new drugs. An industry insider advises considering the older options if you need a prescription. Interview by Sarah Baldauf. | U.S. news & world report 20081101 |
| Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions. | PLoS medicine 20081101 |
| Bias, spin, and misreporting: time for full access to trial protocols and results. | PLoS medicine 20081101 |
| Seeds of doubt--ADVANTAGE no one. | International journal of clinical practice 20081101 |
| Clinical trials and tribulations. Allegations of waste: the 'seeding' study. | Science (New York, N.Y.) 20081010 |
| Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. | Cancer chemotherapy and pharmacology 20081001 |
| Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam. | Journal of applied toxicology : JAT 20081001 |
| A randomized trial of the peri-operative use of COX-2 inhibitors in Lichtenstein herniorrhaphy. | Hernia : the journal of hernias and abdominal wall surgery 20081001 |
| 4 years after withdrawal of rofecoxib: where do we stand today? | Rheumatology international 20081001 |
| Celecoxib inhibits 5-lipoxygenase. | Biochemical pharmacology 20081001 |
| Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. | Pharmacoepidemiology and drug safety 20081001 |
| Low-intensity pulsed ultrasound-promoted bone healing is not entirely cyclooxgenase 2 dependent. | Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine 20081001 |
| The SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines for quality improvement reporting: explanation and elaboration. | Quality & safety in health care 20081001 |
| Solubility and dissolution improvement of Rofecoxib using solid dispersion technique. | Pakistan journal of pharmaceutical sciences 20081001 |
| Off-label promotion, on-target sales. | PLoS medicine 20081001 |
| Risk management profile of etoricoxib: an example of personalized medicine. | Therapeutics and clinical risk management 20081001 |
| Elevation of inducible nitric oxide synthase and cyclooxygenase-2 expression in the mouse brain after chronic nonylphenol exposure. | International journal of molecular sciences 20081001 |
| Kinetic Changes of COX-2 Expression during Reperfusion Period after Ischemic Preconditioning Play a Role in Protection Against Ischemic Damage in Rat Brain. | The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20081001 |
| Effects of lactone derivatives on aromatase (CYP19) activity in H295R human adrenocortical and (anti)androgenicity in transfected LNCaP human prostate cancer cells. | European journal of pharmacology 20080928 |
| Using the CatWalk method to assess weight-bearing and pain behaviour in walking rats with ankle joint monoarthritis induced by carrageenan: effects of morphine and rofecoxib. | Journal of neuroscience methods 20080915 |
| In vivo and in vitro metabolism of lefucoxib in rats. | Journal of pharmaceutical and biomedical analysis 20080910 |
| Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. | The Journal of pharmacology and experimental therapeutics 20080901 |
| Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). | Critical care medicine 20080901 |
| Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. | Medical care 20080901 |
| Selective COX-2 inhibitors: new insights into mechanisms of side effects? | Critical care medicine 20080901 |
| Publication of clinical trials supporting successful new drug applications: a literature analysis. | PLoS medicine 20080901 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| Guest authorship, mortality reporting, and integrity in rofecoxib studies. | JAMA 20080827 |
| The ADVANTAGE seeding trial: a review of internal documents. | Annals of internal medicine 20080819 |
| Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. | Arthritis and rheumatism 20080815 |
| Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. | Arthritis and rheumatism 20080815 |
| Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. | Arthritis and rheumatism 20080815 |
| Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. | Journal of medicinal chemistry 20080814 |
| The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. | Pharmacoepidemiology and drug safety 20080801 |
| Thermodynamic behavior of glassy state of structurally related compounds. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20080801 |
| Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? | European journal of clinical pharmacology 20080801 |
| Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. | Trends in pharmacological sciences 20080801 |
| Ghostwriters, data manipulation and dollar diplomacy: how drug companies pull the strings in clinical research. | Annals of emergency medicine 20080801 |
| Rofecoxib impairs adipose tissue development in a murine model of nutritionally induced obesity. | Thrombosis and haemostasis 20080801 |
| A postgenomic integrated view of prostaglandins in reproduction: implications for other body systems. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080801 |
| Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20080801 |
| In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. | Basic & clinical pharmacology & toxicology 20080801 |
| Present and prospective clinical therapeutic regimens for Alzheimer's disease. | Neuropsychiatric disease and treatment 20080801 |
| The anti-proliferative potency of celecoxib is not a class effect of coxibs. | Biochemical pharmacology 20080715 |
| Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. | Annals of the rheumatic diseases 20080701 |
| Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. | Molecular carcinogenesis 20080701 |
| COX inhibitors downregulate PDE4D expression in a clinical model of inflammatory pain. | Clinical pharmacology and therapeutics 20080701 |
| Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the risk for stroke. | Stroke 20080701 |
| Proposed standards for medical education submissions to the Journal of General Internal Medicine. | Journal of general internal medicine 20080701 |
| Comparison of parecoxib and proparacetamol in endoscopic nasal surgery patients. | Yonsei medical journal 20080630 |
| Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and chronic pain. | Clinical pharmacology and therapeutics 20080601 |
| Validating the effects of drug treatment on blood pressure in the General Practice Research Database. | Pharmacoepidemiology and drug safety 20080601 |
| Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. | Pharmacoepidemiology and drug safety 20080601 |
| Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. | British journal of clinical pharmacology 20080601 |
| Effects of the selective EP4 antagonist, CJ-023,423 on chronic inflammation and bone destruction in rat adjuvant-induced arthritis. | The Journal of pharmacy and pharmacology 20080601 |
| Cardiovascular co-morbidity in rheumatic diseases. | Vascular health and risk management 20080601 |
| Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. | Vascular health and risk management 20080601 |
| Potential bias in ophthalmic pharmaceutical clinical trials. | Clinical ophthalmology (Auckland, N.Z.) 20080601 |
| Merck to pay $58m in settlement over rofecoxib advertising. | BMJ (Clinical research ed.) 20080531 |
| More on subgroup analyses in clinical trials. | The New England journal of medicine 20080508 |
| Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. | European journal of clinical pharmacology 20080501 |
| Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance? | Pharmacoepidemiology and drug safety 20080501 |
| How do US journalists cover treatments, tests, products, and procedures? An evaluation of 500 stories. | PLoS medicine 20080501 |
| Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. | Circulation research 20080425 |
| A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. | British journal of cancer 20080422 |
| Merck accused of disguising its role in research. | Nature 20080417 |
| Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. | JAMA 20080416 |
| Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation. | JAMA 20080416 |
| Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal. | Arthritis and rheumatism 20080415 |
| Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. | Bioorganic & medicinal chemistry 20080401 |
| Computer-aided, rational design of a potent and selective small peptide inhibitor of cyclooxygenase 2 (COX2). | Journal of biomolecular structure & dynamics 20080401 |
| Are NSAIDs and selective cyclo-oxygenase 2 inhibitors associated with increased risk of myocardial infarction? | Nature clinical practice. Rheumatology 20080401 |
| Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma. | Nature clinical practice. Rheumatology 20080401 |
| Rofecoxib potentiates the anticonvulsant effect of topiramate. | Inflammopharmacology 20080401 |
| Merck's Careful Study of Vioxx. | The American journal of cardiology 20080401 |
| The impact of corporate practices on health: implications for health policy. | Journal of public health policy 20080401 |
| Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. | Health technology assessment (Winchester, England) 20080401 |
| Does direct-to-consumer advertising affect patients' choice of pain medications? | Current pain and headache reports 20080401 |
| Review of the cardiovascular safety of COXIBs compared to NSAIDS. | Cardiovascular journal of Africa 20080401 |
| Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis. | Therapeutics and clinical risk management 20080401 |
| Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies. | Bioorganic & medicinal chemistry 20080315 |
| 94% of patients suing Merck over rofecoxib agree to company's offer. | BMJ (Clinical research ed.) 20080315 |
| Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux. | The Journal of surgical research 20080301 |
| Prevention of lipopolysaccharide-induced intussusception in mice by the COX2 inhibitor rofecoxib. | Pediatric surgery international 20080301 |
| Novel 2-(4-methylsulfonylphenyl)pyrimidine derivatives as highly potent and specific COX-2 inhibitors. | Bioorganic & medicinal chemistry 20080301 |
| Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. | British journal of pharmacology 20080301 |
| The interaction between inhibitors of nitric oxide synthase and cyclooxygenase in formalin-induced pain in mice: an isobolographic study. | Anesthesia and analgesia 20080301 |
| Impact of prescriber nonresponse on patient representativeness. | Epidemiology (Cambridge, Mass.) 20080301 |
| Drug safety surveillance in China and other countries: a review and comparison. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080301 |
| Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. | The AAPS journal 20080301 |
| Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. | Bioorganic & medicinal chemistry 20080215 |
| Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation. | European journal of pharmacology 20080202 |
| Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. | The Journal of pharmacology and experimental therapeutics 20080201 |
| Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. | Current Alzheimer research 20080201 |
| Cannabinoids in the management of difficult to treat pain. | Therapeutics and clinical risk management 20080201 |
| Pharmacovigilance inspections. | Indian journal of pharmacology 20080201 |
| Inhibition of delayed rectifier potassium channels and induction of arrhythmia: a novel effect of celecoxib and the mechanism underlying it. | The Journal of biological chemistry 20080118 |
| Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans. | The Journal of biological chemistry 20080111 |
| Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. | European journal of pharmacology 20080106 |
| 2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. | European journal of medicinal chemistry 20080101 |
| Chemoprevention with special reference to inherited colorectal cancer. | Familial cancer 20080101 |
| Cardiovascular disease in patients with spondyloarthropathies. | Joint, bone, spine : revue du rhumatisme 20080101 |
| Effects of a selective cyclooxygenase-2 inhibitor on postoperative inflammatory reaction and pain after total knee replacement. | The journal of pain : official journal of the American Pain Society 20080101 |
| Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal. | Pharmacoepidemiology and drug safety 20080101 |
| Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans. | Clinical biochemistry 20080101 |
| Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: possible involvement of adenosinergic mechanism. | Epilepsy research 20080101 |
| 1-Toluene-sulfonyl-3-[(3'-hydroxy-5'-substituted)-gamma-butyrolactone]-indoles: synthesis, COX-2 inhibition and anti-cancer activities. | Bioorganic & medicinal chemistry letters 20080101 |
| Who is responsible for evaluating the safety and effectiveness of medical devices? The role of independent technology assessment. | Journal of general internal medicine 20080101 |
| Trial registration for public trust: making the case for medical devices. | Journal of general internal medicine 20080101 |
| Use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs in high doses increases mortality and risk of reinfarction in patients with prior myocardial infarction. | The Journal of cardiovascular nursing 20080101 |
| Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation. | Nuclear medicine and biology 20080101 |
| The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model. | Anesthesia and analgesia 20080101 |
| The effect of three cyclo-oxygenase inhibitors on intensity of primary dysmenorrheic pain. | The Clinical journal of pain 20080101 |
| Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. | Journal of translational medicine 20080101 |
| Etoricoxib-induced erythema-multiforme-like eruption. | Dermatology (Basel, Switzerland) 20080101 |
| Use of cox-2 inhibitors in patients with retinal venous occlusive disease. | Retina (Philadelphia, Pa.) 20080101 |
| Rethinking the threats to scientific balance in contexts of litigation and regulation. | Environmental health perspectives 20080101 |
| Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes. | Arthritis research & therapy 20080101 |
| No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. | PloS one 20080101 |
| Cyclooxygenase-2 overexpression is common in serrated and non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated polyp/adenoma. | BMC cancer 20080101 |
| What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs. | Arthritis research & therapy 20080101 |
| OTC analgesics and drug interactions: clinical implications. | Osteopathic medicine and primary care 20080101 |
| The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. | Journal of neuroinflammation 20080101 |
| Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. | Arthritis research & therapy 20080101 |
| Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. | BMC musculoskeletal disorders 20080101 |
| Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. | Current medicinal chemistry 20080101 |
| Risk communication formats for low probability events: an exploratory study of patient preferences. | BMC medical informatics and decision making 20080101 |
| Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. | BMC musculoskeletal disorders 20080101 |
| Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. | PloS one 20080101 |
| Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. | Arthritis research & therapy 20080101 |
| Marching ahead with clinical trial registration. | Indian journal of ophthalmology 20080101 |
| A test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials. | PloS one 20080101 |
| Pediatric patient with systemic lupus erythematosus & congenital acquired immunodeficiency syndrome: An unusual case and a review of the literature. | Pediatric rheumatology online journal 20080101 |
| The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. | Current rheumatology reports 20080101 |
| Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. | PPAR research 20080101 |
| Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. | Arthritis research & therapy 20080101 |
| COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. | Molecular cancer 20080101 |
| Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase-2. | Journal of neuroinflammation 20080101 |
| The relationship between cancer and rheumatoid arthritis: still a large research agenda. | Arthritis research & therapy 20080101 |
| Molecular analysis of the effects of Piroxicam and Cisplatin on mesothelioma cells growth and viability. | Journal of translational medicine 20080101 |
| Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. | Anticancer research 20080101 |
| Patients with rheumatoid arthritis have an altered circulatory aggrecan profile. | BMC musculoskeletal disorders 20080101 |
| Perioperative celecoxib administration for pain management after total knee arthroplasty - a randomized, controlled study. | BMC musculoskeletal disorders 20080101 |
| Peroxisome proliferator-activated receptors and progression of colorectal cancer. | PPAR research 20080101 |
| Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy. | Drug safety 20080101 |
| Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. | Thrombosis research 20080101 |
| PPARgamma and MEK Interactions in Cancer. | PPAR research 20080101 |
| A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. | Arthritis research & therapy 20080101 |
| Effects of COX-2 inhibition on expression of vascular endothelial growth factor and interleukin-8 in lung cancer cells. | BMC cancer 20080101 |
| Virtual screening for novel COX-2 inhibitors using the ZINC database. | Bioinformation 20080101 |
| Risk-benefit perspectives in COX-2 blockade. | Current drug safety 20080101 |
| Infraorbital cutaneous angiosarcoma: a diagnostic and therapeutic dilemma. | Head & face medicine 20080101 |
| Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. | BMC cancer 20080101 |
| Laparoscopic restorative total proctocolectomy with ileal pouch anal anastomosis for familial adenomatous polyposis. | JSLS : Journal of the Society of Laparoendoscopic Surgeons 20080101 |
| Short and medium-term effects of an education self-management program for individuals with osteoarthritis of the knee, designed and delivered by health professionals: a quality assurance study. | BMC musculoskeletal disorders 20080101 |
| A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients. | BMC musculoskeletal disorders 20080101 |
| Sevoflurane requirement during elective ankle day surgery: the effects of etirocoxib premedication, a prospective randomised study. | Journal of orthopaedic surgery and research 20080101 |
| Management of chronic knee pain: a survey of patient preferences and treatment received. | BMC musculoskeletal disorders 20080101 |
| Non-steroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors and paracetamol use in Queensland and in the whole of Australia. | BMC health services research 20080101 |
| The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile. | Nutrition journal 20080101 |
| NSAID use in individuals at risk of renal adverse events: an observational study to investigate trends in Australian veterans. | Drug safety 20080101 |
| Systematic review of dexketoprofen in acute and chronic pain. | BMC clinical pharmacology 20080101 |
| Big pharma and health care: unsolvable conflict of interests between private enterprise and public health. | The Israel journal of psychiatry and related sciences 20080101 |
| Finding multiple target optimal intervention in disease-related molecular network. | Molecular systems biology 20080101 |
| New horizons and perspectives in the treatment of osteoarthritis. | Arthritis research & therapy 20080101 |
| Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. | Arthritis research & therapy 20080101 |
| Role of nitric oxide in the gastrointestinal tract. | Arthritis research & therapy 20080101 |
| Inflammaging as a prodrome to Alzheimer's disease. | Journal of neuroinflammation 20080101 |
| Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. | Cost effectiveness and resource allocation : C/E 20080101 |
| The Role of PPARs in the Endothelium: Implications for Cancer Therapy. | PPAR research 20080101 |
| What can we learn from drug marketing efficiency? | BMJ (Clinical research ed.) 20080101 |
| Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. | BMJ (Clinical research ed.) 20080101 |
| Cyclooxygenase inhibitors: a novel direction for Alzheimer's management. | Pharmacological reports : PR 20080101 |
| Overuse of non-prescription analgesics by dental clinic patients. | BMC oral health 20080101 |
| Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study. | Arthritis research & therapy 20080101 |
| Improving the postmarket surveillance of total joint arthroplasty devices. | The open rheumatology journal 20080101 |
| Clinical Use of PPARgamma Ligands in Cancer. | PPAR research 20080101 |
| PPARs Mediate Lipid Signaling in Inflammation and Cancer. | PPAR research 20080101 |
| PPAR-delta in Vascular Pathophysiology. | PPAR research 20080101 |
| [Cardiovascular risk of cyclooxygenase selective inhibitors]. | Revista medica del Instituto Mexicano del Seguro Social 20080101 |
| Combination Therapy of PPARgamma Ligands and Inhibitors of Arachidonic Acid in Lung Cancer. | PPAR research 20080101 |
| FTIR studies on differential intermolecular association in crystalline and amorphous states of structurally related non-steroidal anti-inflammatory drugs. | Molecular pharmaceutics 20080101 |
| Chronic prostatitis: Current concepts. | Indian journal of urology : IJU : journal of the Urological Society of India 20080101 |
| Herbal excipients in novel drug delivery systems. | Indian journal of pharmaceutical sciences 20080101 |
| A Study on Improvement of Solubility of Rofecoxib and its effect on Permeation of Drug from Topical Formulations. | Indian journal of pharmaceutical sciences 20080101 |
| Optimization of fast dissolving etoricoxib tablets prepared by sublimation technique. | Indian journal of pharmaceutical sciences 20080101 |
| Elderly patient refractory to multiple pain medications successfully treated with integrative East-West medicine. | International journal of general medicine 20080101 |
| Psychological factors in asthma. | Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20080101 |
| Aspirin-exacerbated asthma. | Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20080101 |
| Preemptive versus postoperative lumiracoxib for analgesia in ambulatory arthroscopic knee surgery. | Journal of pain research 20080101 |
| Myocardial Infarction and Its Association with the Use of Nonselective NSAIDs: A Nested Case-Control and Time-to-Event Analysis. | The Permanente journal 20080101 |
| Ethical considerations of publication planning in the pharmaceutical industry. | Open medicine : a peer-reviewed, independent, open-access journal 20080101 |
| Medical ghost-writing. | Mens sana monographs 20080101 |
| Rethinking statistical approaches to evaluating drug safety. | Yonsei medical journal 20071231 |
| Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? | Lancet (London, England) 20071222 |
| Behavioral characterization and effect of clinical drugs in a rat model of pain following spinal cord compression. | Brain research 20071214 |
| Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood-brain barrier. | Brain research 20071212 |
| Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. | British journal of cancer 20071203 |
| Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice. | Seizure 20071201 |
| Orthodontic tooth movement after different coxib therapies. | European journal of orthodontics 20071201 |
| Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers. | Journal of thrombosis and haemostasis : JTH 20071201 |
| Early detection of adverse drug events within population-based health networks: application of sequential testing methods. | Pharmacoepidemiology and drug safety 20071201 |
| Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial. | Melanoma research 20071201 |
| NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20071201 |
| Patterns of analgesic and anti-inflammatory medicine use by Australian veterans. | Internal medicine journal 20071201 |
| Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages. | Nature clinical practice. Rheumatology 20071201 |
| Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs. | Anesthesia and analgesia 20071201 |
| Lipoperoxidation and cyclooxygenase enzyme inhibitory piperidine alkaloids from Cassia spectabilis green fruits. | Journal of natural products 20071201 |
| Rofecoxib associated with diaphragm disease. | Canadian journal of surgery. Journal canadien de chirurgie 20071201 |
| Homeopathy, fundamentalism, and the memory of water. | Current oncology (Toronto, Ont.) 20071201 |
| The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. | Current pain and headache reports 20071201 |
| [What is new about nonsteroidal antiinflamatory drugs?]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20071201 |
| Genomas: battling side effects with physiotypes. | The Yale journal of biology and medicine 20071201 |
| Update on the treatment of ankylosing spondylitis. | Therapeutics and clinical risk management 20071201 |
| Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. | Current neuropharmacology 20071201 |
| Current therapeutic options for Alzheimer's disease. | Current genomics 20071201 |
| Merck to pay $5bn in rofecoxib claims. | BMJ (Clinical research ed.) 20071117 |
| Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. | Alimentary pharmacology & therapeutics 20071115 |
| Diclofenac and acute myocardial infarction in patients with no major risk factors. | British journal of clinical pharmacology 20071101 |
| What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia? | Pharmacoepidemiology and drug safety 20071101 |
| Office based transurethral needle ablation of the prostate with analgesia and local anesthesia. | The Journal of urology 20071101 |
| Cardiovascular effects of cyclooxygenase-2 inhibitors. | Current opinion in gastroenterology 20071101 |
| Clinical inquiries. Do COX-2 inhibitors worsen renal function? | The Journal of family practice 20071101 |
| Increased neuronal injury in transgenic mice with neuronal overexpression of human cyclooxygenase-2 is reversed by hypothermia and rofecoxib treatment. | Current neurovascular research 20071101 |
| Economic evaluation of a rehabilitation program integrating exercise, self-management, and active coping strategies for chronic knee pain. | Arthritis and rheumatism 20071015 |
| Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. | Annals of the rheumatic diseases 20071001 |
| Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition. | Cancer immunology, immunotherapy : CII 20071001 |
| Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. | Molecular carcinogenesis 20071001 |
| What therapies have replaced rofecoxib in Ireland? | British journal of clinical pharmacology 20071001 |
| Covalent binding of rofecoxib, but not other cyclooxygenase-2 inhibitors, to allysine aldehyde in elastin of human aorta. | Drug metabolism and disposition: the biological fate of chemicals 20071001 |
| Cyclooxygenase-2/prostaglandin E2 accelerates the healing of gastric ulcers via EP4 receptors. | American journal of physiology. Gastrointestinal and liver physiology 20071001 |
| The effects of preoperative rofecoxib, metoclopramide, dexamethasone, and ondansetron on postoperative pain and nausea in patients undergoing elective laparoscopic cholecystectomy. | Surgical endoscopy 20071001 |
| Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. | Bioorganic & medicinal chemistry letters 20071001 |
| Post-tonsillectomy pain management in children: can we do better? | Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 20071001 |
| Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal. | Nature clinical practice. Rheumatology 20071001 |
| Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats. | Inflammopharmacology 20071001 |
| Comparative study of acetaminophen-morphine versus rofecoxib-morphine for post-tonsillectomy pain control. | The Journal of otolaryngology 20071001 |
| The role of tramadol in current treatment strategies for musculoskeletal pain. | Therapeutics and clinical risk management 20071001 |
| Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? | Therapeutics and clinical risk management 20071001 |
| Progress update: Pharmacological treatment of Alzheimer's disease. | Neuropsychiatric disease and treatment 20071001 |
| Effects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagus. | Alimentary pharmacology & therapeutics 20070915 |
| Rofecoxib inhibits heterotopic ossification after total hip arthroplasty. | Archives of orthopaedic and trauma surgery 20070901 |
| The ubiquitin- and proteasome-dependent degradation of COX-2 is regulated by the COP9 signalosome and differentially influenced by coxibs. | Journal of molecular medicine (Berlin, Germany) 20070901 |
| Selective COX-2 inhibitors, eicosanoid synthesis and clinical outcomes: a case study of system failure. | Lipids 20070901 |
| Neither antioxidants nor COX-2 inhibition protect against esophageal inflammation in an experimental model of severe reflux. | The Journal of surgical research 20070901 |
| Effect of (S)-4-(1-(5-chloro-2-(4-fluorophenyoxy)benzamido)ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. | The Journal of pharmacology and experimental therapeutics 20070901 |
| Characterization of the effects of cyclooxygenase-2 inhibition in the regulation of apoptosis in human small and non-small cell lung cancer cell lines. | Annals of surgical oncology 20070901 |
| 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. | British journal of pharmacology 20070901 |
| The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. | Current medical research and opinion 20070901 |
| Rofecoxib has different effects on chemokine production in colorectal cancer cells and tumor immune splenocytes. | Journal of immunotherapy (Hagerstown, Md. : 1997) 20070901 |
| Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. | Pharmacological research 20070901 |
| OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. | Osteoarthritis and cartilage 20070901 |
| Chronobiological characteristics of postoperative pain: diurnal variation of both static and dynamic pain and effects of analgesic therapy. | Canadian journal of anaesthesia = Journal canadien d'anesthesie 20070901 |
| Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? | PLoS medicine 20070901 |
| The effects of the short-term administration of low therapeutic doses of anti-COX-2 agents on the healing of fractures. An experimental study in rabbits. | The Journal of bone and joint surgery. British volume 20070901 |
| Involvement of prostaglandin E receptor EP3 subtype and prostacyclin IP receptor in decreased acid response in damaged stomach. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20070901 |
| Rosiglitazone: a disappointing DREAM. | Future cardiology 20070901 |
| Keeping science on top in drug evaluation. | The New England journal of medicine 20070816 |
| Stimulation programs for pediatric drug research--do children really benefit? | European journal of pediatrics 20070801 |
| Channelling of COX-2 inhibitors to patients at higher gastrointestinal risk but not at lower cardiovascular risk: the Cox2 inhibitors and tNSAIDs description of users (CADEUS) study. | Pharmacoepidemiology and drug safety 20070801 |
| Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20070801 |
| Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing and utilization. | Current medical research and opinion 20070801 |
| The prolonged postoperative analgesic effect when dexamethasone is added to a nonsteroidal antiinflammatory drug (rofecoxib) before breast surgery. | Anesthesia and analgesia 20070801 |
| Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers. | Platelets 20070801 |
| A double-blind randomized controlled trial of rofecoxib and multidose oxycodone/acetaminophen in dental impaction pain. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20070801 |
| Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070801 |
| Preoperative cyclooxygenase-2 inhibitor treatment reduces the incidence of heterotopic ossification after hip arthroplasty: six-month follow-up. | Anesthesiology 20070801 |
| Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. | Expert opinion on pharmacotherapy 20070801 |
| General practitioners and pharmaceutical sales representatives: quality improvement research. | Quality & safety in health care 20070801 |
| Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice? | Southern medical journal 20070801 |
| By the way, doctor. First it was Vioxx and now Avandia. Why can't doctors and the government screen out unsafe medicines? | Harvard health letter 20070801 |
| [Effect of electroacupuncture on carrageenan-induced inflammation, IL-1beta and TNF-alpha concentrations and their mRNA expressions in toe tissue in rats]. | Zhen ci yan jiu = Acupuncture research 20070801 |
| Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond. | Acta bio-medica : Atenei Parmensis 20070801 |
| Current treatment options in the management of chronic prostatitis. | Therapeutics and clinical risk management 20070801 |
| Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. | The New England journal of medicine 20070726 |
| The pain game. | Nature 20070726 |
| Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. | Cardiovascular research 20070715 |
| Ameliorative effect of combined administration of inducible nitric oxide synthase inhibitor with cyclooxygenase-2 inhibitors in neuropathic pain in rats. | European journal of pain (London, England) 20070701 |
| Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. | Pharmacoepidemiology and drug safety 20070701 |
| Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of the literature. | Archives of dermatological research 20070701 |
| Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20070701 |
| Perspectives on the failure of pharmaceutical and medical device industries to fully protect public health interests. | The American journal of cardiology 20070701 |
| [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs]. | Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS 20070701 |
| Don't blame it all on the bogey. | BMJ (Clinical research ed.) 20070616 |
| Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. | Pain 20070601 |
| The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE-/- mice. | Journal of molecular medicine (Berlin, Germany) 20070601 |
| Treatment of the mild cognitive impairment (MCI). | Human psychopharmacology 20070601 |
| Topical dosage form of valdecoxib: preparation and pharmacological evaluation. | Acta pharmaceutica (Zagreb, Croatia) 20070601 |
| Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. | The Lancet. Oncology 20070601 |
| Antifibrotic activity of rofecoxib in vivo is associated with reduced portal hypertension in rats with carbon tetrachloride-induced liver injury. | Journal of gastroenterology and hepatology 20070601 |
| The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. | Current oncology (Toronto, Ont.) 20070601 |
| Process optimization and characterization of poloxamer solid dispersions of a poorly water-soluble drug. | AAPS PharmSciTech 20070601 |
| Prospective, double-blinded, randomized, placebo-controlled comparison of local anesthetic and nonsteroidal anti-inflammatory drugs for postoperative pain management after laparoscopic surgery. | The American surgeon 20070601 |
| Challenges facing age-management/longevity medicine. | Clinical interventions in aging 20070601 |
| Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. | Therapeutics and clinical risk management 20070601 |
| Acute migraine: Current treatment and emerging therapies. | Therapeutics and clinical risk management 20070601 |
| Tramadol extended-release in the management of chronic pain. | Therapeutics and clinical risk management 20070601 |
| Current aproach to cancer pain management: Availability and implications of different treatment options. | Therapeutics and clinical risk management 20070601 |
| Mechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders. | Neuropsychiatric disease and treatment 20070601 |
| Man on a mission. | Nature 20070531 |
| [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs]. | Nederlands tijdschrift voor geneeskunde 20070512 |
| Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study. | Pharmacoepidemiology and drug safety 20070501 |
| The CADEUS study: methods and logistics. | Pharmacoepidemiology and drug safety 20070501 |
| [Rofecoxib-induced psychosis]. | Psychiatrische Praxis 20070501 |
| Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. | Journal of natural products 20070501 |
| COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-gamma and IL-10 production by inhibiting T-bet expression. | Journal of neuroimmunology 20070501 |
| Octreotide alone or in combination with rofecoxib as palliative treatment for advanced hepatocellular cancer. | Zeitschrift fur Gastroenterologie 20070501 |
| The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study. | Pharmacopsychiatry 20070501 |
| Moment of reckoning. | Nature 20070419 |
| Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: a class effect? | Arthritis and rheumatism 20070415 |
| [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain]. | Nederlands tijdschrift voor geneeskunde 20070407 |
| NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. | Journal of medicinal chemistry 20070405 |
| Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol. | European journal of pain (London, England) 20070401 |
| Characterizing new users of NSAIDs before and after rofecoxib withdrawal. | British journal of clinical pharmacology 20070401 |
| Role of cyclooxygenases in oedema-forming activity of bothropic venoms. | Toxicon : official journal of the International Society on Toxinology 20070401 |
| Sperm quality and pregnancy rate after COX-2 inhibitor therapy of infertile males with abacterial leukocytospermia. | Human reproduction (Oxford, England) 20070401 |
| Cyclophosphamide induced cystitis: role of nitric oxide synthase, cyclooxygenase-1 and 2, and NK(1) receptors. | The Journal of urology 20070401 |
| Long-term risk of ischemic stroke associated with rofecoxib. | Cardiovascular drugs and therapy 20070401 |
| Cerebrovascular events after discontinuation of rofecoxib treatment. | Cardiovascular drugs and therapy 20070401 |
| Characteristics and impact of drug detailing for gabapentin. | PLoS medicine 20070401 |
| Influence of water soluble polymers on hydroxypropyl-beta-cyclodextrin complexation of rofecoxib. | Die Pharmazie 20070401 |
| Merck appeals rofecoxib verdict. | BMJ (Clinical research ed.) 20070324 |
| Experts call for active surveillance of drug safety. | Nature 20070322 |
| Cyclooxygenase-2 inhibitors dilemma in cardiovascular medicine: are all family members bad players? | International journal of cardiology 20070320 |
| Determinants of platelet activation in Alzheimer's disease. | Neurobiology of aging 20070301 |
| Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk. | Rheumatology international 20070301 |
| GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. | Pain 20070301 |
| Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. | Pain 20070301 |
| Mechanism for covalent binding of rofecoxib to elastin of rat aorta. | The Journal of pharmacology and experimental therapeutics 20070301 |
| Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. | Rheumatology (Oxford, England) 20070301 |
| Cyclooxygenase-2 inhibition increases gastric tone and delays gastric emptying in rats. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070301 |
| The Institute of Medicine report on the FDA: where is the science? | Health economics 20070301 |
| Appropriate use of NSAIDs: considering cardiovascular risk in the elderly. | Geriatrics 20070301 |
| Short-term efficacy of rofecoxib and diclofenac in acute shoulder pain: a placebo-controlled randomized trial. | PLoS clinical trials 20070301 |
| Dynamic simulations on the arachidonic acid metabolic network. | PLoS computational biology 20070301 |
| Selective inhibition of prostacyclin synthase activity by rofecoxib. | Journal of cellular and molecular medicine 20070301 |
| [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] 20070301 |
| Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. | British journal of cancer 20070226 |
| Cardiac risks with COX-2 inhibitors. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070213 |
| Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study. | European journal of pharmacology 20070205 |
| [Transient global amnesia (TGA) during an oral provocation test]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20070201 |
| The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. | Heart (British Cardiac Society) 20070201 |
| Selective cyclooxygenase-2 inhibitors stimulate glucose transport in L6 myotubes in a protein kinase Cdelta-dependent manner. | Biochemical pharmacology 20070201 |
| Preconditioning stress prevents cold restraint stress-induced gastric lesions in rats: roles of COX-1, COX-2, and PLA2. | Digestive diseases and sciences 20070201 |
| Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial. | Gastroenterology 20070201 |
| NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. | PLoS medicine 20070201 |
| Drug-induced thrombosis--experimental, clinical, and mechanistic considerations. | Toxicologic pathology 20070201 |
| Similar effects of rofecoxib and indomethacin on the incidence of heterotopic ossification after hip arthroplasty. | Acta orthopaedica 20070201 |
| Selective COX-2 inhibitor versus indomethacin for the prevention of heterotopic ossification after hip replacement: a double-blind randomized trial of 100 patients with 1-year follow-up. | Acta orthopaedica 20070201 |
| C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. | British journal of cancer 20070129 |
| Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. | Circulation 20070123 |
| What have we learnt from Vioxx? | BMJ (Clinical research ed.) 20070120 |
| Synthesis and biological evaluation of methanesulfonamide analogues of rofecoxib: Replacement of methanesulfonyl by methanesulfonamido decreases cyclooxygenase-2 selectivity. | Bioorganic & medicinal chemistry 20070115 |
| Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats. | European journal of pharmacology 20070105 |
| Quebec allows Vioxx class-action suit. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20070102 |
| Coxibs and heart disease: what we have learned and what else we need to know. | Journal of the American College of Cardiology 20070102 |
| Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20070101 |
| Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. | The Journal of pharmacology and experimental therapeutics 20070101 |
| Inflammation-induced reduction of spontaneous activity by adjuvant: A novel model to study the effect of analgesics in rats. | The Journal of pharmacology and experimental therapeutics 20070101 |
| Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. | Pharmacology 20070101 |
| Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. | Journal of clinical epidemiology 20070101 |
| Pharmacodynamic of cyclooxygenase inhibitors in humans. | Prostaglandins & other lipid mediators 20070101 |
| Better ways to target pain. | Scientific American 20070101 |
| Exercise can be pyrogenic in humans. | American journal of physiology. Regulatory, integrative and comparative physiology 20070101 |
| Herbal medicine for low back pain: a Cochrane review. | Spine 20070101 |
| Review: risk for cardiovascular events is increased with rofecoxib, diclofenac, and indomethacin but not celecoxib. | ACP journal club 20070101 |
| Review: rofecoxib increases renal events and arrhythmia, but a COX-2-inhibitor class effect does not exist. | ACP journal club 20070101 |
| The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain. | Current medical research and opinion 20070101 |
| A pathogenetic mechanism for COX-2 inhibitor-induced cardiovascular events proposed to be useful in structuring medical testimony in rofecoxib trials. | Medical hypotheses 20070101 |
| NSAIDs, Myocardial infarction, rebound effect and similitude. | Homeopathy : the journal of the Faculty of Homeopathy 20070101 |
| Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. | Arthritis research & therapy 20070101 |
| Conflicts of interest in health care: who guards the guardians? | Perspectives in biology and medicine 20070101 |
| Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis. | Arthritis research & therapy 20070101 |
| Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain. | Arthritis research & therapy 20070101 |
| What do clinicians want? Interest in integrative health services at a North Carolina academic medical center. | BMC complementary and alternative medicine 20070101 |
| Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. | American journal of therapeutics 20070101 |
| Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. | Current topics in medicinal chemistry 20070101 |
| Exploring the potential chemopreventative effect of aspirin and rofecoxib on hereditary nonpolyposis colorectal cancer-like endometrial cancer cells in vitro through mechanisms involving apoptosis, the cell cycle, and mismatch repair gene expression. | International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20070101 |
| Mycobacterium avium-intracellulare cellulitis occurring with septic arthritis after joint injection: a case report. | BMC infectious diseases 20070101 |
| Rheumatoid peripheral blood phagocytes are primed for activation but have impaired Fc-mediated generation of reactive oxygen species. | Arthritis research & therapy 20070101 |
| Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. | Arthritis research & therapy 20070101 |
| Techniques for assessing knee joint pain in arthritis. | Molecular pain 20070101 |
| The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions. | Drug safety 20070101 |
| Emerging from the shadow of Vioxx. | Current topics in medicinal chemistry 20070101 |
| Increased prothrombin time and lactic acidosis: rofecoxib drug interaction with acenocoumarin and metformin. | Annals of cardiac anaesthesia 20070101 |
| Calotropis procera latex extract affords protection against inflammation and oxidative stress in Freund's complete adjuvant-induced monoarthritis in rats. | Mediators of inflammation 20070101 |
| Dual carbonic anhydrase--cyclooxygenase-2 inhibitors. | Current topics in medicinal chemistry 20070101 |
| Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. | Arthritis research & therapy 20070101 |
| Rebound pain scores as a function of femoral nerve block duration after anterior cruciate ligament reconstruction: retrospective analysis of a prospective, randomized clinical trial. | Regional anesthesia and pain medicine 20070101 |
| A proposed fairer method for conducting rofecoxib trials. | Medical hypotheses 20070101 |
| Arthritis and pain. Future targets to control osteoarthritis pain. | Arthritis research & therapy 20070101 |
| Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition. | Molecular vision 20070101 |
| Co-administration of rofecoxib and tramadol results in additive or sub-additive interaction during arthritic nociception in rat. | Pharmacology, biochemistry, and behavior 20070101 |
| New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: focus on use in the elderly. | Drugs & aging 20070101 |
| Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. | International journal of biological sciences 20070101 |
| Bayesian confidence propagation neural network. | Drug safety 20070101 |
| An economic model of long-term use of celecoxib in patients with osteoarthritis. | BMC gastroenterology 20070101 |
| Anti-inflammatory drugs in the 21st century. | Sub-cellular biochemistry 20070101 |
| COX-2 inhibitors and cardiovascular risk. | Sub-cellular biochemistry 20070101 |
| A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAids. | Sub-cellular biochemistry 20070101 |
| Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. | Breast cancer research : BCR 20070101 |
| Gabapentin and postoperative pain: a qualitative and quantitative systematic review, with focus on procedure. | BMC anesthesiology 20070101 |
| Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. | Breast cancer research : BCR 20070101 |
| The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent. | Cardiovascular toxicology 20070101 |
| Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. | BMC neuroscience 20070101 |
| Anti-inflammatory and side effects of cyclooxygenase inhibitors. | Pharmacological reports : PR 20070101 |
| Melanoma inhibition by cyclooxygenase inhibitors: role of interleukin-6 suppression, a putative mechanism of action, and clinical implications. | Medical oncology (Northwood, London, England) 20070101 |
| Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. | BMC musculoskeletal disorders 20070101 |
| Prostacyclin, atherothrombosis, and cardiovascular disease. | Current medicinal chemistry 20070101 |
| Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks. | Current pharmaceutical design 20070101 |
| Design and synthesis of new rofecoxib analogs as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of the methanesulfonyl pharmacophore by a N-acetylsulfonamido bioisostere. | Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20070101 |
| Anithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy. | Thrombosis journal 20070101 |
| The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. | BMC neurology 20070101 |
| Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. | Scandinavian journal of rheumatology 20070101 |
| The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. | PloS one 20070101 |
| Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention. | Cancer genomics & proteomics 20070101 |
| Modulation of hypericin photodynamic therapy by pretreatment with 12 various inhibitors of arachidonic acid metabolism in colon adenocarcinoma HT-29 cells. | Photochemistry and photobiology 20070101 |
| Family physicians' perceptions of academic detailing: a quantitative and qualitative study. | BMC medical education 20070101 |
| Single dose oral lumiracoxib for postoperative pain. | The Cochrane database of systematic reviews 20070101 |
| Comparison of glucosamine sulfate and a polyherbal supplement for the relief of osteoarthritis of the knee: a randomized controlled trial [ISRCTN25438351]. | BMC complementary and alternative medicine 20070101 |
| The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production. | Journal of carcinogenesis 20070101 |
| Prostacyclin, but not nitric oxide, is the major mediator of acetylcholine-induced vasodilatation in the isolated mouse heart. | Pharmacological reports : PR 20070101 |
| Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. | Arthritis research & therapy 20070101 |
| Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations. | Pharmacological reports : PR 20070101 |
| Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs. | Current pharmaceutical design 20070101 |
| Reflectance changes in clotting native blood: evidence of a red-cell process. | Pathophysiology of haemostasis and thrombosis 20070101 |
| Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. | Oncology 20070101 |
| Formulation and ex vivo evaluation of rofecoxib gel for topical application. | Acta poloniae pharmaceutica 20070101 |
| Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. | Journal of gastrointestinal cancer 20070101 |
| Global tumor RNA expression in early establishment of experimental tumor growth and related angiogenesis following COX-inhibition evaluated by microarray analysis. | Cancer informatics 20070101 |
| Robotic surgery: India is not ready yet. | Indian journal of urology : IJU : journal of the Urological Society of India 20070101 |
| Nonsteroidal anti-inflammatory drug hypersensitivity in preschool children. | Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20070101 |
| Clinical management of adult patients with a history of nonsteroidal anti-inflammatory drug-induced urticaria/angioedema: update. | Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 20070101 |
| Statistical fallacies in orthopedic research. | Indian journal of orthopaedics 20070101 |
| Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. | Core evidence 20070101 |
| Effect of cyclooxygenase inhibitors on pentylenetetrazol (PTZ)-induced convulsions: Possible mechanism of action. | Progress in neuro-psychopharmacology & biological psychiatry 20061230 |
| [Bartter syndrome--a rare cause of severe polyhydramnios]. | Ugeskrift for laeger 20061211 |
| Effects of non-steroidal anti-inflammatory drugs on cell proliferation and death in cultured epiphyseal-articular chondrocytes of fetal rats. | Toxicology 20061207 |
| Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. | Gut 20061201 |
| Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs). | Bioorganic & medicinal chemistry 20061201 |
| Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases. | Bioorganic & medicinal chemistry 20061201 |
| Nephrotoxicity with cyclooxygenase 2 inhibitor use in children. | Pediatric nephrology (Berlin, Germany) 20061201 |
| Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration. | The Journal of pharmacology and experimental therapeutics 20061201 |
| Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. | Drug metabolism and disposition: the biological fate of chemicals 20061201 |
| The impact of NSAID or COX-2 inhibitor use on the initiation of antihypertensive therapy. | Pharmacoepidemiology and drug safety 20061201 |
| Structure-based pharmacophore of COX-2 selective inhibitors and identification of original lead compounds from 3D database searching method. | European journal of medicinal chemistry 20061201 |
| Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. | Pharmacoepidemiology and drug safety 20061201 |
| A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. | Gastroenterology 20061201 |
| Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor potentiates the anticonvulsant activity of tiagabine against pentylenetetrazol-induced convulsions in mice. | Inflammopharmacology 20061201 |
| Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20061201 |
| Chemoprevention of colorectal cancer: two steps forward, one step back? | Future oncology (London, England) 20061201 |
| Open conflict on the handling of the Merck drug Vioxx by editorial giants. | Reproductive biomedicine online 20061201 |
| Rofecoxib provides relief of pain following third molar extractions. | The journal of evidence-based dental practice 20061201 |
| Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. | Journal of clinical pharmacy and therapeutics 20061201 |
| Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? | Gastroenterology 20061201 |
| Involvement of cyclooxygenase-1, prostaglandin E2 and EP1 receptors in acid-induced HCO3- secretion in stomach. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20061201 |
| Rofecoxib, diclofenac, and indomethacin increase risk of CVD. | The Journal of family practice 20061201 |
| Citrobacter rodentium infection causes iNOS-independent intestinal epithelial dysfunction in mice. | Canadian journal of physiology and pharmacology 20061201 |
| Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? | European journal of pharmacology 20061121 |
| Outcome of peptic ulcer bleeding among users of traditional non-steroidal anti-inflammatory drugs and selective cyclo-oxygenase-2 inhibitors. | Alimentary pharmacology & therapeutics 20061115 |
| Viewpoint: an explanation for the cardiovascular effects of bevacizumab and rofecoxib? | Circulation 20061107 |
| Pain after elective arthroscopy of the knee: a prospective, randomised, study comparing conventional NSAID to coxib. | Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA 20061101 |
| An analgesic model for assessment of acute pain response in osteoarthritis of the knee. | Osteoarthritis and cartilage 20061101 |
| Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. | Journal of cancer research and clinical oncology 20061101 |
| The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. | European journal of clinical pharmacology 20061101 |
| Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. | American journal of epidemiology 20061101 |
| Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? | International journal of clinical practice 20061101 |
| Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. | Arthritis and rheumatism 20061101 |
| Nonsteroidal anti-inflammatory drug-induced fracture nonunion: an inhibition of angiogenesis? | The Journal of bone and joint surgery. American volume 20061101 |
| Educating health professionals about drug and device promotion: advocates' recommendations. | PLoS medicine 20061101 |
| Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). | PLoS clinical trials 20061101 |
| ADAPT: the wrong way to stop a clinical trial. | PLoS clinical trials 20061101 |
| Possible role for human leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and cholestatic hepatitis. | Clinical pharmacology and therapeutics 20061101 |
| [The effects of refecoxib on inhibiting the growth and inducing apoptosis of hepatocellular carcinoma cell lines HepG2 and human normal liver cell line QSG7701]. | Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20061101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20061101 |
| Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20061101 |
| New warnings about painkillers, new advice on what you can do. | Heart advisor 20061101 |
| Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. | Biochemical and biophysical research communications 20061020 |
| Synthesis and biological evaluation of 1,3-diphenylprop-2-en-1-ones possessing a methanesulfonamido or an azido pharmacophore as cyclooxygenase-1/-2 inhibitors. | Bioorganic & medicinal chemistry 20061015 |
| Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndromes. | International journal of cardiology 20061010 |
| Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. | JAMA 20061004 |
| Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. | JAMA 20061004 |
| Surgically induced osteoarthritis in the rat results in the development of both osteoarthritis-like joint pain and secondary hyperalgesia. | Osteoarthritis and cartilage 20061001 |
| Prostaglandin/cyclooxygenase pathway in ghrelin-induced gastroprotection against ischemia-reperfusion injury. | The Journal of pharmacology and experimental therapeutics 20061001 |
| Risk of hospitalization for angio-oedema among users of newer COX-2 selective inhibitors and other nonsteroidal anti-inflammatory drugs. | British journal of clinical pharmacology 20061001 |
| Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? | Journal of hypertension 20061001 |
| Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. | Pharmacotherapy 20061001 |
| Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. | Clinical and experimental pharmacology & physiology 20061001 |
| COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. | Thrombosis and haemostasis 20061001 |
| Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor. | Thrombosis and haemostasis 20061001 |
| Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects. | Thrombosis and haemostasis 20061001 |
| Possible mechanisms of drug-induced aspirin and clopidogrel resistance. | Journal of thrombosis and thrombolysis 20061001 |
| Co-existence of spontaneous splenic rupture and tuberculosis of the spleen. | Saudi medical journal 20061001 |
| Evidence of the principle of similitude in modern fatal iatrogenic events. | Homeopathy : the journal of the Faculty of Homeopathy 20061001 |
| Response to 'Lapses at the NEJM'. | Journal of the Royal Society of Medicine 20061001 |
| Postoperative pain management after craniotomy: evaluation and cost analysis. | Neurosurgery 20061001 |
| Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals. | Die Pharmazie 20061001 |
| Possible mechanism for testicular focal necrosis induced by hCG in rats. | The Journal of toxicological sciences 20061001 |
| Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. | Harvard heart letter : from Harvard Medical School 20061001 |
| The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit. | European journal of pharmacology 20060928 |
| US judge dismisses 50m dollars damages in Vioxx lawsuit. | BMJ (Clinical research ed.) 20060909 |
| Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. | Pharmacoepidemiology and drug safety 20060901 |
| Effect of COX-2 inhibitors and non-steroidal anti-inflammatory drugs on a mouse fracture model. | Injury 20060901 |
| Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel injury in rats. | The Journal of surgical research 20060901 |
| Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report. | Human reproduction (Oxford, England) 20060901 |
| Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors. | Bioorganic & medicinal chemistry letters 20060901 |
| Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. | Haemophilia : the official journal of the World Federation of Hemophilia 20060901 |
| The NSAID roller coaster: more about rofecoxib. | British journal of clinical pharmacology 20060901 |
| Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. | British journal of clinical pharmacology 20060901 |
| Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships. | British journal of clinical pharmacology 20060901 |
| The effect of the withdrawal of rofecoxib on prescribing patterns of COX-2 inhibitors in Scotland. | British journal of clinical pharmacology 20060901 |
| Valdecoxib does not interfere with the CYP2D6 substrate metoprolol. | International journal of clinical pharmacology and therapeutics 20060901 |
| [A case of complete regression of hepatocellular carcinoma during administration of COX-2 inhibitor]. | The Korean journal of hepatology 20060901 |
| Ibuprofen as a pre-emptive analgesic is as effective as rofecoxib for mandibular third molar surgery. | Odontology 20060901 |
| Impact of cyclooxygenase inhibitors in the Women's Health Initiative hormone trials: secondary analysis of a randomized trial. | PLoS clinical trials 20060901 |
| Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain: Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studies. | Clinical therapeutics 20060901 |
| Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort. | The American journal of geriatric pharmacotherapy 20060901 |
| [What do we know about the cardiovascular toxicity of the NSAIDs?]. | Presse medicale (Paris, France : 1983) 20060901 |
| [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. | Presse medicale (Paris, France : 1983) 20060901 |
| [The role of cyclooxygenase on angiogenesis and endothelial progenitor cell mobilization in rat ischemic myocardium]. | Zhonghua xin xue guan bing za zhi 20060901 |
| Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. | Vascular health and risk management 20060901 |
| [What do we know about the cardiovascular toxicity of the NSAIDs?]. | Presse medicale (Paris, France : 1983) 20060901 |
| [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. | Presse medicale (Paris, France : 1983) 20060901 |
| The use of combination therapies in the acute management of migraine. | Neuropsychiatric disease and treatment 20060901 |
| [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib]. | Medizinische Klinik (Munich, Germany : 1983) 20060815 |
| [How many harmed by rofecoxib in Germany?]. | Medizinische Klinik (Munich, Germany : 1983) 20060815 |
| [Overestimated]. | Medizinische Klinik (Munich, Germany : 1983) 20060815 |
| An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models. | European journal of pain (London, England) 20060801 |
| A selective COX-2 inhibitor suppresses chronic pancreatitis in an animal model (WBN/Kob rats): significant reduction of macrophage infiltration and fibrosis. | Gut 20060801 |
| Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats. | Drug metabolism and disposition: the biological fate of chemicals 20060801 |
| Roles of endogenous prostaglandins and cyclooxygenase isozymes in healing of indomethacin-induced small intestinal lesions in rats. | The Journal of pharmacology and experimental therapeutics 20060801 |
| Upregulation of cerebrospinal fluid and peripheral prostaglandin E2 in a rat postoperative pain model. | Anesthesia and analgesia 20060801 |
| The COX-2 inhibitors--an update. | American heart journal 20060801 |
| The effect of gabapentin on post-operative pain following tonsillectomy in adults. | Acta anaesthesiologica Scandinavica 20060801 |
| Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. | BJU international 20060801 |
| Vioxx should be allowed back on the market advises expert panel. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060801 |
| Lapses at the new England journal of medicine. | Journal of the Royal Society of Medicine 20060801 |
| Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060801 |
| Combining paracetamol with a selective cyclooxygenase-2 inhibitor for acute pain relief after third molar surgery: a randomized, double-blind, placebo-controlled study. | European journal of oral sciences 20060801 |
| The COX-2 controversy continues ...but NSAIDs are still in the lead. New studies shed light on risks associated with popular arthritis painkillers. | Health news (Waltham, Mass.) 20060801 |
| Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2. | Nature clinical practice. Rheumatology 20060801 |
| Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20060801 |
| [Relationship between the central nervous system injury and the heterotopic ossification]. | Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 20060801 |
| How specific are 'target-specific' drugs? Celecoxib as a case in point. | Molecular interventions 20060801 |
| Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. | Clinical therapeutics 20060801 |
| Galactose derivative immobilized glow discharge processed polyethersulfone membranes maintain the liver cell metabolic activity. | Journal of nanoscience and nanotechnology 20060801 |
| NEJM 'failed its readers' by delay in publishing its concerns about VIGOR trial. | BMJ (Clinical research ed.) 20060715 |
| Time-to-event analyses for long-term treatments--the APPROVe trial. | The New England journal of medicine 20060713 |
| Adverse cardiovascular effects of rofecoxib. | The New England journal of medicine 20060713 |
| Adverse cardiovascular effects of rofecoxib. | The New England journal of medicine 20060713 |
| Therapy switching and associated costs in elderly patients receiving COX-2 selective inhibitors or non-selective non-steroidal anti-inflammatory drugs in Quebec, Canada. | Rheumatology (Oxford, England) 20060701 |
| Increased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20060701 |
| Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan. | Neuropharmacology 20060701 |
| The Wnt-dependent signaling pathways as target in oncology drug discovery. | Investigational new drugs 20060701 |
| Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. | Stroke 20060701 |
| Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases. | Gut 20060701 |
| Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. | Alimentary pharmacology & therapeutics 20060701 |
| Gastric mucosal cell model for estimating relative gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. | Prostaglandins, leukotrienes, and essential fatty acids 20060701 |
| Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. | Current medical research and opinion 20060701 |
| Rationality of drug uses: its Bangladeshi perspectives. | Mymensingh medical journal : MMJ 20060701 |
| Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography. | Die Pharmazie 20060701 |
| Patient retention in a clinical trial: a lesson from the rofecoxib (VIOXX) study. | Digestive diseases and sciences 20060701 |
| Factors involved in upregulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs. | Digestive diseases and sciences 20060701 |
| [Cyclooxygenase inhibitors: a never ending story?]. | Giornale italiano di cardiologia (2006) 20060701 |
| Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies. | Clinical therapeutics 20060701 |
| Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. | Circulation 20060627 |
| Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia. | Bioorganic & medicinal chemistry letters 20060615 |
| Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. | Journal of the National Cancer Institute 20060607 |
| Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor. | European journal of pharmacology 20060606 |
| Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. | Neuropharmacology 20060601 |
| Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee. | Rheumatology (Oxford, England) 20060601 |
| Getting it right: being smarter about clinical trials. | PLoS medicine 20060601 |
| Effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, on various biochemical parameters of brain associated with pentylenetetrazol-induced chemical kindling in mice. | Fundamental & clinical pharmacology 20060601 |
| Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. | Melanoma research 20060601 |
| Patient empowerment: rofecoxib revisited. | The Journal of rheumatology 20060601 |
| The patient's perspective on the recall of Vioxx. | The Journal of rheumatology 20060601 |
| Effect of indomethacin and selective cyclooxygenase-2 inhibitors on proteinuria and renal function in patients with AA type renal amyloidosis. | Nephrology (Carlton, Vic.) 20060601 |
| Cold leg in patient with high coated platelets: possible association with the use of rofecoxib. | The Journal of invasive cardiology 20060601 |
| Low-intensity electromagnetic millimeter waves for pain therapy. | Evidence-based complementary and alternative medicine : eCAM 20060601 |
| Cyclooxygenase-2 inhibitors: a painful lesson. | Cardiovascular & hematological disorders drug targets 20060601 |
| Merck's actions surrounding Vioxx. | PLoS medicine 20060601 |
| Formulation and optimization of mouth dissolve tablets containing rofecoxib solid dispersion. | AAPS PharmSciTech 20060601 |
| Experimental study of the action of COX-2 selective nonsteroidal anti-inflammatory drugs and traditional anti-inflammatory drugs in bone regeneration. | Clinics (Sao Paulo, Brazil) 20060601 |
| Changes in the immune system in depression and dementia: causal or coincidental effects? | Dialogues in clinical neuroscience 20060601 |
| Detection of overexpressed COX-2 in precancerous lesions of hamster pancreas and lungs by molecular imaging: implications for early diagnosis and prevention. | ChemMedChem 20060601 |
| Risk of cardiovascular events and cyclooxygenase-2 inhibitors. | Vascular health and risk management 20060601 |
| [Cyclooxygenase-2: a new therapeutic target in atherosclerosis?]. | Medicina clinica 20060527 |
| Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060523 |
| Balancing the cyclooxygenase portfolio. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060523 |
| Why the data diverge on the dangers of Vioxx: even in medical journals, statistics can be subject to broad interpretation. | The New York times on the Web 20060522 |
| How does a painkiller harm the heart? | Nature 20060518 |
| Celecoxib shown effective in preventing colon polyps. | Journal of the National Cancer Institute 20060517 |
| Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060515 |
| [COX-2 inhibitors and other non-steroidal anti-inflammatory agents--what is their future?]. | Ugeskrift for laeger 20060515 |
| How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as 'punching bag'. | Wall Street journal (Eastern ed.) 20060515 |
| [The withdrawal of Vioxx: how did the patients react?]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20060511 |
| Dispute over Vioxx study plays out in New England journal. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060509 |
| Evaluating drug effects in the post-Vioxx world: there must be a better way. | Circulation 20060509 |
| Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs. | Circulation 20060509 |
| RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells. | British journal of cancer 20060508 |
| [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences]. | Nederlands tijdschrift voor geneeskunde 20060506 |
| Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. | Blood 20060501 |
| Intracellular degradation of insulin and crinophagy are maintained by nitric oxide and cyclo-oxygenase 2 activity in isolated pancreatic islets. | Biology of the cell 20060501 |
| Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum. | Molecular pharmacology 20060501 |
| Lessons on ethical decision making from the bioscience industry. | PLoS medicine 20060501 |
| Update on nonsteriodal anti-inflammatory drugs. | Current opinion in rheumatology 20060501 |
| Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. | The Journal of rheumatology 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. | Arthritis and rheumatism 20060501 |
| Genetically mediated interindividual variation in analgesic responses to cyclooxygenase inhibitory drugs. | Clinical pharmacology and therapeutics 20060501 |
| Rofecoxib-induced hepatotoxicity: a forgotten complication of the coxibs. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20060501 |
| Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach. | Urology 20060501 |
| Simultaneous determination of celecoxib, meloxicam, and rofecoxib using capillary electrophoresis with surfactant and application in drug formulations. | Journal of separation science 20060501 |
| Principles for strengthening the integrity of clinical research. | PLoS clinical trials 20060501 |
| The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. | Current drug safety 20060501 |
| Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. | Circulation 20060425 |
| Court awards claimant 13.5m dollars in rofecoxib lawsuit. | BMJ (Clinical research ed.) 20060422 |
| Herbal medicine for low back pain. | The Cochrane database of systematic reviews 20060419 |
| Design, synthesis, and biological evaluation of 1,3-diarylprop-2-en-1-ones : a novel class of cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry 20060415 |
| Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation. | Modern healthcare 20060410 |
| Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. | AIDS (London, England) 20060404 |
| The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial. | European journal of obstetrics, gynecology, and reproductive biology 20060401 |
| COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003. | The British journal of oral & maxillofacial surgery 20060401 |
| Clinical trials in mild cognitive impairment: lessons for the future. | Journal of neurology, neurosurgery, and psychiatry 20060401 |
| Role of the different isoforms of cyclooxygenase and nitric oxide synthase during gastric ulcer healing in cyclooxygenase-1 and -2 knockout mice. | American journal of physiology. Gastrointestinal and liver physiology 20060401 |
| The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. | American journal of physiology. Heart and circulatory physiology 20060401 |
| Bias from industry trial funding? A framework, a suggested approach, and a negative result. | Pain 20060401 |
| Effect of cyclooxygenase inhibitors on the micturition reflex in rats: correlation with inhibition of cyclooxygenase isozymes. | BJU international 20060401 |
| Dementia and its implications for public health. | Preventing chronic disease 20060401 |
| The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus. | Alimentary pharmacology & therapeutics 20060401 |
| Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors. | Clinical pharmacology and therapeutics 20060401 |
| Rofecoxib versus hydrocodone/acetaminophen for postoperative analgesia in functional endoscopic sinus surgery. | The Laryngoscope 20060401 |
| Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? | Naunyn-Schmiedeberg's archives of pharmacology 20060401 |
| Disease mongering in drug promotion: do governments have a regulatory role? | PLoS medicine 20060401 |
| COX-2 inhibitors and the heart: are all coxibs the same? | Postgraduate medical journal 20060401 |
| Comparison of adjunctive use of rofecoxib versus ibuprofen in the management of postoperative pain after uterine artery embolization. | Journal of vascular and interventional radiology : JVIR 20060401 |
| Effect of cyclooxygenase-2 (COX-2) inhibitors in various animal models (bicuculline, picrotoxin, maximal electroshock-induced convulsions) of epilepsy with possible mechanism of action. | Indian journal of experimental biology 20060401 |
| Products of cyclooxygenase-2 depress duodenal function in rats subjected to abdominal surgery. | Acta physiologica (Oxford, England) 20060401 |
| Ultrasonic vocalization response elicited in adjuvant-induced arthritic rats as a useful method for evaluating analgesic drugs. | Experimental animals 20060401 |
| Extract of the bristles of Dirphia sp. increases nitric oxide in a rat pleurisy model. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20060401 |
| Are there differences in the renal effects of selective cyclo-oxygenase 2 inhibitors? | Nature clinical practice. Nephrology 20060401 |
| A randomized, double-blind, placebo-controlled trial of a COX-2 inhibitor (Rofecoxib) in patients undergoing coronary artery bypass surgery. | Interactive cardiovascular and thoracic surgery 20060401 |
| Protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) on immobilization stress-induced behavioral and biochemical alterations in mice. | European journal of pharmacology 20060327 |
| Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. | British journal of cancer 20060327 |
| [Intestinal side effects of COX-2 inhibitors]. | Ugeskrift for laeger 20060327 |
| Expression of concern reaffirmed. | The New England journal of medicine 20060316 |
| Response to expression of concern regarding VIGOR study. | The New England journal of medicine 20060316 |
| Make or break time in Vioxx drama. | Nature 20060316 |
| Response to expression of concern regarding VIGOR study. | The New England journal of medicine 20060316 |
| A message from the Vioxx case. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060315 |
| [Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004]. | Medizinische Klinik (Munich, Germany : 1983) 20060315 |
| Molecular dynamics simulations of arachidonic acid-derived pentadienyl radical intermediate complexes with COX-1 and COX-2: insights into oxygenation regio- and stereoselectivity. | Biochemistry 20060314 |
| Vioxx doctors wooed by Merck are now its foes. | Wall Street journal (Eastern ed.) 20060310 |
| Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. | Journal of medicinal chemistry 20060309 |
| NEJM stands by its criticism of Vioxx study. | BMJ (Clinical research ed.) 20060304 |
| Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy. | Blood 20060301 |
| Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060301 |
| Does perioperative administration of rofecoxib improve analgesia after spine, breast and orthopaedic surgery? | European journal of anaesthesiology 20060301 |
| Cyclooxygenase-2 (PTGS2) inhibitors augment the rate of hexose transport in L6 myotubes in an insulin- and AMPKalpha-independent manner. | Diabetologia 20060301 |
| Cyclooxygenase-2 inhibitors: what went wrong? | Current opinion in clinical nutrition and metabolic care 20060301 |
| Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. | Journal of the Royal Society of Medicine 20060301 |
| Upregulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. | Anesthesiology 20060301 |
| Observational studies and the withdrawal of rofecoxib. | Pharmacoepidemiology and drug safety 20060301 |
| Constriction of the ductus arteriosus by selective inhibition of cyclooxygenase-1 and -2 in near-term and preterm fetal rats. | Prostaglandins & other lipid mediators 20060301 |
| Orthodontic tooth movement after inhibition of cyclooxygenase-2. | American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 20060301 |
| What are the public health effects of direct-to-consumer drug advertising? | PLoS medicine 20060301 |
| Preoperative administration of rofecoxib versus ketoprofen for pain relief after tonsillectomy. | The Annals of otology, rhinology, and laryngology 20060301 |
| Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. | Basic & clinical pharmacology & toxicology 20060301 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060301 |
| A comparative study on the efficacy of rofecoxib in monoarticular arthritis induced by latex of Calotropis procera and Freund's complete adjuvant. | Inflammopharmacology 20060301 |
| Etoricoxib for arthritis and pain management. | Therapeutics and clinical risk management 20060301 |
| Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib? | Arthritis and rheumatism 20060215 |
| The vexations of Vioxx. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060214 |
| COX inhibitors and breast cancer. | British journal of cancer 20060213 |
| NEJM editor gives pretrial evidence in Vioxx case. | BMJ (Clinical research ed.) 20060204 |
| Roles of cyclooxygenase-2 and prostacyclin/IP receptors in mucosal defense against ischemia/reperfusion injury in mouse stomach. | The Journal of pharmacology and experimental therapeutics 20060201 |
| [Adverse drugs reactions: diagnosis and assessment]. | Der Pathologe 20060201 |
| Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2 selective agents with and without inhibitory potency against carbonic anhydrase II. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20060201 |
| Postsurgical safety of opioid-sparing cyclooxygenase-2 inhibitors. | Anesthesiology 20060201 |
| tNOX, an alternative target to COX-2 to explain the anticancer activities of non-steroidal anti-inflammatory drugs (NSAIDS). | Molecular and cellular biochemistry 20060201 |
| Ocular adverse effects associated with cyclooxygenase-2 inhibitors. | Archives of ophthalmology (Chicago, Ill. : 1960) 20060201 |
| Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20060201 |
| Potentiation of antinociceptive effect of NSAIDs by a specific lipooxygenase inhibitor, acetyl 11-keto-beta boswellic acid. | Indian journal of experimental biology 20060201 |
| Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20060201 |
| Rofecoxib in the acute treatment of migraine: a randomized controlled clinical trial. | Headache 20060201 |
| [Pseudoporphyria and coxib]. | Annales de dermatologie et de venereologie 20060201 |
| Rofecoxib in mild cognitive impairment. | Current psychiatry reports 20060201 |
| Effects of a cyclooxygenase-2 inhibitor (rofecoxib) on bone healing. | American journal of orthopedics (Belle Mead, N.J.) 20060201 |
| Acetaminophen for osteoarthritis. | The Cochrane database of systematic reviews 20060125 |
| Synthesis of a NO-releasing prodrug of rofecoxib. | The Journal of organic chemistry 20060120 |
| A fall from grace. Cleveland clinic's ethical lapses put spotlight on healthcare conflicts of interest. | Modern healthcare 20060109 |
| An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. | The Journal of rheumatology 20060101 |
| Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. | Arthritis research & therapy 20060101 |
| Gabapentin: an alternative to the cyclooxygenase-2 inhibitors for perioperative pain management. | Anesthesia and analgesia 20060101 |
| Pharmacological strategies for the prevention of Alzheimer's disease. | Expert opinion on pharmacotherapy 20060101 |
| More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. | Arthritis and rheumatism 20060101 |
| [Role of cyclo-oxygenases in the effects of angiotensin II]. | Medecine sciences : M/S 20060101 |
| Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients? | Alimentary pharmacology & therapeutics 20060101 |
| Prostanoid receptor EP1 and Cox-2 in injured human nerves and a rat model of nerve injury: a time-course study. | BMC neurology 20060101 |
| Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies. | Current medical research and opinion 20060101 |
| Cyclooxygenase-2 induction after oral surgery does not entirely account for analgesia after selective blockade of cyclooxygenase 2 in the preoperative period. | Anesthesiology 20060101 |
| Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. | Clinical cancer research : an official journal of the American Association for Cancer Research 20060101 |
| Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making. | Journal of clinical pharmacology 20060101 |
| Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. | Gastroenterology 20060101 |
| Chemoprevention of colorectal cancer with nonsteroidal anti-inflammatory drugs. | Chinese journal of digestive diseases 20060101 |
| Postoperative pain scores and analgesic requirements after thyroid surgery: comparison of three intraoperative opioid regimens. | International journal of medical sciences 20060101 |
| Reply to the Vioxx debacle. | The American journal of medicine 20060101 |
| Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20060101 |
| Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. | BMC cancer 20060101 |
| Decisions without blinders. | Harvard business review 20060101 |
| NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. | Drug safety 20060101 |
| First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]. | Arthritis research & therapy 20060101 |
| Reversible attenuation of the ECG voltage due to peripheral edema associated with treatment with a COX-2 inhibitor. | Congestive heart failure (Greenwich, Conn.) 20060101 |
| Dexamethasone impairs the gastric mucosal integrity in rats treated with a cyclooxygenase-1 but not with a cyclooxygenase-2 inhibitor. | Pharmacology 20060101 |
| Physician, divest thyself. | The American journal of bioethics : AJOB 20060101 |
| Effects of the selective cyclooxygenase-2 inhibitor rofecoxib on cell death following traumatic brain injury in the rat. | Restorative neurology and neuroscience 20060101 |
| Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. | Drug safety 20060101 |
| Cyclooxygenase inhibitory natural products: current status. | Current medicinal chemistry 20060101 |
| Coxibs and cardiovascular side-effects: from light to shadow. | Current pharmaceutical design 20060101 |
| Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk. | Arthritis research & therapy 20060101 |
| Evaluation of the effect of perioperative rofecoxib treatment on pain control and clinical outcomes in patients recovering from gynecologic abdominal surgery: a randomized, double-blind, placebo-controlled clinical study. | Regional anesthesia and pain medicine 20060101 |
| Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. | European annals of allergy and clinical immunology 20060101 |
| Do coxibs reduce prescription of gastroprotective agents? Results of a record linkage study. | Cost effectiveness and resource allocation : C/E 20060101 |
| Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. | Journal of neuroinflammation 20060101 |
| Cyclooxygenase expression is not required for release of arachidonic acid from cells by some nonsteroidal anti-inflammatory drugs and cancer preventive agents. | BMC pharmacology 20060101 |
| Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients. | Journal of investigational allergology & clinical immunology 20060101 |
| The chrondoprotective actions of a natural product are associated with the activation of IGF-1 production by human chondrocytes despite the presence of IL-1beta. | BMC complementary and alternative medicine 20060101 |
| [The case of rofecoxib(Vioxx)-what do we learn from this case]. | Duodecim; laaketieteellinen aikakauskirja 20060101 |
| NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression. | Toxicologic pathology 20060101 |
| Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. | Arthritis research & therapy 20060101 |
| NSAID-associated dyspepsia and ulcers: a prospective cohort study in primary care. | Digestive diseases (Basel, Switzerland) 20060101 |
| Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. | Molecular cancer 20060101 |
| Laparoscopic cholecystectomy and management of biliary tract stones in a freestanding ambulatory surgery center. | JSLS : Journal of the Society of Laparoendoscopic Surgeons 20060101 |
| Anti-inflammatory and immunosuppressive drugs and reproduction. | Arthritis research & therapy 20060101 |
| Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. | Radiation oncology (London, England) 20060101 |
| Gitelman-like syndrome after cisplatin therapy: a case report and literature review. | BMC nephrology 20060101 |
| Enhanced plasma concentration by selective deuteration of rofecoxib in rats. | Arzneimittel-Forschung 20060101 |
| Accounting for the increase in NSAID expenditure: substitution or leakage? | Cost effectiveness and resource allocation : C/E 20060101 |
| The next epidemic. | Genome biology 20060101 |
| Update on guidelines for the treatment of chronic musculoskeletal pain. | Clinical rheumatology 20060101 |
| [Postoperative pain management in clinics of otolaryngology]. | Kulak burun bogaz ihtisas dergisi : KBB = Journal of ear, nose, and throat 20060101 |
| Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial. | American journal of therapeutics 20060101 |
| Nitronaproxen: AZD 3582, HCT 3012, Naproxen Nitroxybutylester, NO-Naproxen. | Drugs in R&D 20060101 |
| Blood pressure effects of COX-2 inhibitors. | Journal of cardiovascular pharmacology 20060101 |
| Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. | Journal of cardiovascular pharmacology 20060101 |
| Increase in nonfatal digestive perforations and haemorrhages following introduction of selective NSAIDs: a public health concern. | Drug safety 20060101 |
| Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. | Drug safety 20060101 |
| Chemopreventive effects of rofecoxib and folic acid on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. | Chinese journal of digestive diseases 20060101 |
| COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation. | Anticancer research 20060101 |
| Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. | BMC cancer 20060101 |
| Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. | Drugs 20060101 |
| Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. | Drug safety 20060101 |
| Effect of a selective cyclooxygenase-2 inhibitor on renal scarring. | European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes 20060101 |
| Nociceptors in cardiovascular functions: complex interplay as a result of cyclooxygenase inhibition. | Molecular pain 20060101 |
| The Vioxx story: would it have ended differently in the European Union? | American journal of law & medicine 20060101 |
| Use and perceived benefits of handheld computer-based clinical references. | Journal of the American Medical Informatics Association : JAMIA 20060101 |
| C-reactive protein (CRP)-lowering agents. | Cardiovascular drug reviews 20060101 |
| Does rofecoxib increase TNF-alpha levels? | Clinical and experimental rheumatology 20060101 |
| How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. | Health affairs (Project Hope) 20060101 |
| [Problems of cardiovascular toxicity of coxibs and non-selective NSA]. | Vnitrni lekarstvi 20060101 |
| Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. | BMC medicine 20060101 |
| Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. | Arthritis research & therapy 20060101 |
| Responding rapidly to FDA drug withdrawals: design and application of a new approach for a consumer health website. | Journal of medical Internet research 20060101 |
| The radiation response of sarcomas by histologic subtypes: a review with special emphasis given to results achieved with razoxane. | Sarcoma 20060101 |
| Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. | BMC musculoskeletal disorders 20060101 |
| The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry. | Journal of anesthesia 20060101 |
| Impact of rofecoxib withdrawal on cyclooxygenase-2 utilization among patients with and without cardiovascular risk. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20060101 |
| Effect of Gabapentin on morphine demand and pain after laparoscopic sterilization using Filshie clips. A double blind randomized clinical trial. | BMC anesthesiology 20060101 |
| Anticipating a Vioxx defense strategy: will corporate honesty be enough? | Tort trial & insurance practice law journal 20060101 |
| Immunohistochemical measurement of endothelial cell apoptosis and proliferation in formalin-fixed, paraffin-embedded human cancer tissue. | Angiogenesis 20060101 |
| Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. | Arthritis research & therapy 20060101 |
| Prophylactic COX 2 inhibitor: an end to the Yom Kippur headache. | Headache 20060101 |
| Arthritis and pain. Neurogenic origin of joint pain. | Arthritis research & therapy 20060101 |
| [Effects of specific cycloxygenase-2 inhibition on the renal functions of ederly patients with renal function impairment]. | Casopis lekaru ceskych 20060101 |
| Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. | BMC neuroscience 20060101 |
| Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine intravenous patient-controlled analgesia. | Regional anesthesia and pain medicine 20060101 |
| Healing impairment effect of cyclooxygenase inhibitors on dextran sulfate sodium-induced colitis in rats. | Digestion 20060101 |
| Parecoxib is neuroprotective in spontaneously hypertensive rats after transient middle cerebral artery occlusion: a divided treatment response? | Journal of neuroinflammation 20060101 |
| Use of nonsteroidal anti-inflammatory drugs in patients with aspirin hypersensitivity : safety of cyclo-oxygenase-2 inhibitors. | Treatments in respiratory medicine 20060101 |
| A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. | PloS one 20060101 |
| Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: experience of an Italian drug-surveillance center. | Journal of cutaneous medicine and surgery 20060101 |
| Relationship between human leucocyte antigen class I and class II and chronic idiopathic urticaria associated with aspirin and/or NSAIDs hypersensitivity. | Mediators of inflammation 20060101 |
| A case of intranasal meningocele. | McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students 20060101 |
| Collagen biomarkers for arthritis applications. | Biomarker insights 20060101 |
| C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation. | Biomarker insights 20060101 |
| The immune system in atherosclerosis and in acute myocardial infarction. | Heart international 20060101 |
| What clinical pharmacology means to us. | Mens sana monographs 20060101 |
| Expression of concern: Bombardier et al., 'Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,' N Engl J Med 2000;343:1520-8. | The New England journal of medicine 20051229 |
| Merck opts for shake-up to clear drug pipeline. | Nature 20051222 |
| Scientific publishing. Echoing other cases, NEJM says Vioxx Safety data withheld. | Science (New York, N.Y.) 20051216 |
| Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. | Arthritis and rheumatism 20051215 |
| Journal grows suspicious of Vioxx data. | Nature 20051215 |
| Inhibition of Calotropis procera latex-induced inflammatory hyperalgesia by oxytocin and melatonin. | Mediators of inflammation 20051214 |
| Manipulating a journal article. | The New York times on the Web 20051211 |
| Medical journal criticizes Merck over Vioxx data. | The New York times on the Web 20051209 |
| Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. | Pain 20051205 |
| Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. | BMJ (Clinical research ed.) 20051203 |
| Prospective randomized, double-blinded, placebo-controlled trial of preoperative rofecoxib for pain relief in uterine curettage. | Archives of gynecology and obstetrics 20051201 |
| Design, synthesis, and biological evaluation of linear 1-(4-, 3- or 2-methylsulfonylphenyl)-2-phenylacetylenes: a novel class of cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry 20051201 |
| Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. | The Journal of pharmacology and experimental therapeutics 20051201 |
| A new method of oral drug provocation testing for determining safe alternatives for patients with non-steroidal anti-inflammatory drug intolerance: the triple test. | International archives of allergy and immunology 20051201 |
| Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus. | Pediatric nephrology (Berlin, Germany) 20051201 |
| Assessment of the effects of the cyclooxygenase-2 inhibitor rofecoxib on visuospatial learning and hippocampal cell death following kainate-induced seizures in the rat. | Brain research. Cognitive brain research 20051201 |
| An update on nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors. | Current pain and headache reports 20051201 |
| Continuous femoral nerve blockade or epidural analgesia after total knee replacement: a prospective randomized controlled trial. | Anesthesia and analgesia 20051201 |
| Protective effect of cyclooxygenase-2 (COX-2) inhibitors but not non-selective cyclooxygenase (COX)-inhibitors on ethanol withdrawal-induced behavioural changes. | Addiction biology 20051201 |
| The Systemic Theory of Living Systems. Part IV: Systemic Medicine--The Praxis. | Evidence-based complementary and alternative medicine : eCAM 20051201 |
| Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs. | Joint, bone, spine : revue du rhumatisme 20051201 |
| NSAIDs and cardiovascular risk. | Cell metabolism 20051201 |
| Efficacy and safety of fast-track recovery strategy for patients undergoing laparoscopic nephrectomy. | Journal of endourology 20051201 |
| Use of cyclooxygenase-2 inhibitor for prevention of urethral strictures secondary to transurethral resection of the prostate. | Urology 20051201 |
| Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population. | Journal of Korean medical science 20051201 |
| A new therapeutic approach in patients with advanced sarcoma. | International journal of clinical oncology 20051201 |
| ['Wise be aware of your sayings'--about gaps between epidemiological data base, experimental results and decision making in health administration]. | Harefuah 20051201 |
| Safety update: a year after Vioxx. | The Johns Hopkins medical letter health after 50 20051201 |
| Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers. | Canadian journal of physiology and pharmacology 20051201 |
| Five fixes to improve drug safety. Ideas for how to prevent another Vioxx debacle. | Minnesota medicine 20051201 |
| Inhibition of prostaglandin F(2alpha) by selective cyclooxygenase 2 inhibitors accounts for reduced rat leukocyte migration. | Inflammation 20051201 |
| More bad news about anti-inflammatory agents. | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20051201 |
| Spin cycles. Healthcare marketing-communications efforts have taken on increasing strategic importance. | Modern healthcare 20051121 |
| How Vioxx is changing US drug regulation. | Lancet (London, England) 20051119 |
| Merck cleared in personal injury case against Vioxx. | BMJ (Clinical research ed.) 20051112 |
| Causation, Vioxx, and legal issues. | Science (New York, N.Y.) 20051111 |
| Grapefruit-seed extract attenuates ethanol-and stress-induced gastric lesions via activation of prostaglandin, nitric oxide and sensory nerve pathways. | World journal of gastroenterology 20051107 |
| Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors. | Journal of medicinal chemistry 20051103 |
| Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. | Bioorganic & medicinal chemistry letters 20051101 |
| Pharmacological investigation of trimetazidine in models of inflammation, pain and gastric injury in rodents. | Pharmacology 20051101 |
| Importance of the pineal gland, endogenous prostaglandins and sensory nerves in the gastroprotective actions of central and peripheral melatonin against stress-induced damage. | Journal of pineal research 20051101 |
| Cyclooxygenase-2 inhibitors. | Current opinion in gastroenterology 20051101 |
| Beyond trial registration: a global trial bank for clinical trial reporting. | PLoS medicine 20051101 |
| A real time quantitative PCR analysis and correlation of COX-1 and COX-2 enzymes in inflamed dental pulps following administration of three different NSAIDs. | Journal of endodontics 20051101 |
| Celecoxib and cardiovascular risks. | Expert opinion on drug safety 20051101 |
| COX-2 inhibitors and the heart: putting risk in perspective. | Advance for nurse practitioners 20051101 |
| Cardiovascular issues of COX-2 inhibitors and NSAIDs. | Australian family physician 20051101 |
| [Rofecoxib increases myocardial infarction risk in seniors]. | Medizinische Monatsschrift fur Pharmazeuten 20051101 |
| Worsening effect of partial sleep deprivation on indomethacin-induced gastric mucosal damage. | Pharmacology, biochemistry, and behavior 20051101 |
| [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases]. | Yao xue xue bao = Acta pharmaceutica Sinica 20051101 |
| Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? | Nature clinical practice. Neurology 20051101 |
| Effect of early statin and selective cyclooxygenase-2 inhibitor therapy on C-reactive protein level after percutaneous coronary angioplasty in unstable angina. | EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20051101 |
| The cardiovascular safety of celecoxib. | Future cardiology 20051101 |
| Medicine as a corporate enterprise, patient welfare centered profession, or patient welfare centered professional enterprise? | Mens sana monographs 20051101 |
| Molecular targets of dietary polyphenols with anti-inflammatory properties. | Yonsei medical journal 20051031 |
| Ischemic preconditioning inhibits development of edematous cerulein-induced pancreatitis: involvement of cyclooxygenases and heat shock protein 70. | World journal of gastroenterology 20051014 |
| Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis. | The New Zealand medical journal 20051007 |
| Cancer chemoprevention: lessons learned and future directions. | British journal of cancer 20051003 |
| Protective role of heat shock protein 27 in gastric mucosal injury. | The Journal of pathology 20051001 |
| A general method for the synthesis of aryl [11C]methylsulfones: potential PET probes for imaging cyclooxygenase-2 expression. | Bioorganic & medicinal chemistry letters 20051001 |
| Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. | The Journal of clinical endocrinology and metabolism 20051001 |
| Comparison of conventional NSAIDs and cyclooxygenase-2 inhibitors in outpatients. | Joint, bone, spine : revue du rhumatisme 20051001 |
| Effect of warmed, humidified insufflation gas and anti-inflammatory agents on cytokine response to laparoscopic nephrectomy: porcine model. | The Journal of urology 20051001 |
| Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? | Journal of neurology, neurosurgery, and psychiatry 20051001 |
| Mechanism of the solution oxidation of rofecoxib under alkaline conditions. | Pharmaceutical research 20051001 |
| Analgesic efficacy of rofecoxib compared with codeine/acetaminophen using a model of acute dental pain. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20051001 |
| Essay: the political logic of regulatory error. | Nature reviews. Drug discovery 20051001 |
| Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. | Journal of general internal medicine 20051001 |
| Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. | Thorax 20051001 |
| A randomized, placebo-controlled study of rofecoxib with paracetamol in early post-tonsillectomy pain in adults. | European journal of anaesthesiology 20051001 |
| Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. | The oncologist 20051001 |
| Implications of the rofecoxib trials. | Managed care interface 20051001 |
| Celecoxib still on the market: but for whose benefit? | Prescrire international 20051001 |
| Preoperative oral rofecoxib and postoperative pain in patients after laparoscopic cholecystectomy: a prospective, randomized, double-blinded, placebo-controlled trial. | The American surgeon 20051001 |
| [Celecoxib-induced aquagenic keratoderma]. | Actas dermo-sifiliograficas 20051001 |
| The lessons of Vioxx. | The New England journal of medicine 20050929 |
| Vioxx award good news for Canadian lawsuits. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050927 |
| An overview of the recent developments in analytical methodologies for determination of COX-2 inhibitors in bulk drugs, pharmaceuticals and biological matrices. | Journal of pharmaceutical and biomedical analysis 20050915 |
| Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? | The American journal of cardiology 20050915 |
| High-performance liquid chromatography method for the quantification of entacapone in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050905 |
| Merck faces ongoing claims after Texan ruling on rofecoxib. | BMJ (Clinical research ed.) 20050903 |
| The law. Vioxx verdict: too little or too much science? | Science (New York, N.Y.) 20050902 |
| The influence of anti-inflammatory drugs on the proliferation of fibroblast derived from nasal polyps. | Auris, nasus, larynx 20050901 |
| Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. | Journal of molecular and cellular cardiology 20050901 |
| A double-blind, placebo controlled comparison of the morphine sparing effect of oral rofecoxib and diclofenac for acute renal colic. | The Journal of urology 20050901 |
| Efficacy of the NSAIDs depends on multiple factors. | Anesthesia and analgesia 20050901 |
| Preoperative use of selective COX-II inhibitors for pain management in laparoscopic nissen fundoplication. | Surgical endoscopy 20050901 |
| COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database. | European journal of clinical pharmacology 20050901 |
| Blood-nourishing and hard-softening capsule costs less in the management of osteoarthritic knee pain: a randomized controlled trial. | Evidence-based complementary and alternative medicine : eCAM 20050901 |
| The effect of non-steroidal anti-inflammatory drugs on inflammatory cystoid macular edema. | American journal of ophthalmology 20050901 |
| Prophylactic effect of highly selective COX-2 inhibition in acute monosodium urate crystal induced inflammation in the rat subcutaneous air pouch. | The Journal of rheumatology 20050901 |
| Science star over Asia. | PLoS biology 20050901 |
| Analysis and prevalence of inflammatory cells in subtypes of lumbar disc herniations under cyclooxygenase-2 inhibitor therapy. | Neurological research 20050901 |
| Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment. | International journal of clinical pharmacology and therapeutics 20050901 |
| The Vioxx debacle revisited. | The American journal of medicine 20050901 |
| The Vioxx debacle revisited. | The American journal of medicine 20050901 |
| The Vioxx debacle revisited. | The American journal of medicine 20050901 |
| The Vioxx debacle revisited. | The American journal of medicine 20050901 |
| The Vioxx debacle revisited. | The American journal of medicine 20050901 |
| Simplified search strategies were effective in identifying clinical trials of pharmaceuticals and physical modalities. | Journal of clinical epidemiology 20050901 |
| A double-blind prospective comparison of rofecoxib vs ketorolac in reducing postoperative pain after arthroscopic knee surgery. | Journal of clinical anesthesia 20050901 |
| [Cardiovascular events: a class effect by COX-2 inhibitors]. | Arquivos brasileiros de cardiologia 20050901 |
| Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications. | Journal (Canadian Dental Association) 20050901 |
| The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. | The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20050901 |
| Cyclooxygenase-2 inhibition in colon experimental carcinogenesis. | Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20050901 |
| Test people, not animals. | New scientist (1971) 20050901 |
| COX-2 inhibition and pain management: a review summary. | Expert review of clinical immunology 20050901 |
| Calotropis procera latex-induced inflammatory hyperalgesia--effect of antiinflammatory drugs. | Mediators of inflammation 20050831 |
| [Rofecoxib-related cutaneous vasculitis]. | Presse medicale (Paris, France : 1983) 20050827 |
| Painkiller verdict shows mistrust of Merck. | Nature 20050825 |
| Drug firms back-pedal on direct advertising. | Nature 20050818 |
| Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. | Circulation 20050816 |
| Health Canada lukewarm on Vioxx panel findings. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050816 |
| Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis. | Arthritis and rheumatism 20050815 |
| The preacher who's raising hell with Merck. | Fortune 20050808 |
| Combining restricted access material (RAM) and turbulent flow for the rapid on-line extraction of the cyclooxygenase-2 inhibitor rofecoxib in plasma samples. | Journal of chromatography. A 20050805 |
| An individual approach. | Nature 20050804 |
| A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts. | The Journal of pharmacology and experimental therapeutics 20050801 |
| Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050801 |
| Prostaglandin E2 production in ovarian cancer cell lines is regulated by cyclooxygenase-1, not cyclooxygenase-2. | Prostaglandins, leukotrienes, and essential fatty acids 20050801 |
| Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. | Pain 20050801 |
| Powering our way to the elusive side effect: a composite outcome 'basket' of predefined designated endpoints in each organ system should be included in all controlled trials. | Journal of clinical epidemiology 20050801 |
| Is COX-2 a 'collateral' target in cancer prevention? | Biochemical Society transactions 20050801 |
| Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? | Current medical research and opinion 20050801 |
| Role of thromboxane A2 in the induction of apoptosis of immature thymocytes by lipopolysaccharide. | Clinical and diagnostic laboratory immunology 20050801 |
| Potential use of COX-2-aromatase inhibitor combinations in breast cancer. | British journal of cancer 20050801 |
| Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis? | Current drug targets. Cardiovascular & haematological disorders 20050801 |
| Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography. | Journal of chromatographic science 20050801 |
| [Drug evaluation and supreme responsibility of medical practitioners]. | Zhonghua nei ke za zhi 20050801 |
| Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. | Clinical therapeutics 20050801 |
| Painkiller in the dock. | Nature 20050728 |
| Report of specific cardiovascular outcomes of the ADVANTAGE trial. | Annals of internal medicine 20050719 |
| Perspectives on drug withdrawals. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050719 |
| Drug safety and regulation. | BMJ (Clinical research ed.) 20050702 |
| Cancer prevention: a new era beyond cyclooxygenase-2. | The Journal of pharmacology and experimental therapeutics 20050701 |
| A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. | Rheumatology (Oxford, England) 20050701 |
| Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. | The Journal of pharmacology and experimental therapeutics 20050701 |
| Mechanisms underlying the relaxation response induced by bradykinin in the epithelium-intact guinea-pig trachea in vitro. | British journal of pharmacology 20050701 |
| Pre-column derivatization of rofecoxib for determination in serum by HPLC. | Analytical and bioanalytical chemistry 20050701 |
| Why PLoS sponsored a roundtable of medical whistleblowers. | PLoS medicine 20050701 |
| What can we learn from medical whistleblowers? | PLoS medicine 20050701 |
| The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. | Pharmacoepidemiology and drug safety 20050701 |
| Transfer of rofecoxib into human milk. | European journal of clinical pharmacology 20050701 |
| Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. | Annals of surgery 20050701 |
| Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. | Current Alzheimer research 20050701 |
| Perioperative rofecoxib plus local anesthetic field block diminishes pain and recovery time after outpatient inguinal hernia repair. | Anesthesia and analgesia 20050701 |
| Monitoring the safety of licensed medicines. | Nature reviews. Drug discovery 20050701 |
| Pesticide testing on human subjects: weighing benefits and risks. | Environmental health perspectives 20050701 |
| Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program. | Pharmacotherapy 20050701 |
| Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20050701 |
| The furoxan system: design of selective nitric oxide (NO) donor inhibitors of COX-2 endowed with anti-aggregatory and vasodilating activities. | Chemistry & biodiversity 20050701 |
| The lessons of Vioxx--drug safety and sales. | The New England journal of medicine 20050623 |
| Tailoring arthritis therapy in the wake of the NSAID crisis. | The New England journal of medicine 20050623 |
| Cardiovascular risk associated with celecoxib. | The New England journal of medicine 20050623 |
| What ails the FDA? | The New England journal of medicine 20050616 |
| What ails the FDA? | The New England journal of medicine 20050616 |
| Effect of selective cyclooxygenase-2 inhibitors on heart rate in healthy young men. | The American journal of cardiology 20050615 |
| Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. | Cancer research 20050615 |
| Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. | BMJ (Clinical research ed.) 20050611 |
| Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. | BMJ (Clinical research ed.) 20050611 |
| [Selective cyclooxygenase-2 inhibitors. A population-based analysis of use in France over a three-year period and comparison with randomised clinical trials]. | Presse medicale (Paris, France : 1983) 20050604 |
| 3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation. | Journal of medicinal chemistry 20050602 |
| Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids. | Biomedical chromatography : BMC 20050601 |
| A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20050601 |
| Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. | Hypertension (Dallas, Tex. : 1979) 20050601 |
| Simultaneous presentation of rofecoxib-induced acute hepatitis and acute interstitial nephritis. | Internal medicine journal 20050601 |
| Efficacy of preoperative oral rofecoxib in pain control for third molar surgery. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20050601 |
| AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050601 |
| TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk. | BJOG : an international journal of obstetrics and gynaecology 20050601 |
| Doubt is their product. | Scientific American 20050601 |
| Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies. | The Journal of rheumatology 20050601 |
| Adverse drug reactions to nonsteroidal anti-inflammatory drugs, COX-2 inhibitors and paracetamol in a paediatric hospital. | British journal of clinical pharmacology 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20050601 |
| Treating critical illness: the importance of first doing no harm. | PLoS medicine 20050601 |
| Cox-2 inhibitors: still no decisive action. | Prescrire international 20050601 |
| How to avoid future Vioxx-type scandals. | Prescrire international 20050601 |
| Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat. | Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20050601 |
| Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now? | Nature clinical practice. Cardiovascular medicine 20050601 |
| Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. | Vascular health and risk management 20050601 |
| Systematic overview of warfarin and its drug and food interactions. | Archives of internal medicine 20050523 |
| Responsibility for pharmaceutical company samples. | The New Zealand medical journal 20050520 |
| Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. | Archives of internal medicine 20050509 |
| 1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors. | Journal of medicinal chemistry 20050505 |
| Drug samples bring scrutiny. | Modern healthcare 20050502 |
| Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity. | The Journal of pharmacology and experimental therapeutics 20050501 |
| The effect of analgesic agents on the healing rat medial collateral ligament. | The American journal of sports medicine 20050501 |
| Role of cyclooxygenase-2 in deoxynivalenol-induced immunoglobulin a nephropathy. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20050501 |
| Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. | Rheumatology (Oxford, England) 20050501 |
| Blood pressure in Native Americans switched from celecoxib to rofecoxib. | The Annals of pharmacotherapy 20050501 |
| Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. | European journal of neurology 20050501 |
| Angioedema associated with aspirin and rofecoxib. | The Annals of pharmacotherapy 20050501 |
| Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy? | American journal of physiology. Regulatory, integrative and comparative physiology 20050501 |
| Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies. | Acta anaesthesiologica Scandinavica 20050501 |
| Comment on: Gilron I, Orr E, Tu D, O'Neill JP, Zamora JE, Bell AC. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. Pain 113 (2005) 191-200. | Pain 20050501 |
| Ischemic colitis associated with rofecoxib. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20050501 |
| Cerebrospinal fluid and plasma pharmacokinetics of the cyclooxygenase 2 inhibitor rofecoxib in humans: single and multiple oral drug administration. | Anesthesia and analgesia 20050501 |
| COX-2 inhibitors still eyed for cancer prevention. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050501 |
| High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. | Canadian journal of anaesthesia = Journal canadien d'anesthesie 20050501 |
| Rofecoxib as adjunctive therapy for haemophilic arthropathy. | Haemophilia : the official journal of the World Federation of Hemophilia 20050501 |
| Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20050501 |
| Celecoxib-induced nephrotoxicity in a renal transplant recipient. | Pharmacotherapy 20050501 |
| Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. | Clinical pharmacology and therapeutics 20050501 |
| [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions]. | Zeitschrift fur Rheumatologie 20050501 |
| COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. | Clinical nephrology 20050501 |
| Life after Vioxx: the clinical implications. | Hospital medicine (London, England : 1998) 20050501 |
| The safety of rofecoxib. | Expert opinion on drug safety 20050501 |
| Assessing potential risks and evaluating expected benefits. | Managed care interface 20050501 |
| Merck VIOXX 'warning' is questioned. | Texas medicine 20050501 |
| [The medical reason for the prescription of COX-2 selective cyclo oxygenase inhibitor rofecoxib for the treatment of rheumatoid arthritis. A post-marketing surveillance study from Austria]. | Wiener medizinische Wochenschrift (1946) 20050501 |
| Vioxx, radiology, and the Food and Drug Administration. | Journal of the American College of Radiology : JACR 20050501 |
| National consumer drug safety network launched. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050426 |
| Evidence in Vioxx suits shows intervention by Merck officials. | The New York times on the Web 20050424 |
| Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. | Journal of the National Cancer Institute 20050420 |
| A general carbometalation, three component coupling strategy for the synthesis of alpha,beta-unsaturated gamma-sultines including thio-rofecoxib, a selective COX-2 inhibitor. | Bioorganic & medicinal chemistry letters 20050415 |
| Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. | Arthritis and rheumatism 20050415 |
| [Probable cardiac failure due to rofecoxib]. | Atencion primaria 20050415 |
| [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)]. | Medizinische Klinik (Munich, Germany : 1983) 20050415 |
| Does the dose make the poison? | Science (New York, N.Y.) 20050408 |
| [COX-2 inhibitors--one step forward and two steps back]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20050407 |
| Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. | Circulation 20050405 |
| The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. | Annals of internal medicine 20050405 |
| Cellular mechanisms of acetaminophen: role of cyclo-oxygenase. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050401 |
| Factors associated with celecoxib and rofecoxib utilization. | The Annals of pharmacotherapy 20050401 |
| Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib. | European journal of clinical pharmacology 20050401 |
| Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050401 |
| Adoption of celecoxib and rofecoxib: a nationwide database study. | Journal of clinical pharmacy and therapeutics 20050401 |
| Vioxx withdrawal--an opportunity to review primary care management for osteoarthritis. | Hong Kong medical journal = Xianggang yi xue za zhi 20050401 |
| Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. | Journal of neurochemistry 20050401 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050401 |
| Increased risk of cardiovascular events with coxibs and NSAIDs. | Lancet (London, England) 20050401 |
| Increased risk of cardiovascular events with coxibs and NSAIDs. | Lancet (London, England) 20050401 |
| Increased risk of cardiovascular events with coxibs and NSAIDs. | Lancet (London, England) 20050401 |
| Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. | Expert opinion on investigational drugs 20050401 |
| The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20050401 |
| [Severe acute cholestatic and cytolytic hepatitis induced by rofecoxib]. | Gastroenterologie clinique et biologique 20050401 |
| Preemptive oral rofecoxib plus postoperative intraarticular bupivacaine for pain relief after arthroscopic knee surgery. | Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology 20050401 |
| In vitro and in vivo evaluation of guar gum-based matrix tablets of rofecoxib for colonic drug delivery. | Current drug delivery 20050401 |
| Raising the safety bar--the FDA's coxib meeting. | The New England journal of medicine 20050331 |
| Learning the value of drugs--is rofecoxib a regulatory success story? | The New England journal of medicine 20050331 |
| Drug safety on trial. | Nature 20050331 |
| Drug safety special: the safety catch. | Nature 20050331 |
| Drug safety special: chasing shadows. | Nature 20050331 |
| Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: an isobolographic study. | European journal of pharmacology 20050328 |
| Reassessment of the benefit/risk-ratio of selective COX-2-inhibitors. | Swiss medical weekly 20050319 |
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. | The New England journal of medicine 20050317 |
| COX-2 inhibitors--lessons in drug safety. | The New England journal of medicine 20050317 |
| COX-2 inhibitors--a lesson in unexpected problems. | The New England journal of medicine 20050317 |
| What ails the FDA? | The New England journal of medicine 20050317 |
| Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. | Archives of internal medicine 20050314 |
| The preferences of 600 patients for different descriptions of randomisation. | British journal of cancer 20050314 |
| COX-2 inhibitors--first, do no harm. | The New Zealand medical journal 20050311 |
| Europe also needs agency for postmarketing surveillance. | BMJ (Clinical research ed.) 20050305 |
| Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity. | The Journal of pharmacology and experimental therapeutics 20050301 |
| The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization. | The Journal of pharmacology and experimental therapeutics 20050301 |
| Some key points emerging from the COX-2 controversy. | Pharmacoepidemiology and drug safety 20050301 |
| Temporal effects of a COX-2-selective NSAID on bone ingrowth. | Journal of biomedical materials research. Part A 20050301 |
| The withdrawal of rofecoxib. | Pharmacoepidemiology and drug safety 20050301 |
| Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults. | British journal of haematology 20050301 |
| Increased constriction of the ductus arteriosus by dexamethasone, indomethacin, and rofecoxib in fetal rats. | Circulation journal : official journal of the Japanese Circulation Society 20050301 |
| Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. | The Annals of thoracic surgery 20050301 |
| Drug safety on trial. Last year's withdrawal of the anti-arthritis drug Vioxx triggered a debate about how to better monitor drug safety even after approval. | EMBO reports 20050301 |
| Painful lessons. | Nature structural & molecular biology 20050301 |
| The Vioxx debacle. | The American journal of medicine 20050301 |
| The safety of the perioperative administration of cyclooxygenase-2 inhibitors for post-surgical pain. | Acta anaesthesiologica Scandinavica 20050301 |
| Anaphylactic shock caused by a selective allergy to celecoxib, with no allergy to rofecoxib or sulfamethoxazole. | The Journal of allergy and clinical immunology 20050301 |
| Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050301 |
| What happened to the coxibs on the way to the cardiologist? | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20050301 |
| Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. | Annals of vascular surgery 20050301 |
| Vioxx fears prompt call for user fee evaluation. | Nature reviews. Drug discovery 20050301 |
| Cyclooxygenase-2 inhibitors and cardiovascular risk. | The Canadian journal of cardiology 20050301 |
| Is it always unethical to use a placebo in a clinical trial? | PLoS medicine 20050301 |
| Uptake of new drugs in rural and urban areas of Queensland, Australia: the example of COX-2 inhibitors. | European journal of clinical pharmacology 20050301 |
| A tale of two coxibs. | JAAPA : official journal of the American Academy of Physician Assistants 20050301 |
| Vioxx and Merck: a preventable situation? | Orthopedics 20050301 |
| COX-2 inhibitors and cardiovascular toxicity: a class effect? | South Dakota journal of medicine 20050301 |
| Professional pill pusher. | Minnesota medicine 20050301 |
| The Vioxx fallout. | Minnesota medicine 20050301 |
| COX-2 selective nonsteroidal anti-inflammatory drugs: current status. | The Journal of the Association of Physicians of India 20050301 |
| Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. preparation and properties of rofecoxib hydroxypropyl beta-cyclodextrin inclusion complex: a technical note. | AAPS PharmSciTech 20050301 |
| Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks. | Harvard health letter 20050301 |
| Coxibs: can this class of drugs survive? | Vascular health and risk management 20050301 |
| Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. | Vascular health and risk management 20050301 |
| Public welfare agenda or corporate research agenda? | Mens sana monographs 20050301 |
| Was Vioxx really that dangerous? | Time 20050227 |
| FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. | BMJ (Clinical research ed.) 20050226 |
| Drug safety. FDA panel urges caution on many anti-inflammatory drugs. | Science (New York, N.Y.) 20050225 |
| Vioxx may go back on sale after scraping past FDA panel. | Nature 20050224 |
| Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. | Arthritis and rheumatism 20050215 |
| [Gastro-intestinal toxicity of rofecoxib]. | Atencion primaria 20050215 |
| Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20050215 |
| Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians? | Canadian family physician Medecin de famille canadien 20050210 |
| Application of HPLC and HPTLC for the simultaneous determination of tizanidine and rofecoxib in pharmaceutical dosage form. | Journal of pharmaceutical and biomedical analysis 20050207 |
| Simultaneous LC determination of tizanidine and rofecoxib in tablets. | Journal of pharmaceutical and biomedical analysis 20050207 |
| [Could Vioxx have been recalled earlier?]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20050203 |
| Are all COX-2 inhibitors created equal? | Hypertension (Dallas, Tex. : 1979) 20050201 |
| In vivo endothelial interaction between ACE and COX inhibitors. | Prostaglandins, leukotrienes, and essential fatty acids 20050201 |
| Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. | Hypertension (Dallas, Tex. : 1979) 20050201 |
| COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions. | International immunopharmacology 20050201 |
| Preemptive rofecoxib and dexamethasone for prevention of pain and trismus following third molar surgery *. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20050201 |
| Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. | Pain 20050201 |
| Rofecoxib and inflammatory bowel disease: clinical and pathologic observations. | Journal of clinical gastroenterology 20050201 |
| Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. | Anesthesiology 20050201 |
| Clinical trials report. The APPROVe study: what we should learn from the VIOXX withdrawal. | Current hypertension reports 20050201 |
| Summaries for patients. Cyclooxygenase-2 inhibitors and heart attacks: varying effects? | Annals of internal medicine 20050201 |
| Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. | Annals of internal medicine 20050201 |
| Responding to the rofecoxib withdrawal crisis: a new model for notifying patients at risk and their health care providers. | Annals of internal medicine 20050201 |
| Using information technology to transfer knowledge: a medical institution steps up to the plate. | Annals of internal medicine 20050201 |
| Coxibs and caution. | Journal of the Royal Society of Medicine 20050201 |
| Don't throw out the baby with the bathwater! | Journal of pediatric hematology/oncology 20050201 |
| COX-2 inhibitors: cancer prevention or cardiovascular risk? | The Lancet. Oncology 20050201 |
| COX-2 selective inhibitors--important lessons learned. | Lancet (London, England) 20050201 |
| Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. | Lancet (London, England) 20050201 |
| Avoiding another Vioxx. | Scientific American 20050201 |
| Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review. | Acta anaesthesiologica Scandinavica 20050201 |
| Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs. | Journal of veterinary pharmacology and therapeutics 20050201 |
| Effect of non-steroidal anti-inflammatory drugs on natural killer cell activity in patients with dementia. | The Israel Medical Association journal : IMAJ 20050201 |
| Design, synthesis and pharmacological evaluation of some novel 2-(4-nitrophenyl)-3-methylthio-3-(substituted)arylamino acrylamides as potential anti-inflammatory agents. | Die Pharmazie 20050201 |
| Preoperative analgesia management with rofecoxib in thoracotomy patients. | Journal of cardiothoracic and vascular anesthesia 20050201 |
| Coxib toxicity: a likely class effect. | Prescrire international 20050201 |
| Retroperitoneal hematoma following rofecoxib and enoxaparin coadministration in a patient with atrial fibrillation. | Saudi medical journal 20050201 |
| Easing arthritis pain in the post-Vioxx era. | The Johns Hopkins medical letter health after 50 20050201 |
| Safety, scrutiny and conflicts: assessing the fallout and lessons learned from pharmaceuticals. | Photomedicine and laser surgery 20050201 |
| Institutional review boards must conduct safety review. | Human research report 20050201 |
| Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease. | Acta medica Okayama 20050201 |
| Misery loves company. | Texas medicine 20050201 |
| Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. | British journal of cancer 20050131 |
| Life after Vioxx. | Newsweek 20050131 |
| Sentinel systems are needed for long term adverse drug reactions. | BMJ (Clinical research ed.) 20050129 |
| Experts point to lessons learned from controversy over rofecoxib safety. | JAMA 20050126 |
| Rofecoxib for osteoarthritis. | The Cochrane database of systematic reviews 20050125 |
| Rofecoxib for rheumatoid arthritis. | The Cochrane database of systematic reviews 20050125 |
| Single dose oral rofecoxib for postoperative pain. | The Cochrane database of systematic reviews 20050125 |
| The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. | Archives of internal medicine 20050124 |
| National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. | Archives of internal medicine 20050124 |
| Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. | Archives of internal medicine 20050124 |
| Design and synthesis of (E)-1,1,2-triarylethenes: novel inhibitors of the cyclooxygenase-2 (COX-2) isozyme. | Bioorganic & medicinal chemistry letters 20050117 |
| Agencies 'failed miserably' over COX-2 inhibitor. | BMJ (Clinical research ed.) 20050115 |
| The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. | European journal of pharmacology 20050110 |
| Perspectives. Medicine & Health 2004 Health Person of the Year. | Medicine & health (1997) 20050110 |
| The price of pain. | U.S. news & world report 20050110 |
| Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils. | World journal of gastroenterology 20050107 |
| Vioxx: lessons for Health Canada and the FDA. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20050104 |
| Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. | Arteriosclerosis, thrombosis, and vascular biology 20050101 |
| Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? | Hypertension (Dallas, Tex. : 1979) 20050101 |
| Reflections on the withdrawal of rofecoxib. | Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20050101 |
| Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. | Journal of cancer research and clinical oncology 20050101 |
| Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). | European urology 20050101 |
| Cyclooxygenase 1 and/or 2 blockade ameliorates the renal tissue damage triggered by ischemia and reperfusion injury. | International immunopharmacology 20050101 |
| Crossing the line: part 2. | Neurourology and urodynamics 20050101 |
| Functional mechanism underlying cyclooxygenase-2 expression in rat small intestine following administration of indomethacin: relation to intestinal hypermotility. | Journal of gastroenterology and hepatology 20050101 |
| A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. | Pain 20050101 |
| Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. | Annals of surgery 20050101 |
| Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. | The Journal of rheumatology 20050101 |
| Under surveillance. | Nature biotechnology 20050101 |
| Discontinuation of Vioxx. | Lancet (London, England) 20050101 |
| Discontinuation of Vioxx. | Lancet (London, England) 20050101 |
| Discontinuation of Vioxx. | Lancet (London, England) 20050101 |
| Discontinuation of Vioxx. | Lancet (London, England) 20050101 |
| Discontinuation of Vioxx. | Lancet (London, England) 20050101 |
| Discontinuation of Vioxx. | Lancet (London, England) 20050101 |
| Discontinuation of Vioxx. | Lancet (London, England) 20050101 |
| Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not? | Rapid communications in mass spectrometry : RCM 20050101 |
| Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. | The Journal of international medical research 20050101 |
| Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. | Fertility and sterility 20050101 |
| Intracranial hypertension induced by rofecoxib. | Headache 20050101 |
| Editorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads. | Current opinion in investigational drugs (London, England : 2000) 20050101 |
| [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall]. | Klinische Monatsblatter fur Augenheilkunde 20050101 |
| Taking stock of coxibs. | Drug and therapeutics bulletin 20050101 |
| VIOXX and cardiovascular events: a class effect? | Joint, bone, spine : revue du rhumatisme 20050101 |
| Lessons to be learned from the Vioxx debacle. | Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20050101 |
| How to avoid another 'Vioxx'. | Nature reviews. Drug discovery 20050101 |
| [Funtional phase IV?]. | Medizinische Monatsschrift fur Pharmazeuten 20050101 |
| A 1-year follow-up after a pilot study with Doloteffin for low back pain. | Phytomedicine : international journal of phytotherapy and phytopharmacology 20050101 |
| Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20050101 |
| Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20050101 |
| [Vioxx: reasons for a premature retirement]. | Medecine sciences : M/S 20050101 |
| [The best of clinical pharmacology in 2004]. | Archives des maladies du coeur et des vaisseaux 20050101 |
| Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. | Clinical laboratory 20050101 |
| Treating pain after Vioxx. Should you switch to another COX-2, a traditional non-steroidal anti-inflammatory, or acetaminophen. | Health news (Waltham, Mass.) 20050101 |
| The lessons of Vioxx. | Cutis 20050101 |
| Do selective cyclo-oxygenase-2 inhibitors have a future? | Drug safety 20050101 |
| Prescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control study. | Arthritis research & therapy 20050101 |
| JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. | BMC cancer 20050101 |
| Drug fiasco highlights need for more openness. | British journal of community nursing 20050101 |
| Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat. | Canadian journal of physiology and pharmacology 20050101 |
| The great rofecoxib feeding frenzy. | JPEN. Journal of parenteral and enteral nutrition 20050101 |
| Stepping into the Vioxx void. Answers to four questions after the popular pain reliever was yanked off the market. | Harvard health letter 20050101 |
| NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. | Drug safety 20050101 |
| The 'Statinth' wonder of the world: a panacea for all illnesses or a bubble about to burst. | Journal of negative results in biomedicine 20050101 |
| [Tubulointerstitial nephritis associated with treatment with selective Cox-2 inhibitors, celecoxib and rofecoxib]. | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20050101 |
| [VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases]. | Casopis lekaru ceskych 20050101 |
| Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib). | European journal of epidemiology 20050101 |
| Reversal of LPS-induced central and peripheral hyperalgesia by green tea extract. | Phytotherapy research : PTR 20050101 |
| Cyclo-oxygenase-2 inhibitors: when should they be used in the elderly? | Drugs & aging 20050101 |
| Growth inhibitory effect of celecoxib and rofecoxib on human colorectal carcinoma cell lines. | Anticancer research 20050101 |
| The time to onset and overall analgesic efficacy of rofecoxib 50 mg: a meta-analysis of 13 randomized clinical trials. | The Clinical journal of pain 20050101 |
| Why is this woman smiling? The hard sell of bad medicine. | Revolution (Oakland, Calif.) 20050101 |
| The Vioxx debacle. | IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society 20050101 |
| The changing landscape for COX-2 inhibitors: a summary of recent events. | Healthcare quarterly (Toronto, Ont.) 20050101 |
| Cyclo-oxygenase-2 inhibitors : beneficial or detrimental for athletes with acute musculoskeletal injuries? | Sports medicine (Auckland, N.Z.) 20050101 |
| Effect of rofecoxib on antihypertensive effects of candesartan in experimental models of hypertension. | Methods and findings in experimental and clinical pharmacology 20050101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050101 |
| Rofecoxib does not inhibit aberrant crypt foci formation but inhibits later steps in the development of experimental colorectal cancer: rofecoxib in experimental colon cancer. | Scandinavian journal of gastroenterology 20050101 |
| Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme. | Drug safety 20050101 |
| Rofecoxib in migraine. | Expert review of neurotherapeutics 20050101 |
| Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration. | Current medical research and opinion 20050101 |
| Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. | Arthritis research & therapy 20050101 |
| Can chronic use of anti-inflammatory agents paradoxically promote chronic inflammation through compensatory host response? | Medical hypotheses 20050101 |
| Relative thromboembolic risks associated with COX-2 inhibitors. | The Annals of pharmacotherapy 20050101 |
| Transdermal fentanyl for the treatment of pain caused by osteoarthritis of the knee or hip: an open, multicentre study. | BMC musculoskeletal disorders 20050101 |
| COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. | Current topics in medicinal chemistry 20050101 |
| Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective. | Current topics in medicinal chemistry 20050101 |
| COX inhibition and NSAID-induced gastric damage--roles in various pathogenic events. | Current topics in medicinal chemistry 20050101 |
| Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided. | American journal of nephrology 20050101 |
| Selective COX-2 inhibitors and risk of myocardial infarction. | Journal of vascular research 20050101 |
| Tetrandrine and thapsigargin release arachidonic acid from cells in culture and stimulate prostacyclin production in rat liver cells, but may do so by different pathways. | BMC pharmacology 20050101 |
| Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. | Breast cancer research : BCR 20050101 |
| Rofecoxib increased thrombotic events in patients with colorectal adenomas. | ACP journal club 20050101 |
| Quantification and characterisation of cyclo-oxygenase and lipid peroxidation inhibitory anthocyanins in fruits of Amelanchier. | Phytochemical analysis : PCA 20050101 |
| Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines. | The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique 20050101 |
| The effects of rofecoxib on 24-h ambulatory blood pressure and heart rate monitoring in patients with hypertension and osteoarthritis. | International journal of tissue reactions 20050101 |
| What are the real lessons from Vioxx? | Drug safety 20050101 |
| The problem of new uses. | Yale journal of health policy, law, and ethics 20050101 |
| Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. | Yale journal of health policy, law, and ethics 20050101 |
| Risk of retinal vein occlusions in patients treated with rofecoxib (vioxx). | Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 20050101 |
| A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. | Drug safety 20050101 |
| FDA announces changes affecting the marketing of non-steroidal anti-inflammatory drugs. | FDA consumer 20050101 |
| The effect of conflict of interest on biomedical research and clinical practice guidelines: can we trust the evidence in evidence-based medicine? | The Journal of the American Board of Family Practice 20050101 |
| COX-2 inhibitors and hypercoagulability. | Clinical advances in hematology & oncology : H&O 20050101 |
| Current state of therapy for pain and inflammation. | Arthritis research & therapy 20050101 |
| Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. | Arthritis research & therapy 20050101 |
| Practical approaches to minimizing gastrointestinal and cardiovascular safety concerns with COX-2 inhibitors and NSAIDs. | Arthritis research & therapy 20050101 |
| Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. | Arthritis research & therapy 20050101 |
| Biphasic effect of prostaglandin E2 in a rat model of esophagitis mediated by EP1 receptors: relation to pepsin secretion. | Digestion 20050101 |
| Haemorrhagic gastritis and bleeding following rofecoxib administration. | Clinical and experimental rheumatology 20050101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050101 |
| Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. | Drug safety 20050101 |
| The efficacy of preoperative versus postoperative rofecoxib for preventing acute postoperative dental pain: a prospective randomized crossover study using bilateral symmetrical oral surgery. | The Clinical journal of pain 20050101 |
| Cardiovascular effects of coxibs. | Lupus 20050101 |
| Adverse interactions of rofecoxib with lisinopril in spontaneously hypertensive rats. | Clinical toxicology (Philadelphia, Pa.) 20050101 |
| Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: a randomized controlled trial [ISRCTN38432711]. | Journal of inflammation (London, England) 20050101 |
| Cardiovascular complications of non-steroidal anti-inflammatory drugs. | Annals of clinical and laboratory science 20050101 |
| What if Derek Willoughby were right? Cyclo-oxygenase is an anti-inflammatory enzyme. | Inflammopharmacology 20050101 |
| Development of intestinal, but not gastric damage caused by a low dose of indomethacin in the presence of rofecoxib. | Inflammopharmacology 20050101 |
| TOIB Study. Are topical or oral ibuprofen equally effective for the treatment of chronic knee pain presenting in primary care: a randomised controlled trial with patient preference study. [ISRCTN79353052]. | BMC musculoskeletal disorders 20050101 |
| Effects of co-administered dexamethasone and diclofenac potassium on pain, swelling and trismus following third molar surgery. | Head & face medicine 20050101 |
| Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors. | Inflammopharmacology 20050101 |
| [Cyclooxygenase-2 inhibitors and the ethics of research]. | Medicina 20050101 |
| Identification of a trace colored impurity in drug substance by preparative liquid chromatography and mass spectrometry. | Rapid communications in mass spectrometry : RCM 20050101 |
| Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. | BMC medicine 20050101 |
| Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. | BMC musculoskeletal disorders 20050101 |
| Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. | BMC cancer 20050101 |
| Introduction - The coxib controversies. | Inflammopharmacology 20050101 |
| COX-2 controversy: where are we and where do we go from here? | Inflammopharmacology 20050101 |
| COX-2 inhibitors: a story of greed, deception and death. | Inflammopharmacology 20050101 |
| Low dose rofecoxib, inflammation and prostacyclin synthesis in acute coronary syndromes. | Roczniki Akademii Medycznej w Bialymstoku (1995) 20050101 |
| Characteristics of rofecoxib-polyethylene glycol 4000 solid dispersions and tablets based on solid dispersions. | Pharmaceutical development and technology 20050101 |
| The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. | Pharmacological reports : PR 20050101 |
| [Untoward interactions between antihypertensives and nonsteroidal anti-inflammatory drugs]. | Lijecnicki vjesnik 20050101 |
| COX-2 inhibitors and heart. | Indian heart journal 20050101 |
| Recent developments in health law. Merck and the Vioxx decision: playing by the changing rules of the chemical exposure game. | The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 20050101 |
| Concern about one drug or entire class of drugs. | Reumatizam 20050101 |
| [Quo vadetis coxibs?]. | Reumatizam 20050101 |
| [Nonsteroidal antirheumatics and the kidney]. | Reumatizam 20050101 |
| Lack of Pharmacokinetic Interaction between Esomeprazole and the Nonsteroidal Anti-Inflammatory Drugs Naproxen and Rofecoxib in Healthy Subjects. | Clinical drug investigation 20050101 |
| Teaching exercise of drug utilization by medical students. | JNMA; journal of the Nepal Medical Association 20050101 |
| COX-2 selective inhibitors and heart health. | Postgraduate medicine 20050101 |
| Rofecoxib, Merck, and the FDA. | The New England journal of medicine 20041230 |
| Rofecoxib, Merck, and the FDA. | The New England journal of medicine 20041230 |
| Rofecoxib, Merck, and the FDA. | The New England journal of medicine 20041230 |
| 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors. | Bioorganic & medicinal chemistry letters 20041220 |
| A bitter pill for one Merck critic. | Fortune 20041213 |
| What is a 'safe' drug? | U.S. news & world report 20041213 |
| COX-2-derived prostacyclin confers atheroprotection on female mice. | Science (New York, N.Y.) 20041210 |
| [Rofecoxib--a recall with implications]. | Ugeskrift for laeger 20041206 |
| UK patients seek compensation after taking rofecoxib. | BMJ (Clinical research ed.) 20041204 |
| Crisis deepens at the US Food and Drug Administration. | BMJ (Clinical research ed.) 20041204 |
| Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs. | BMJ (Clinical research ed.) 20041204 |
| Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten. | BMJ (Clinical research ed.) 20041204 |
| Clinical trials. Nail-biting time for trials of COX-2 drugs. | Science (New York, N.Y.) 20041203 |
| New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy. | Journal of medicinal chemistry 20041202 |
| Suppressed study raises spectre of flawed drug regulation in US. | Nature 20041202 |
| [Expectations, hopes--and profit]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20041202 |
| [One man's loss is another man's gain]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20041202 |
| [Gastrointestinal complications under NSAID treatment in the doctor's office]. | MMW Fortschritte der Medizin 20041202 |
| Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). | Spinal cord 20041201 |
| ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor. | The Journal of pharmacology and experimental therapeutics 20041201 |
| Rofecoxib decreases renal injury in obese Zucker rats. | Clinical science (London, England : 1979) 20041201 |
| Effects of a selective cyclo-oxygenase 2 inhibitor on colonic anastomotic and skin wound integrity. | The British journal of surgery 20041201 |
| Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease. | Current gastroenterology reports 20041201 |
| Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. | Atherosclerosis 20041201 |
| Tocolysis and preterm labour. | Current opinion in obstetrics & gynecology 20041201 |
| Cyclooxygenase 1 is required for pH control at the mouse gastric surface. | Gut 20041201 |
| Balancing risks and benefits in pain medicine: wither Vioxx. | Pain medicine (Malden, Mass.) 20041201 |
| Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an acute muscle injury. | The American journal of sports medicine 20041201 |
| Vioxx withdrawal alarms cancer prevention researchers. | Journal of the National Cancer Institute 20041201 |
| Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. | Postgraduate medical journal 20041201 |
| Vioxx, the implosion of Merck, and aftershocks at the FDA. | Lancet (London, England) 20041201 |
| Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. | Lancet (London, England) 20041201 |
| Cutaneous vasculitis induced by cyclo-oxygenase-2 selective inhibitors. | Journal of the American Academy of Dermatology 20041201 |
| Vioxx removed from market. | Mayo Clinic women's healthsource 20041201 |
| Effect of cyclooxygenase-2 inhibitors on gastric emptying and small intestinal transit in humans. | Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20041201 |
| [Analysis of cost-minimization treatment with paracetamol or COX-2 inhibitors (rofecoxib) for pain from arthrosis of the knee or hip]. | Atencion primaria 20041201 |
| Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma. | Archives of dermatology 20041201 |
| Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20041201 |
| Post-radiation inflammatory reaction controlled with thalidomide and rofecoxib. | Clinical oncology (Royal College of Radiologists (Great Britain)) 20041201 |
| Lessons on prescribing and drug safety from the withdrawal of rofecoxib. | Australian family physician 20041201 |
| The sad story of Vioxx, and what we should learn from it. | Cleveland Clinic journal of medicine 20041201 |
| A randomized crossover trial of tenoxicam compared with rofecoxib for postoperative dental pain control. | Anaesthesia and intensive care 20041201 |
| [Comparison of preemptive analgesia efficacy between etoricoxib and rofecoxib in ambulatory gynecological surgery]. | Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20041201 |
| Top 10 health stories of 2004. | Harvard health letter 20041201 |
| Ask the doctor. The news that Vioxx was pulled from the market rattled me, since I had been taking it for my arthritis for almost two years. I have heard both that it is okay for people like me with heart disease to take one of the other Vioxx-like drugs and that it isn't okay. What do you recommend? | Harvard heart letter : from Harvard Medical School 20041201 |
| [Inflammation, nonsteroidal anti-inflammatory drugs and Alzheimer disease]. | Psychologie & neuropsychiatrie du vieillissement 20041201 |
| Mild cognitive impairment: historical development and summary of research. | Dialogues in clinical neuroscience 20041201 |
| Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. | European journal of pharmacology 20041128 |
| FDA is incapable of protecting US 'against another Vioxx'. | BMJ (Clinical research ed.) 20041127 |
| Public interest group accuses FDA of trying to discredit whistleblower. | BMJ (Clinical research ed.) 20041127 |
| [Reflections on COX, Vioxx and Relifex. Increased cardiovascular risk following selective COX-2 inhibition]. | Lakartidningen 20041125 |
| Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20041123 |
| A new class of acyclic 2-alkyl-1,1,2-triaryl (Z)-olefins as selective cyclooxygenase-2 inhibitors. | Journal of medicinal chemistry 20041118 |
| Merck's recall of rofecoxib--a strategic perspective. | The New England journal of medicine 20041118 |
| The fallout from Vioxx. | Journal of the American College of Cardiology 20041116 |
| Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. | Cancer 20041115 |
| Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. | Analytical biochemistry 20041115 |
| Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. | The Medical journal of Australia 20041115 |
| Despite warnings, drug giant took long path to Vioxx recall. | The New York times on the Web 20041114 |
| Rofecoxib and dental prescribing. | British dental journal 20041113 |
| [MSD about Vioxx--important to learn from the experience without hindsight]. | Lakartidningen 20041111 |
| Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. | International journal of cancer 20041110 |
| [The case of Vioxx requires consideration]. | Lakartidningen 20041104 |
| Cyclooxygenase inhibitors and thalidomide ameliorate vincristine-induced hyperalgesia in rats. | Cancer chemotherapy and pharmacology 20041101 |
| Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry letters 20041101 |
| Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. | Neurobiology of disease 20041101 |
| Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time. | Anaesthesia 20041101 |
| The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. | Expert opinion on investigational drugs 20041101 |
| Disturbance of vision by COX-2 inhibitors. | Expert opinion on drug safety 20041101 |
| Responsiveness of the electronic touch screen WOMAC 3.1 OA Index in a short term clinical trial with rofecoxib. | Osteoarthritis and cartilage 20041101 |
| Withdrawal syndrome. | Nature medicine 20041101 |
| Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. | European journal of clinical pharmacology 20041101 |
| Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. | Gastroenterology 20041101 |
| Adverse oral reactions associated with the COX-2 inhibitor rofecoxib. | Oral diseases 20041101 |
| Will Merck survive Vioxx? | Fortune 20041101 |
| Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders. | Pharmacopsychiatry 20041101 |
| MI risk prompts rofecoxib withdrawal. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20041101 |
| Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. | The journal of pain : official journal of the American Pain Society 20041101 |
| Vioxx risk could signify trouble in class. | Nature reviews. Drug discovery 20041101 |
| Effect of rofecoxib on pain caused by osteoid osteoma. | Orthopedics 20041101 |
| [Really only Vioxx?]. | Medizinische Monatsschrift fur Pharmazeuten 20041101 |
| The Vioxx withdrawal: latest in the COX-2 controversies. | Cleveland Clinic journal of medicine 20041101 |
| A world without Vioxx: to COX-2 or not to COX-2? | Cleveland Clinic journal of medicine 20041101 |
| Lessons learned after the withdrawal of rofecoxib. | Managed care interface 20041101 |
| The intangible magic of celebrity marketing. | PLoS medicine 20041101 |
| [The rise and fall of Vioxx: society, values and their choice]. | Harefuah 20041101 |
| [Is there a future for COX-2 inhibitors?]. | Harefuah 20041101 |
| No need to tax the sick: clinical guidelines for rofecoxib as an alternative effective method to the copayment policy in the advent of increasing pharmaceutical expenditures. | Military medicine 20041101 |
| COX-2 inhibitor use after Vioxx: careful balance or end of the rope? | The American journal of managed care 20041101 |
| Vioxx, pharmacovigilance, flu vaccine, and the 'prepared mind'. | Journal of the Mississippi State Medical Association 20041101 |
| Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis. | Journal of computer-aided molecular design 20041101 |
| Bioequivalence study of sildenafil citrate tablets in healthy human volunteers. | Bollettino chimico farmaceutico 20041101 |
| Risk of admission for CHF is higher for rofecoxib and nonselective NSAID users. Commentary: Cyclo-oxygenase-2 inhibitors versus nonselective, nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20041101 |
| [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk]. | Nederlands tijdschrift voor geneeskunde 20041030 |
| COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. | Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20041029 |
| Rofecoxib (Vioxx) voluntarily withdrawn from market. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20041026 |
| What about celebrex? | The Medical letter on drugs and therapeutics 20041025 |
| US government agency to investigate FDA over rofecoxib. | BMJ (Clinical research ed.) 20041023 |
| Unnecessary withdrawal of Vioxx. | The New Zealand medical journal 20041022 |
| Coxibs and cardiovascular disease. | The New England journal of medicine 20041021 |
| Failing the public health--rofecoxib, Merck, and the FDA. | The New England journal of medicine 20041021 |
| [Slime fight in the lay media. Were the Vioxx fatal cases kept secret?]. | MMW Fortschritte der Medizin 20041021 |
| Drug pullout. Massive recall of Vioxx poses logistical problems. | Modern healthcare 20041018 |
| Out of sight. Pharmaceutical industry temporarily replaces hospitals as target. | Modern healthcare 20041018 |
| Painful withdrawal for makers of Vioxx: pulling of arthritis drug raises questions on marketing, safety risks. | The Washington post 20041018 |
| Lessons from the withdrawal of rofecoxib. | BMJ (Clinical research ed.) 20041016 |
| Indian regulators are accused of laxity in not banning drugs. | BMJ (Clinical research ed.) 20041016 |
| Multiple comparisons with a control in families with both one-sided and two-sided hypotheses. | Statistics in medicine 20041015 |
| Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. | Science (New York, N.Y.) 20041015 |
| Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. | Cancer research 20041015 |
| [Cardiovascular risk: a class effect of coxibs? How to manage patients taking Vioxx?]. | MMW Fortschritte der Medizin 20041014 |
| Merck withdraws arthritis drug worldwide. | BMJ (Clinical research ed.) 20041009 |
| Anti-inflammatory drugs and tumor necrosis factor-alpha production from monocytes: role of transcription factor NF-kappa B and implication for rheumatoid arthritis therapy. | European journal of pharmacology 20041006 |
| A new class of acyclic 2-alkyl-1,2-diaryl (E)-olefins as selective cyclooxygenase-2 (COX-2) inhibitors. | Bioorganic & medicinal chemistry letters 20041004 |
| The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. | The Journal of pharmacology and experimental therapeutics 20041001 |
| Efficacy of oral rofecoxib versus intravenous ketoprofen as an adjuvant to PCA morphine after urologic surgery. | Acta anaesthesiologica Scandinavica 20041001 |
| Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients. | Allergy 20041001 |
| Exposure misclassification as a result of free sample drug utilization in automated claims databases and its effect on a pharmacoepidemiology study of selective COX-2 inhibitors. | Pharmacoepidemiology and drug safety 20041001 |
| A case of rofecoxib-associated stevens-johnson syndrome with corneal and conjunctival changes. | Cornea 20041001 |
| Pharmacokinetics of rofecoxib in children with sickle cell hemoglobinopathy. | Journal of pediatric hematology/oncology 20041001 |
| Chlamydial infection preceding the development of rheumatoid arthritis: a brief report. | Clinical rheumatology 20041001 |
| A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain. | Current medical research and opinion 20041001 |
| The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. | Current medical research and opinion 20041001 |
| [Prescribing patterns of rofecoxib in the primary care setting: results of a French survey]. | La Revue de medecine interne 20041001 |
| Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. | Fertility and sterility 20041001 |
| Vioxx: an unequal partnership between safety and efficacy. | Lancet (London, England) 20041001 |
| Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20041001 |
| Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. | Fundamental & clinical pharmacology 20041001 |
| Efficacy of rofecoxib for pain control after knee arthroscopy: a prospective, randomized, double-blinded clinical trial. | Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association 20041001 |
| COX-2 inhibitors and risk of heart failure. | Lancet (London, England) 20041001 |
| Differential effects of naproxen and rofecoxib on the development of hypersensitivity following nerve injury in rats. | Pharmacology, biochemistry, and behavior 20041001 |
| Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20041001 |
| Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20041001 |
| Colorectal cancer and Coxibs. | Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20041001 |
| Influence of rofecoxib on experimental colonic carcinogenesis in rats. | Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva 20041001 |
| Comparison of efficacy of oral rofecoxib and ketorolac in controlling early postoperative outpatient orthopedic surgical pain. | American journal of orthopedics (Belle Mead, N.J.) 20041001 |
| Arthritis drug raises risk of sudden heart attack. | Health news (Waltham, Mass.) 20041001 |
| [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. | Revue medicale de Liege 20041001 |
| The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II. | Inflammation 20041001 |
| Platelet sparing effect of COX II inhibition used with pegylated interferon alfa-2a for the treatment of chronic hepatitis C: a short term pilot study. | Cytokine 20040921 |
| Ischemic preconditioning of remote organs attenuates gastric ischemia-reperfusion injury through involvement of prostaglandins and sensory nerves. | European journal of pharmacology 20040919 |
| Risk assessment of NSAID-induced gastrointestinal toxicity in ambulatory care patients. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040915 |
| RNA profiling of cyclooxygenases 1 and 2 in colorectal cancer. | British journal of cancer 20040913 |
| The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. | European journal of obstetrics, gynecology, and reproductive biology 20040910 |
| Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. | Brain research 20040903 |
| [Rofecoxib versus non-steroidal anti-inflammatory drugs in arthrosis treatment: cost-effectiveness analysis for Spain]. | Revista clinica espanola 20040901 |
| Does preoperative rofecoxib (Vioxx) decrease postoperative pain with laparoscopic cholecystectomy? | American journal of surgery 20040901 |
| Reversal of LPS-induced immobility in mice by green tea polyphenols: possible COX-2 mechanism. | Phytotherapy research : PTR 20040901 |
| Bioequivalence study of rofecoxib tablets. | Arzneimittel-Forschung 20040901 |
| High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina. | Kardiologia polska 20040901 |
| Vioxx curbs knee pain. But the competition, at higher doses, is no slouch when taken with stomach protecting medications. | Health news (Waltham, Mass.) 20040901 |
| Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. | Circulation 20040824 |
| Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature. | Arthritis and rheumatism 20040815 |
| Determination of rofecoxib in human plasma and breast milk by high-performance liquid chromatographic assay. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040805 |
| [Minor rate of side-effects makes it possible. Coxibs accrue new indications]. | MMW Fortschritte der Medizin 20040805 |
| Induction of small intestinal damage in rats following combined treatment with cyclooxygenase-2 and nitric-oxide synthase inhibitors. | The Journal of pharmacology and experimental therapeutics 20040801 |
| Cyclooxygenases 1, 2, and 3 and the production of prostaglandin I2: investigating the activities of acetaminophen and cyclooxygenase-2-selective inhibitors in rat tissues. | The Journal of pharmacology and experimental therapeutics 20040801 |
| Is there an inhibitory effect of COX-2 inhibitors on bone healing? | Pharmacological research 20040801 |
| Bartter syndrome: benefits and side effects of long-term treatment. | Pediatric nephrology (Berlin, Germany) 20040801 |
| Hypertension associated with therapies to treat arthritis and pain. | Hypertension (Dallas, Tex. : 1979) 20040801 |
| Relationship between COX-2 specific inhibitors and hypertension. | Hypertension (Dallas, Tex. : 1979) 20040801 |
| COX-2 inhibitors as adjunctive therapy in schizophrenia. | Expert opinion on investigational drugs 20040801 |
| A role for cyclooxygenase II inhibitors in modulating temporomandibular joint inflammation from a meal pattern analysis perspective. | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20040801 |
| First and second generations of COX-2 selective inhibitors. | Mini reviews in medicinal chemistry 20040801 |
| COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. | Mini reviews in medicinal chemistry 20040801 |
| Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. | Gastroenterology 20040801 |
| Severe cholestasis and acute renal failure related to rofecoxib. | The American journal of gastroenterology 20040801 |
| [Postoperative analgesia with rofecoxib. How effective is the preoperative application of a 25 mg dose?]. | Schmerz (Berlin, Germany) 20040801 |
| Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20040801 |
| Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors. | Journal of medicinal chemistry 20040729 |
| Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. | International journal of cancer 20040720 |
| Antimetastatic activity of a cyclooxygenase-2 inhibitor. | British journal of cancer 20040719 |
| Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. | Biochemical pharmacology 20040715 |
| Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors. | Journal of medicinal chemistry 20040715 |
| The Canadian multicenter trial of pallidal deep brain stimulation for cervical dystonia: preliminary results in three patients. | Neurosurgical focus 20040715 |
| Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells. | British journal of cancer 20040705 |
| Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor. | Age and ageing 20040701 |
| Tolerance induction to rofecoxib in a patient with Bartter's syndrome. | Allergy 20040701 |
| Lipopolysaccharide-induced paw edema model for detection of cytokine modulating anti-inflammatory agents. | International immunopharmacology 20040701 |
| Rofecoxib administration to paediatric patients undergoing adenotonsillectomy. | Paediatric anaesthesia 20040701 |
| Effect of cyclooxygenase inhibitors on gentamicin-induced nephrotoxicity in rats. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20040701 |
| Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice. | Progress in neuro-psychopharmacology & biological psychiatry 20040701 |
| Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040701 |
| Merck Sharpe and Dohme versus Laporte. | Lancet (London, England) 20040701 |
| Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. | Alimentary pharmacology & therapeutics 20040701 |
| Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmacoeconomic analysis linked to a case-control study. | Clinical therapeutics 20040701 |
| Utilization patterns of cyclooxygenase-2 inhibitors among patients with arthritis in a managed care setting. | Managed care interface 20040701 |
| [Cyclooxygenase-2 inhibitors in postoperative pain management]. | Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology 20040701 |
| The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. | Inflammatory bowel diseases 20040701 |
| Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. | Circulation 20040622 |
| COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. | The Journal of surgical research 20040615 |
| Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). | The Journal of surgical research 20040615 |
| Tolerability of rofecoxib versus naproxen. | Annals of internal medicine 20040615 |
| Tolerability of rofecoxib versus naproxen. | Annals of internal medicine 20040615 |
| Tolerability of rofecoxib versus naproxen. | Annals of internal medicine 20040615 |
| Dose of rofecoxib in colorectal cancer. | International journal of cancer 20040610 |
| Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. | The Journal of pharmacology and experimental therapeutics 20040601 |
| Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL. | Atherosclerosis 20040601 |
| Management of osteoarthritis (OA) with an unsupervised home based exercise programme and/or patient administered assessment tools. A cluster randomised controlled trial with a 2x2 factorial design. | Annals of the rheumatic diseases 20040601 |
| Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression. | Kidney international 20040601 |
| Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain control. | Journal of clinical pharmacy and therapeutics 20040601 |
| High frequency of use of rofecoxib at greater than recommended doses: cause for concern. | Pharmacoepidemiology and drug safety 20040601 |
| Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. | The Journal of rheumatology 20040601 |
| Comparison of rofecoxib and a multidose oxycodone/ acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. | Current medical research and opinion 20040601 |
| Comparison of derivative spectrophotometric and liquid chromatographic methods for the determination of rofecoxib. | Die Pharmazie 20040601 |
| Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. | European annals of allergy and clinical immunology 20040601 |
| Prostaglandins: modulators of inflammation and cardiovascular risk. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20040601 |
| Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. | Lancet (London, England) 20040529 |
| Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma. | Biochemical and biophysical research communications 20040528 |
| Interaction of inducible nitric oxide synthase and cyclooxygenase-2 inhibitors in formalin-induced nociception in mice. | European journal of pharmacology 20040525 |
| [Postoperative analgesic and anti-inflammatory effects of rofecoxib after total knee replacement]. | Zhonghua wai ke za zhi [Chinese journal of surgery] 20040522 |
| [General practice study of therapy of acute pain. Patients prefer cox-2 inhibitors]. | MMW Fortschritte der Medizin 20040520 |
| Differential up-regulation of cytosolic and membrane-bound heat shock protein 70 in tumor cells by anti-inflammatory drugs. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040515 |
| Does perioperative oral rofecoxib therapy improve functional recovery after knee replacement surgery? | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20040511 |
| Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. | Neurology 20040511 |
| Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. | Circulation 20040504 |
| Rofecoxib use increases acute myocardial infarction risk. | Circulation 20040504 |
| Pharmacological characterization of the chronic constriction injury model of neuropathic pain. | European journal of pharmacology 20040503 |
| Lichenoid drug eruption probably associated with rofecoxib. | The Annals of pharmacotherapy 20040501 |
| Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry. | British journal of anaesthesia 20040501 |
| Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. | Journal of the American Geriatrics Society 20040501 |
| Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. | The American journal of medicine 20040501 |
| Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors. | Cephalalgia : an international journal of headache 20040501 |
| A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. | Acta anaesthesiologica Scandinavica 20040501 |
| Re: Layton et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. | Rheumatology (Oxford, England) 20040501 |
| Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040501 |
| Valdecoxib versus rofecoxib in acute postsurgical pain: results of a randomized controlled trial. | Journal of pain and symptom management 20040501 |
| Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. | Obstetrics and gynecology 20040501 |
| Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. | Pharmacoepidemiology and drug safety 20040501 |
| Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. | Fertility and sterility 20040501 |
| Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. | Chest 20040501 |
| Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials. | Current medical research and opinion 20040501 |
| Initiation of antihypertensive therapy among new users of cyclooxygenase-2-selective and nonselective NSAIDs. | International journal of clinical pharmacology and therapeutics 20040501 |
| Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. | Joint, bone, spine : revue du rhumatisme 20040501 |
| NSAIDs: gastroprotection or selective COX-2 inhibitor? | Palliative medicine 20040501 |
| Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: a randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model. | Clinical therapeutics 20040501 |
| [Cyclooxygenase 2 inhibitors and lung carcinoma]. | Bulletin du cancer 20040501 |
| [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. | Bulletin du cancer 20040501 |
| [Analgesic effects of cyclooxygenase 2 inhibitors]. | Bulletin du cancer 20040501 |
| [Etoricoxib (Arcoxia)]. | Revue medicale de Liege 20040501 |
| [Cyclooxygenase 2 inhibitors and lung carcinoma]. | Bulletin du cancer 20040501 |
| [Safety of selective cyclooxygenase-2 inhibitors taken for a long time]. | Bulletin du cancer 20040501 |
| [Analgesic effects of cyclooxygenase 2 inhibitors]. | Bulletin du cancer 20040501 |
| Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles. | Journal of medicinal chemistry 20040422 |
| [Selective COX-2 inhibitors--strong medicine for pain]. | MMW Fortschritte der Medizin 20040422 |
| Design of acyclic triaryl olefins: a new class of potent and selective cyclooxygenase-2 (COX-2) inhibitors. | Bioorganic & medicinal chemistry letters 20040419 |
| Sulfonamido, azidosulfonyl and N-acetylsulfonamido analogues of rofecoxib: 4-[4-(N-acetylsulfonamido)phenyl]-3-(4-methanesulfonylphenyl)-2(5H)furanone is a potent and selective cyclooxygenase-2 inhibitor. | Bioorganic & medicinal chemistry letters 20040419 |
| [Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors]. | Presse medicale (Paris, France : 1983) 20040410 |
| Treatment with type-2 selective and non-selective cyclooxygenase inhibitors improves T-cell proliferation in HIV-infected patients on highly active antiretroviral therapy. | AIDS (London, England) 20040409 |
| Quantitation of Valdecoxib in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection using liquid-liquid extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040405 |
| Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. | American journal of physiology. Heart and circulatory physiology 20040401 |
| Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. | British journal of anaesthesia 20040401 |
| Rofecoxib-induced pseudoporphyria. | Journal of the American Academy of Dermatology 20040401 |
| Perioperative rofecoxib improves early recovery after outpatient herniorrhaphy. | Anesthesia and analgesia 20040401 |
| Preoperative oral rofecoxib reduces postoperative pain and tramadol consumption in patients after abdominal hysterectomy. | Anesthesia and analgesia 20040401 |
| Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression. | Anesthesia and analgesia 20040401 |
| Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. | Alimentary pharmacology & therapeutics 20040401 |
| COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. | Alimentary pharmacology & therapeutics 20040401 |
| Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. | Journal of pediatric and adolescent gynecology 20040401 |
| Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. | Hepatology (Baltimore, Md.) 20040401 |
| Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data. | Journal of clinical pharmacy and therapeutics 20040401 |
| Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib. | Journal of medical ethics 20040401 |
| Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. | European journal of clinical investigation 20040401 |
| [Effects of rofecoxib on angiogenesis of pancreatic cancer xenograft in nude mice]. | Ai zheng = Aizheng = Chinese journal of cancer 20040401 |
| Comment on efficacy of rofecoxib and nimesulide in controlling post-extraction pain in oral surgery: a randomised comparative study. | Current medical research and opinion 20040401 |
| Diltiazem-induced hyperpigmentation. | Cutis 20040401 |
| Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. | International journal of clinical practice 20040401 |
| Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. | Seminars in oncology 20040401 |
| [Pharmacology and classification of cyclooxygenase inhibitors]. | Gastroenterologie clinique et biologique 20040401 |
| [Selective COX-2 inhibitors: do they retain any gastroduodenal toxicity]. | Gastroenterologie clinique et biologique 20040401 |
| Merck Sharp and Dohme versus Laporte. | Lancet (London, England) 20040327 |
| Hypoxic regulation of angiopoietin-2 expression in endothelial cells. | The Journal of biological chemistry 20040326 |
| [Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine]. | MMW Fortschritte der Medizin 20040325 |
| Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. | The Medical journal of Australia 20040315 |
| Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2. | Bioorganic & medicinal chemistry letters 20040308 |
| Comparison of some effects of acetylsalicylic acid and rofecoxib during orthodontic tooth movement. | American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics 20040301 |
| Drugs in palliative care: results from a representative survey in Germany. | Palliative medicine 20040301 |
| Effect of a selective nonsteroidal anti-inflammatory inhibitor of cyclooxygenase-2 on the small bowel of rats. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20040301 |
| Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland. | Pharmacoepidemiology and drug safety 20040301 |
| Molecular inclusion of rofecoxib with cyclodextrin: pharmacological properties in laboratory animals. | Die Pharmazie 20040301 |
| Roles of endogenous prostaglandins and cyclooxygenase izoenzymes in mucosal defense of inflamed rat stomach. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20040301 |
| Effects of indomethacin and rofecoxib on gastric mucosal damage in normal and Helicobacter pylori-infected mongolian gerbils. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20040301 |
| The perioperative use of cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs may offer a safer alternative. | Anesthesiology 20040301 |
| A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. | Clinical therapeutics 20040301 |
| Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. | International journal of clinical practice 20040301 |
| Acute cholestatic hepatitis associated with long-term use of rofecoxib. | Digestive diseases and sciences 20040301 |
| Cardiovascular effects of selective cyclooxygenase-2 inhibitors. | Expert review of cardiovascular therapy 20040301 |
| Inhibition of cyclooxygenase-2 reduces the protective effect of hepatocyte growth factor in experimental pancreatitis. | European journal of pharmacology 20040213 |
| In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. | Journal of medicinal chemistry 20040212 |
| Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. | British journal of cancer 20040209 |
| Spanish drug editor wins case brought by Merck, Sharp Dohme. | BMJ (Clinical research ed.) 20040207 |
| Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. | The Medical journal of Australia 20040202 |
| Studies on the anti-inflammatory effect of fluoxetine in the rat. | Pharmacological research 20040201 |
| Evaluation of the anti-inflammatory, anti-nociceptive and gastric effects of Ginkgo biloba in the rat. | Pharmacological research 20040201 |
| Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. | The Journal of urology 20040201 |
| Chronic COX-2 inhibition reduces medullary HSP70 expression and induces papillary apoptosis in dehydrated rats. | Kidney international 20040201 |
| Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. | Journal of neurochemistry 20040201 |
| Rofecoxib in the prevention of perimenstrual migraine: an open-label pilot trial. | Headache 20040201 |
| Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. | The Journal of rheumatology 20040201 |
| Derivative spectrophotometric and fluorimetric methods for determination of rofecoxib in tablets and in human plasma in presence of its photo-degradation product. | Farmaco (Societa chimica italiana : 1989) 20040201 |
| Results of a multimodal analgesic trial involving patients with total hip or total knee arthroplasty. | American journal of orthopedics (Belle Mead, N.J.) 20040201 |
| The 'high solubility' definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. | Pharmaceutical research 20040201 |
| Role of direct cytotoxic effects of NSAIDs in the induction of gastric lesions. | Biochemical pharmacology 20040201 |
| Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib. | The Journal of asthma : official journal of the Association for the Care of Asthma 20040201 |
| The preventive effect of Rofecoxib in postoperative intraperitoneal adhesions. | Acta chirurgica Belgica 20040201 |
| Functional mechanism underlying COX-2 expression following administration of indomethacin in rat stomachs: importance of gastric hypermotility. | Digestive diseases and sciences 20040201 |
| Cyclooxygenase-2 inhibitors: do they have a role in emergency department prescribing? | Emergency medicine Australasia : EMA 20040201 |
| Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. | Journal of medicinal chemistry 20040129 |
| [Homeopathy suppresses COX- and LOX activity. Soft therapy for arthrosis ills]. | MMW Fortschritte der Medizin 20040129 |
| Participation of the L-arginine-nitric oxide-cyclic GMP-ATP-sensitive K+ channel cascade in the antinociceptive effect of rofecoxib. | European journal of pharmacology 20040126 |
| Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. | Neurology 20040113 |
| Isomer-specific effects of conjugated linoleic acid on lipid peroxidation in humans: regulation by alpha-tocopherol and cyclo-oxygenase-2 inhibitor. | Clinical science (London, England : 1979) 20040101 |
| Determination of rofecoxib, in the presence of its photodegradation product, in pharmaceutical preparations by micellar electrokinetic capillary chromatography. | Analytical and bioanalytical chemistry 20040101 |
| Preoperative rofecoxib oral suspension as an analgesic adjunct after lower abdominal surgery: the effects on effort-dependent pain and pulmonary function. | Anesthesia and analgesia 20040101 |
| Efficacy and safety of tramadol/acetaminophen tablets (Ultracet) as add-on therapy for osteoarthritis pain in subjects receiving a COX-2 nonsteroidal antiinflammatory drug: a multicenter, randomized, double-blind, placebo-controlled trial. | The Journal of rheumatology 20040101 |
| Pharmacological treatments for persistent non-malignant pain in older persons. | Drugs & aging 20040101 |
| Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. | Cancer biology & therapy 20040101 |
| Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040101 |
| COX-2 inhibitor improves pain outcomes. | OR manager 20040101 |
| Efficacy of rofecoxib and nimesulide in controlling postextraction pain in oral surgery: a randomised comparative study. | Current medical research and opinion 20040101 |
| Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis. | Drug safety 20040101 |
| Quantitative determination of rofecoxib in pharmaceutical preparations. | Die Pharmazie 20040101 |
| Clinical pharmacology of novel selective COX-2 inhibitors. | Current pharmaceutical design 20040101 |
| Single dose oral rofecoxib for postoperative pain. | The Cochrane database of systematic reviews 20040101 |
| Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials. | Clinical therapeutics 20040101 |
| A cross-media content analysis of motivational themes in direct-to-consumer prescription drug advertising. | Clinical therapeutics 20040101 |
| Acute treatment of migraine. Breaking the paradigm of monotherapy. | BMC neurology 20040101 |
| Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. | Neuroscience 20040101 |
| Efficacy and safety of acupuncture for chronic pain caused by gonarthrosis: a study protocol of an ongoing multi-centre randomised controlled clinical trial [ISRCTN27450856]. | BMC complementary and alternative medicine 20040101 |
| Rofecoxib does not adversely affect skin graft survival in a rat model. | Current surgery 20040101 |
| Acute congestive heart failure induced by rofecoxib. | The Journal of the American Board of Family Practice 20040101 |
| Analgesics for acute pain: Meeting the United States Food and Drug Administration's requirements for proof of efficacy. | The Clinical journal of pain 20040101 |
| S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. | BMC musculoskeletal disorders 20040101 |
| Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. | Drugs & aging 20040101 |
| A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy. | Drug safety 20040101 |
| Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiology. | Drug safety 20040101 |
| Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. | Drug safety 20040101 |
| Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. | Drugs 20040101 |
| Lithium intoxication as a result of an interaction with rofecoxib. | The Annals of pharmacotherapy 20040101 |
| COX-2 inhibitors: a CLASS act or Just VIGORously promoted. | MedGenMed : Medscape general medicine 20040101 |
| Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. | BMC neurology 20040101 |
| Delirium From the COX-2 inhibitor refecoxib. | Psychosomatics 20040101 |
| Synergistic anti-inflammatory activity of omega-3 lipid and rofecoxib pretreatment on macrophage proinflammatory cytokine production occurs via divergent NF-kappaB activation. | JPEN. Journal of parenteral and enteral nutrition 20040101 |
| Impact on drug costs and utilization of a clinical pharmacist in a multisite primary care medical group. | Journal of managed care pharmacy : JMCP 20040101 |
| Treatment of retinopathy of prematurity with topical ketorolac tromethamine: a preliminary study. | BMC pediatrics 20040101 |
| Encouraging physician appropriate prescribing of non-steroidal anti-inflammatory therapies: protocol of a randomized controlled trial [ISRCTN43532635]. | BMC health services research 20040101 |
| [Therapeutic advances with coxibs: few certainties and a lot of doubts]. | Therapie 20040101 |
| Inhibition of COX isoforms by nutraceuticals. | Journal of herbal pharmacotherapy 20040101 |
| [Coxibs, which real therapeutic advance?: Recent pharmacoepidemiological data]. | Therapie 20040101 |
| Harpgophytum procumbens for osteoarthritis and low back pain: a systematic review. | BMC complementary and alternative medicine 20040101 |
| COX-2 inhibition and cancer: experimental findings and clinical correlates. | The West Virginia medical journal 20040101 |
| [Rofecoxib and gynecomastia: the first case]. | Annales de dermatologie et de venereologie 20040101 |
| Chronic urticaria: aetiology, management and current and future treatment options. | Drugs 20040101 |
| The coxib conundrum: lessons from the rise and fall of rofecoxib. | American journal of therapeutics 20040101 |
| The politics of therapeutics. | American journal of therapeutics 20040101 |
| Cardiovascular complications of COX2 selective inhibitors cause considerable concern. | Blood pressure 20040101 |
| Market withdrawal of Vioxx: is it time to rethink the use of COX-2 inhibitors? | Journal of managed care pharmacy : JMCP 20040101 |
| Linking pharmacovigilance with pharmacogenetics. | Drug safety 20040101 |
| [Rofecoxib (Vioxx) has been withdrawn, what next?]. | Duodecim; laaketieteellinen aikakauskirja 20040101 |
| Participation of the serotonin system in rofecoxib-induced antinociception. | Proceedings of the Western Pharmacology Society 20040101 |
| Anti-inflammatory effects of selective COX-2 inhibitors. | Polish journal of pharmacology 20040101 |
| Merck withdraws Vioxx; FDA issues public health advisory. | FDA consumer 20040101 |
| Drug recalls and notification of practitioners. | Orthopedic nursing 20040101 |
| [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy]. | Revista de gastroenterologia de Mexico 20040101 |
| Effect of nimesulide-a preferential COX-2 inhibitor on arterial blood pressure, compared to ketoprofen. | Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina 20040101 |
| Withdrawal of rofecoxib - a wake up call for drug safety. | Kathmandu University medical journal (KUMJ) 20040101 |
| Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). | Clinical drug investigation 20040101 |
| Management of premenstrual acne with Cox-2 inhibitors: a placebo controlled study. | Indian journal of dermatology, venereology and leprology 20040101 |
| Vioxx(R): What should we tell our patients? | Journal of chiropractic medicine 20040101 |
| Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. | Cancer letters 20031230 |
| Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. | Journal of medicinal chemistry 20031204 |
| Preincisional treatment to prevent pain after ambulatory hernia surgery. | Anesthesia and analgesia 20031201 |
| Metformin lactic acidosis, acute renal failure and rofecoxib. | British journal of anaesthesia 20031201 |
| Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. | Gut 20031201 |
| Dysmenorrhea treatment with a single daily dose of rofecoxib. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20031201 |
| [Clinical pharmacology of the selective COX-2 inhibitors]. | Der Orthopade 20031201 |
| Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. | Canadian journal of anaesthesia = Journal canadien d'anesthesie 20031201 |
| A randomized double-blind prospective study evaluating patient tolerance of transrectal ultrasound-guided biopsy of the prostate using prebiopsy rofecoxib. | Urology 20031201 |
| Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. | Archives of dermatology 20031201 |
| Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention. | Current cancer drug targets 20031201 |
| Tolerability of cyclooxygenase 2 inhibitors and the advisability of oral challenge. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20031201 |
| A rare case of rofecoxib-induced cholestatic hepatitis. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20031201 |
| An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. | Clinical therapeutics 20031201 |
| Cyclooxygenase-2 inhibitors decrease interleukin-1beta-stimulated prostaglandin E2 and IL-6 production by human gingival fibroblasts. | Journal of periodontology 20031201 |
| Misdiagnosed iuxta-articular osteoid osteoma of the calcaneus following an injury. | Acta bio-medica : Atenei Parmensis 20031201 |
| Role of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20031201 |
| Patient perception of the burden of weight gain and blood pressure increase among RA patients using celecoxib, rofecoxib, and non-specific NSAIDs. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20031201 |
| Impaired gastric ulcer healing in diabetic rats: role of heat shock protein, growth factors, prostaglandins and proinflammatory cytokines. | European journal of pharmacology 20031128 |
| The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats. | European journal of pharmacology 20031128 |
| Why don't we initiate more large simple randomized controlled trials? | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20031125 |
| Celecoxib, rofecoxib, and acute temporary visual impairment. | BMJ (Clinical research ed.) 20031122 |
| [Role of Helicobacter pylori in drug-induced gastrointestinal bleeding]. | Presse medicale (Paris, France : 1983) 20031122 |
| Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. | Journal of the American College of Cardiology 20031119 |
| Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. | Cancer 20031115 |
| Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. | Cancer research 20031115 |
| Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. | JAMA 20031112 |
| Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. | Circulation 20031111 |
| Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. | Journal of medicinal chemistry 20031106 |
| Comparison of the incidence rates of thromboembolic events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. | Rheumatology (Oxford, England) 20031101 |
| Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. | Cancer chemotherapy and pharmacology 20031101 |
| Cyclooxygenase isozymes involved in adaptive functional responses in rat stomach after barrier disruption. | The Journal of pharmacology and experimental therapeutics 20031101 |
| Leukocytoclastic vasculitis related to rofecoxib. | The Annals of pharmacotherapy 20031101 |
| Metabolism of rofecoxib in vitro using human liver subcellular fractions. | Drug metabolism and disposition: the biological fate of chemicals 20031101 |
| Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer's disease. | Evidence-based mental health 20031101 |
| Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. | Rheumatology (Oxford, England) 20031101 |
| Underutilization of preventive strategies in patients receiving NSAIDs. | Rheumatology (Oxford, England) 20031101 |
| The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. | Rheumatology (Oxford, England) 20031101 |
| Gastroprotection by coxibs: what do the Celecoxib Long-Term Arthritis Safety Study and the Vioxx Gastrointestinal Outcomes Research Trial tell us? | Rheumatic diseases clinics of North America 20031101 |
| Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. | Osteoarthritis and cartilage 20031101 |
| Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. | Arthritis and rheumatism 20031101 |
| Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. | Arthritis and rheumatism 20031101 |
| Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. | Pharmacotherapy 20031101 |
| Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. | The Journal of clinical psychiatry 20031101 |
| Lessons from early large-scale adoption of celecoxib and rofecoxib by Australian general practitioners. | The Medical journal of Australia 20031020 |
| A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031015 |
| Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. | Annals of internal medicine 20031007 |
| Summaries for patients. Gastrointestinal side effects of rofecoxib and naproxen. | Annals of internal medicine 20031007 |
| Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. | Pediatric nephrology (Berlin, Germany) 20031001 |
| Lower gastrointestinal complications of nonsteroidal anti-inflammatory drugs. | Current gastroenterology reports 20031001 |
| A comparative study of the effect of rofecoxib (a COX 2 inhibitor) and naproxen sodium on analgesic requirements after abdominal hysterectomy. | Archives of gynecology and obstetrics 20031001 |
| Cutaneous vasculitis associated with rofecoxib. | Rheumatology (Oxford, England) 20031001 |
| Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance. | Allergy 20031001 |
| Effects of rofecoxib, celecoxib, and parecoxib on anti-IgE-induced histamine release from human skin mast cells and basophils. | Allergy 20031001 |
| An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. | Journal of clinical pharmacology 20031001 |
| Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. | The Annals of pharmacotherapy 20031001 |
| Pharmacological characterization of mouse hind paw oedema induced by Bothrops insularis (jararaca ilhoa) snake venom. | Toxicon : official journal of the International Society on Toxinology 20031001 |
| Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. | Arthritis and rheumatism 20031001 |
| Matters of the heart: assessing the cardiovascular safety of new drugs. | American heart journal 20031001 |
| Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. | American heart journal 20031001 |
| Acute renal failure after administration of a single dose of a highly selective COX-2 inhibitor. | Clinical nephrology 20031001 |
| Persistence with COX-2 inhibitors in managed care: an analysis of claims data. | Managed care interface 20031001 |
| Rofecoxib reduces polyp recurrence in familial polyposis. | Digestive diseases and sciences 20031001 |
| Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients. | Digestive diseases and sciences 20031001 |
| Effect of NSAIDs on risk of Alzheimer's disease: confounding factors were not discussed. | BMJ (Clinical research ed.) 20030927 |
| [New studies of COX-inhibitors, yet issues remain]. | Lakartidningen 20030918 |
| Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation. | Journal of medicinal chemistry 20030911 |
| Rofecoxib interaction with oral anticoagulant acenocoumarol. | European journal of clinical pharmacology 20030901 |
| Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. | Gut 20030901 |
| Adverse Drug Events Involving COX-2 Inhibitors. | The Annals of pharmacotherapy 20030901 |
| Non-selective and cyclo-oxygenase-2-specific non-steroidal anti-inflammatory drugs impair the hyperaemic response of skin to brief axillary artery occlusion. | British journal of anaesthesia 20030901 |
| The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. | Gastroenterology 20030901 |
| Psoriasis associated with rofecoxib. | Archives of dermatology 20030901 |
| Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds. | Phytotherapy research : PTR 20030901 |
| Intensive monitoring of new drugs based on first prescription signals from pharmacists: a pilot study. | Pharmacoepidemiology and drug safety 20030901 |
| The effects of a cyclo-oxygenase II inhibitor on placental artery production of thromboxane and prostacyclin. | American journal of obstetrics and gynecology 20030901 |
| Rofecoxib-beta-cyclodextrin inclusion complex for solubility enhancement. | Die Pharmazie 20030901 |
| Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. | International archives of allergy and immunology 20030901 |
| Solubility enhancement of Cox-2 inhibitors using various solvent systems. | AAPS PharmSciTech 20030901 |
| [Synthesis and anti-inflammatory activity of alpha-substituted p-(methanesulfonyl)phenylpropenamides]. | Yao xue xue bao = Acta pharmaceutica Sinica 20030901 |
| Modulation of D-penicillamine-induced autoimmunity in the Brown Norway rat using pharmacological agents that interfere with arachidonic acid metabolism or synthesis of inducible nitric oxide synthase. | Toxicology 20030828 |
| [Less pain after surgical intervention. Starting analgesia already before surgery]. | MMW Fortschritte der Medizin 20030821 |
| [Selective COX 2 inhibitor rofecoxib. To 'defy' the pain]. | MMW Fortschritte der Medizin 20030807 |
| [Meta-analysis on acute pain. Rofecoxib helped three quarters of patients]. | MMW Fortschritte der Medizin 20030807 |
| Successful treatment of unresectable inflammatory pseudotumor of the lung with COX-2 inhibitor. | Pediatric pulmonology 20030801 |
| Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. | Journal of neurochemistry 20030801 |
| Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents. | Diabetologia 20030801 |
| Rofecoxib versus placebo in prostatitis. | Current urology reports 20030801 |
| Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. | British journal of pharmacology 20030801 |
| Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. | Clinical pharmacology and therapeutics 20030801 |
| The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. | Gastroenterology 20030801 |
| Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease. | Gastroenterology 20030801 |
| Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. | British journal of clinical pharmacology 20030801 |
| COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy: reports from a symposium held in conjunction with the Radiation Therapy Oncology Group June 2001 Meeting. | American journal of clinical oncology 20030801 |
| Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer. | American journal of clinical oncology 20030801 |
| Pass the tablet please. | Alternative medicine review : a journal of clinical therapeutic 20030801 |
| Prevention of heterotopic ossification after total hip replacement with NSAIDs. | Pharmacy world & science : PWS 20030801 |
| COX-2 inhibitors prolong trauma-induced elevations of iris hyaluronan. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20030801 |
| [Clinical pharmacology of selective inhibitors of cyclooxygenase-2]. | Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale 20030801 |
| High performance liquid chromatographic determination of cox-2 inhibitor rofecoxib in human plasma. | Journal of the Indian Medical Association 20030801 |
| Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles. | Journal of medicinal chemistry 20030731 |
| Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. | International journal of cancer 20030720 |
| Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation. | Spine 20030715 |
| 6-Alkyl, alkoxy, or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry letters 20030707 |
| Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. | American journal of physiology. Gastrointestinal and liver physiology 20030701 |
| Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor into clinical practice. | Rheumatology (Oxford, England) 20030701 |
| Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement. | Osteoarthritis and cartilage 20030701 |
| An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. | Anesthesia and analgesia 20030701 |
| Assessing the relationship between the use of nonsteroidal antiinflammatory drugs and necrotizing fasciitis caused by group A streptococcus. | Medicine 20030701 |
| Acute interstitial nephritis and COX-2 inhibition. | Hospital medicine (London, England : 1998) 20030701 |
| Interaction of rofecoxib and celecoxib with warfarin. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20030701 |
| Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. | Inflammatory bowel diseases 20030701 |
| Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. | The Journal of pharmacy and pharmacology 20030701 |
| [The effects of selective cyclooxygenase-2 inhibitors on the growth of gastric adenocarcinoma]. | Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20030701 |
| The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. | Arthritis and rheumatism 20030615 |
| Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention. | Alimentary pharmacology & therapeutics 20030615 |
| Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. | JAMA 20030604 |
| Role of cyclooxygenase-1 and -2, phospholipase C, and protein kinase C in prostaglandin-mediated gastroprotection. | The Journal of pharmacology and experimental therapeutics 20030601 |
| The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins. | Clinical oral investigations 20030601 |
| Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men. | Arteriosclerosis, thrombosis, and vascular biology 20030601 |
| Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. | Gut 20030601 |
| Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. | Journal of the American Society of Nephrology : JASN 20030601 |
| The role of COX-2 in angiogenesis and rheumatoid arthritis. | Experimental and molecular pathology 20030601 |
| An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. | Alimentary pharmacology & therapeutics 20030601 |
| Preoperative oral celecoxib versus preoperative oral rofecoxib for pain relief after thyroid surgery. | European journal of anaesthesiology 20030601 |
| Rofecoxib in rheumatoid arthritis: new indication. No better that other NSAIDS. | Prescrire international 20030601 |
| On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion. | Journal of pharmacological sciences 20030601 |
| The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. | Annals of internal medicine 20030520 |
| Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis. | Annals of internal medicine 20030520 |
| Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis. | The American journal of cardiology 20030515 |
| NSAIDs and hypertension. | Archives of internal medicine 20030512 |
| Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism. | Drug metabolism and disposition: the biological fate of chemicals 20030501 |
| Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. | Rheumatology (Oxford, England) 20030501 |
| Probable rofecoxib-induced thrombocytopenia. | Rheumatology (Oxford, England) 20030501 |
| Rofecoxib for the treatment of chronic paroxysmal hemicrania. | Cephalalgia : an international journal of headache 20030501 |
| Acute onset of neutrophilic dermatosis in patients after therapy with a COX-2-specific inhibitor. | International journal of dermatology 20030501 |
| Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments against the motion. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20030501 |
| Motion--Cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs are as safe as placebo for the stomach: arguments for the motion. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20030501 |
| A trial of adjuvant therapy in colorectal cancer: the VICTOR trial. | Clinical colorectal cancer 20030501 |
| Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib. | Postgraduate medical journal 20030501 |
| [Acute ulcerative colitis in a patient treated with rofecoxib who took aspirin as self-medication]. | Gastroenterologie clinique et biologique 20030501 |
| [The combination of octreotide to rofecoxib enhanced the inhibitory effect on growth of human hepatocellular carcinoma]. | Zhonghua nei ke za zhi 20030501 |
| Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. | Spine 20030501 |
| Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. | Seminars in vascular medicine 20030501 |
| Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. | Cancer research 20030415 |
| Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site? | Journal of medicinal chemistry 20030410 |
| A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. | The Journal of urology 20030401 |
| Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery. | Anesthesia and analgesia 20030401 |
| Prevention and treatment of reactions to NSAIDs. | Clinical reviews in allergy & immunology 20030401 |
| Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20030401 |
| Cyclooxygenase-2 inhibitors in aspirin-induced asthma. | Chest 20030401 |
| Relative efficacy of selective COX-2 inhibitors compared with over-the-counter ibuprofen. | International journal of clinical practice. Supplement 20030401 |
| Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs. | International journal of clinical practice. Supplement 20030401 |
| Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib. | Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 20030401 |
| A side effect of COX-2 inhibitors. | Harvard health letter 20030401 |
| [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030401 |
| [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030401 |
| Cyclooxygenase inhibitory and antioxidant compounds from crabapple fruits. | Journal of agricultural and food chemistry 20030326 |
| 3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility. | Bioorganic & medicinal chemistry letters 20030324 |
| Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. | British journal of cancer 20030324 |
| [The future of peptic ulcer disease without Helicobacter]. | Praxis 20030319 |
| [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart]. | MMW Fortschritte der Medizin 20030313 |
| [Gastrointestinal complications caused by NSAIDs. Over 60% of arthrosis patients are endangered]. | MMW Fortschritte der Medizin 20030306 |
| Role of macula densa cyclooxygenase-2 in renovascular hypertension. | American journal of physiology. Renal physiology 20030301 |
| COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. | Investigative ophthalmology & visual science 20030301 |
| Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation. | The Journal of pharmacology and experimental therapeutics 20030301 |
| Selective inhibitors of cyclooxygenase-2 delay the activation of nuclear factor kappa B and attenuate the expression of inflammatory genes in murine macrophages treated with lipopolysaccharide. | Molecular pharmacology 20030301 |
| Rofecoxib-induced acute interstitial nephritis. | American journal of kidney diseases : the official journal of the National Kidney Foundation 20030301 |
| Effect of cyclooxygenase-2 inhibitors on blood pressure. | The Annals of pharmacotherapy 20030301 |
| The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria. | The British journal of dermatology 20030301 |
| Anti-inflammatory drugs may put on the pressure. | Harvard heart letter : from Harvard Medical School 20030301 |
| [Renal protective effects of specific cyclooxygenase-2 inhibitor in rats with subtotal renal ablation]. | Zhonghua nei ke za zhi 20030301 |
| Valdecoxib: a review. | Clinical therapeutics 20030301 |
| Age-related mild cognitive deficit: a ready-to-use concept? | Dialogues in clinical neuroscience 20030301 |
| Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. | Journal of medicinal chemistry 20030227 |
| Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. | Archives of internal medicine 20030224 |
| Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors. | Bioorganic & medicinal chemistry letters 20030224 |
| [Clinical trials with rofecoxib: analysis of the information from the gender perspective]. | Medicina clinica 20030222 |
| Ab initio structure determination of rofecoxib from powder diffraction data using molecular packing analysis method and direct space method. | International journal of pharmaceutics 20030218 |
| [When dental extraction or surgical intervention is anticipated. Coxib decreases postoperative pain]. | MMW Fortschritte der Medizin 20030213 |
| [Hypoglycemia associated with the production of insulin-like growth factor (IGF)-II by a hemangiopericytoma]. | Deutsche medizinische Wochenschrift (1946) 20030207 |
| Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20030201 |
| Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. | Gastroenterology 20030201 |
| Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors. | Alimentary pharmacology & therapeutics 20030201 |
| Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. | Cancer research 20030201 |
| Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. | Clinical cancer research : an official journal of the American Association for Cancer Research 20030201 |
| Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. | British journal of clinical pharmacology 20030201 |
| Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib. | The Journal of rheumatology 20030201 |
| Effect of rofecoxib on prednisolone and prednisone pharmacokinetics in healthy subjects. | Journal of clinical pharmacology 20030201 |
| Testing for interaction in studies of noninferiority. | Journal of biopharmaceutical statistics 20030201 |
| A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. | Clinical therapeutics 20030201 |
| Novel drug designing approach for dual inhibitors as anti-inflammatory agents: implication of pyridine template. | Biochemical and biophysical research communications 20030131 |
| Enhancement of antinociception by co-administration of an opioid drug (morphine) and a preferential cyclooxygenase-2 inhibitor (rofecoxib) in rats. | European journal of pharmacology 20030124 |
| [Rapid, strong and long-term effectiveness. Coxib also effective in toothache]. | MMW Fortschritte der Medizin 20030116 |
| Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. | Cancer letters 20030110 |
| Adverse events associated with rofecoxib therapy: results of a large study in community-derived osteoarthritic patients. | Drug safety 20030101 |
| A randomized double-blind pilot study comparing Doloteffin and Vioxx in the treatment of low back pain. | Rheumatology (Oxford, England) 20030101 |
| Effectiveness of prophylactic use of rofecoxib in comparison with ibuprofen on postendodontic pain. | Journal of endodontics 20030101 |
| COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. | Pharmacoepidemiology and drug safety 20030101 |
| Cyclooxygenase-2: from arthritis treatment to new indications for the prevention and treatment of cancer. | Clinical journal of oncology nursing 20030101 |
| The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. | Clinical therapeutics 20030101 |
| The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care. | Clinical therapeutics 20030101 |
| [Information on preoperative analgesia. Acute pain therapy with rofecoxib]. | Schmerz (Berlin, Germany) 20030101 |
| The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20030101 |
| The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo. | Neuroscience 20030101 |
| [Pharmacology of cyclooxygenase 2 inhibition]. | Wiener medizinische Wochenschrift (1946) 20030101 |
| [Cyclooxygenase 2 selective antirheumatic analgesics]. | Wiener medizinische Wochenschrift (1946) 20030101 |
| Selective COX-2 inhibitors: a health economic perspective. | Wiener medizinische Wochenschrift (1946) 20030101 |
| Cox-2: Where are we in 2003? - The role of cyclooxygenase-2 in bone repair. | Arthritis research & therapy 20030101 |
| Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors. | Arthritis research & therapy 20030101 |
| COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease. | Arthritis research & therapy 20030101 |
| COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. | Arthritis research & therapy 20030101 |
| COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred. | Arthritis research & therapy 20030101 |
| Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. | Clinical and experimental rheumatology 20030101 |
| Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital. | Internal medicine journal 20030101 |
| Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. | Clinical pharmacokinetics 20030101 |
| Clinical review: fever in intensive care unit patients. | Critical care (London, England) 20030101 |
| Ibuprofen for Alzheimer's disease. | The Cochrane database of systematic reviews 20030101 |
| Acetaminophen for osteoarthritis. | The Cochrane database of systematic reviews 20030101 |
| Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity. | Acta dermato-venereologica 20030101 |
| Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. | Current medical research and opinion 20030101 |
| Effects of renal insufficiency and hemodialysis on the pharmacokinetics of rofecoxib. | American journal of therapeutics 20030101 |
| Prenatal effects of DuP-697-the irreversible, highly selective cyclooxygenase-2 inhibitor. | Reproductive toxicology (Elmsford, N.Y.) 20030101 |
| Chronic urticaria with multiple NSAID intolerance: is tramadol always a safe alternative analgesic? | Journal of investigational allergology & clinical immunology 20030101 |
| Inhibition of proliferation of human cancer cells and cyclooxygenase enzymes by anthocyanidins and catechins. | Nutrition and cancer 20030101 |
| A retrospective review of the effect of COX-2 inhibitors on blood pressure change. | American journal of therapeutics 20030101 |
| The quality of clinical trials with Harpagophytum procumbens. | Phytomedicine : international journal of phytotherapy and phytopharmacology 20030101 |
| Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. | Current medical research and opinion 20030101 |
| [Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis]. | Zentralblatt fur Gynakologie 20030101 |
| A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. | Drugs 20030101 |
| [Pain management after third molar extraction. Observations of the use of mefenamic acid and rofecoxib in the treatment of postoperative pain in the dental office]. | Schweizer Monatsschrift fur Zahnmedizin = Revue mensuelle suisse d'odonto-stomatologie = Rivista mensile svizzera di odontologia e stomatologia 20030101 |
| Gastroduodenal safety of cyclooxygenase-2 inhibitors. | Current pharmaceutical design 20030101 |
| COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications. | Current pharmaceutical design 20030101 |
| COX-2 and COX-2 enzyme inhibition. | International journal of immunopathology and pharmacology 20030101 |
| COX-2 specific inhibitors in NSAID-intolerant patients. | International journal of immunopathology and pharmacology 20030101 |
| Clinical pharmacology of selective COX-2 inhibitors. | International journal of immunopathology and pharmacology 20030101 |
| [Chronic recurrent multifocal osteomyelitis of the mandible: report of three cases]. | Jornal de pediatria 20030101 |
| Laparoscopic bilateral adrenalectomy with the use of a single midline hand-assist port. | JSLS : Journal of the Society of Laparoendoscopic Surgeons 20030101 |
| [Rofecoxib-induced aquagenic edema with puckering of the palms of the hands: the first case]. | Annales de dermatologie et de venereologie 20030101 |
| [Role of allopurinol and rofecoxib in agranulocytosis and acute tubular necrosis]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20030101 |
| Effect of nimesulide, rofecoxib and celecoxib on gastric tissue glutathione level in rats with indomethacin-induced gastric ulcerations. | Polish journal of pharmacology 20030101 |
| Both selective COX-1 and COX-2 inhibitors aggravate gastric damage induced in rats by 2-deoxy-D-glucose. relation to gastric hypermotility and COX-2 expression. | Digestion 20030101 |
| Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. | Drug safety 20030101 |
| Weight uniformity of split tablets required by a Veterans Affairs policy. | Journal of managed care pharmacy : JMCP 20030101 |
| Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. | American journal of therapeutics 20030101 |
| Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. | Journal of molecular neuroscience : MN 20030101 |
| Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. | Anticancer research 20030101 |
| Participation of the NO-cyclic GMP pathway in rofecoxib-induced antinociception. | Proceedings of the Western Pharmacology Society 20030101 |
| Assessment of the safety of selective cyclo-oxygenase-2 inhibitors: where are we in 2003? | Inflammopharmacology 20030101 |
| [Rofecoxib: its efficacy in rheumatoid arthritis and acute pain]. | Reumatizam 20030101 |
| Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations. | Clinical drug investigation 20030101 |
| Utilisation Pattern of Nonspecific Nonsteroidal Anti-Inflammatory Drugs and COX-2 Inhibitors in a Local Health Service Unit in Northeast Italy. | Clinical drug investigation 20030101 |
| Reinvestigation of mucohalic acids, versatile and useful building blocks for highly functionalized alpha,beta-unsaturated gamma-butyrolactones. | Organic letters 20021212 |
| Enantioselective deprotonation of meso-cycloheptanone derivative: application to the synthesis of a potential intermediate for pseudomonic acid B. | Organic letters 20021212 |
| Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. | Journal of the National Cancer Institute 20021204 |
| Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. | The Journal of pharmacology and experimental therapeutics 20021201 |
| Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain. | Archives of internal medicine 20021201 |
| NSAID-sensitive patients tolerate rofecoxib. | Allergy 20021201 |
| Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure. | Hypertension (Dallas, Tex. : 1979) 20021201 |
| Cardiovascular adverse effects of coxibs. | Prescrire international 20021201 |
| Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. | Arthritis and rheumatism 20021201 |
| Exacerbation of Crohn's colitis with severe colonic hemorrhage in a patient on rofecoxib. | The American journal of gastroenterology 20021201 |
| Patient detection of a drug dispensing error by use of physician-provided drug samples. | Pharmacotherapy 20021201 |
| New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. | Seminars in arthritis and rheumatism 20021201 |
| Anti-inflammatory agents and renal function. | Seminars in arthritis and rheumatism 20021201 |
| Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20021201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021201 |
| Epstein-Barr virus-associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib: idiosyncratic reaction or pharmacogenetics? | Delaware medical journal 20021201 |
| Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile. | Bioorganic & medicinal chemistry letters 20021118 |
| Effect of ibuprofen and rofecoxib transport parameters in the frog corneal epithelium. | The Journal of membrane biology 20021115 |
| [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain]. | MMW Fortschritte der Medizin 20021114 |
| Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20021112 |
| The double-edged sword of COX-2 selective NSAIDs. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20021112 |
| Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. | FEBS letters 20021106 |
| Monolithic silica liquid chromatography columns for the determination of cyclooxygenase II inhibitors in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20021105 |
| Rofecoxib improves quality of life in patients with hip or knee osteoarthritis. | Swiss medical weekly 20021102 |
| Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. | The Journal of pharmacology and experimental therapeutics 20021101 |
| Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. | The American journal of cardiology 20021101 |
| Analgesic effects of rofecoxib in ear-nose-throat surgery. | Anesthesia and analgesia 20021101 |
| Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. | Gastroenterology 20021101 |
| Factor-sparing use of the COX-2 inhibitor rofecoxib in haemophilic arthropathy. | Haemophilia : the official journal of the World Federation of Hemophilia 20021101 |
| Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. | British journal of pharmacology 20021101 |
| Vioxx-Viagra confusion. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20021101 |
| The role of COX-2 inhibitors in lung cancer. | The Annals of thoracic surgery 20021101 |
| Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay. | Journal of natural products 20021101 |
| A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. | British journal of clinical pharmacology 20021101 |
| Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective. | The American journal of managed care 20021101 |
| Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs. | The American journal of managed care 20021101 |
| COX-2 selective NSAID decreases bone ingrowth in vivo. | Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20021101 |
| Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. | Neurobiology of disease 20021101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021101 |
| [Economic evaluation of a new selective COX-2 NSAID, rofecoxib, in a real practice context]. | Atencion primaria 20021031 |
| [At what care level are cyclo-oxygenase-2 inhibitors prescribed?]. | Atencion primaria 20021015 |
| [80,000 patients with arthrosis treated. Coxib gets through a practice test, too]. | MMW Fortschritte der Medizin 20021010 |
| Isomeric acetoxy analogues of rofecoxib: a novel class of highly potent and selective cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry letters 20021007 |
| COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. | Lancet (London, England) 20021005 |
| Central retinal vein occlusion in a patient with rheumatoid arthritis taking rofecoxib. | Lancet (London, England) 20021005 |
| [Financial interests characterize published reports on coxiber. Whom can we rely on?]. | Lakartidningen 20021003 |
| [The CLASS study and its scientific statement. Ethical publishing rules neglected]. | Lakartidningen 20021003 |
| Cyclooxygenase-2 and atherosclerosis. | Current opinion in lipidology 20021001 |
| Cost-efficacy of rofecoxib versus acetaminophen for preventing pain after ambulatory surgery. | Anesthesiology 20021001 |
| Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. | Gastroenterology 20021001 |
| Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. | Pharmacotherapy 20021001 |
| COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs. | The American journal of managed care 20021001 |
| HMO drug formulary access increases for COX-2s. | Managed care (Langhorne, Pa.) 20021001 |
| Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. | The American journal of managed care 20021001 |
| Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors. | The American journal of managed care 20021001 |
| Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. | The American journal of managed care 20021001 |
| Differences between COX-2-specific inhibitors: clinical and economic implications. | The American journal of managed care 20021001 |
| The COX-2 inhibitors: new analgesic and anti-inflammatory drugs. | Dental clinics of North America 20021001 |
| A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. | Clinical therapeutics 20021001 |
| N-Acetylcysteine enhances the action of anti-inflammatory drugs as suppressors of prostaglandin production in monocytes. | Mediators of inflammation 20021001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021001 |
| [Anti-inflammatory non-steroidal selective cyclooxygenase 2 inhibitors and gastroduodenal lesions]. | Presse medicale (Paris, France : 1983) 20020928 |
| Efficacy and safety of COX 2 inhibitors. | BMJ (Clinical research ed.) 20020921 |
| Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. | BMJ (Clinical research ed.) 20020921 |
| [...bad example of a miserable 'research on order']. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20020920 |
| The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. | The Biochemical journal 20020915 |
| [Analgesic in osteoporosis. Why so conservative with dosage?]. | MMW Fortschritte der Medizin 20020905 |
| Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). | Journal of hepatology 20020901 |
| Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors. | The Journal of urology 20020901 |
| Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat. | Pharmacological research 20020901 |
| In vitro study of tocolytic effect of rofecoxib, a specific cyclo-oxygenase 2 inhibitor. Comparison and combination with other tocolytic agents. | BJOG : an international journal of obstetrics and gynaecology 20020901 |
| COX and NOS isoforms involved in acid-induced duodenal bicarbonate secretion in rats. | Digestive diseases and sciences 20020901 |
| COX-2 inhibition and the control of pain. | Current opinion in investigational drugs (London, England : 2000) 20020901 |
| Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? | European journal of gastroenterology & hepatology 20020901 |
| Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases. | Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020901 |
| COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. | Journal of hypertension. Supplement : official journal of the International Society of Hypertension 20020901 |
| [Wrong information concerning rofecoxib]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20020830 |
| Antiangiogenic effect of a highly selective cyclooxygenase-2 inhibitor on gastric ulcer healing in rats. | Toxicology and applied pharmacology 20020815 |
| [Already the drug of choices in the USA. Coxibe in joint pain]. | MMW Fortschritte der Medizin 20020808 |
| Role of prostanoids in regulation of the renin-angiotensin-aldosterone system by salt intake. | American journal of physiology. Renal physiology 20020801 |
| Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages. | Acta pharmacologica Sinica 20020801 |
| Cyclo-oxygenase-2 inhibition increases blood pressure in rats. | British journal of pharmacology 20020801 |
| Tracing the origins of COX-2 inhibitors' structures. | Current medicinal chemistry 20020801 |
| Selecting new drugs for pain control: evidence-based decisions or clinical impressions? | Journal of the American Dental Association (1939) 20020801 |
| COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs. | Health news (Waltham, Mass.) 20020801 |
| The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. | Arthritis and rheumatism 20020801 |
| Fixed drug eruption to rofecoxib. | Cutis 20020801 |
| Non-steroidal anti-inflammatory drugs in orofacial pain management--an update. | SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging 20020801 |
| [Selective cyclooxygenase-2 inhibitors and the digestive tract]. | La Tunisie medicale 20020801 |
| The role of rofecoxib, a cyclooxygenase-2-specific inhibitor, for the treatment of non-cancer pain: a review. | The journal of pain : official journal of the American Pain Society 20020801 |
| Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. | Circulation 20020730 |
| Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs. | BMJ (Clinical research ed.) 20020720 |
| Are selective COX 2 inhibitors superior to traditional NSAIDs? Little is known about COX 2 inhibitors. | BMJ (Clinical research ed.) 20020720 |
| Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis. | BMJ (Clinical research ed.) 20020720 |
| Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. | Behavioural brain research 20020718 |
| Seminal pharmaceutical trials: maintaining masking in analysis. | Lancet (London, England) 20020713 |
| Cyclooxygenase inhibitors attenuate endothelin ET(B) receptor-mediated contraction in human temporal artery. | European journal of pharmacology 20020712 |
| Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome. | Kidney international 20020701 |
| The cyclooxygenase inhibitors indomethacin and Rofecoxib reduce regional cerebral blood flow evoked by somatosensory stimulation in rats. | Experimental biology and medicine (Maywood, N.J.) 20020701 |
| Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. | Gastroenterology 20020701 |
| Successful treatment by cyclooxyenase-2 inhibitor of refractory hypokalemia in a patient with Gitelman's syndrome. | Clinical nephrology 20020701 |
| Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020701 |
| Fatal haemorrhagic pulmonary oedema and associated angioedema after the ingestion of rofecoxib. | Postgraduate medical journal 20020701 |
| Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. | Clinical pharmacology and therapeutics 20020701 |
| Anti-hyperalgesic effects of nimesulide: studies in rats and humans. | International journal of clinical practice. Supplement 20020701 |
| Ask Dr. Francis. I am taking a medication called rofecoxib for knee arthritis, and it works well. But I've heard reports that this type of medication may be dangerous for people with heart disease. Should I be worried? | Heart advisor 20020701 |
| Designing selective COX-2 inhibitors: molecular modeling approaches. | Current opinion in drug discovery & development 20020701 |
| Role of COX-2 inhibitors in the evolution of acute pain management. | Journal of pain and symptom management 20020701 |
| The impact of pain management on quality of life. | Journal of pain and symptom management 20020701 |
| Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. | CJEM 20020701 |
| [No chance for pain. Rofecoxib eases not only tooth extraction]. | MMW Fortschritte der Medizin 20020627 |
| [Rofecoxib in surgical pain. Saving morphine!]. | MMW Fortschritte der Medizin 20020627 |
| What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20020625 |
| Isolation and characterisation of process-related impurities in rofecoxib. | Journal of pharmaceutical and biomedical analysis 20020620 |
| Examination of rofecoxib solution decomposition under alkaline and photolytic stress conditions. | Journal of pharmaceutical and biomedical analysis 20020615 |
| Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. | Cancer letters 20020606 |
| The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. | Drug metabolism and disposition: the biological fate of chemicals 20020601 |
| The different patterns of blood pressure elevation by rofecoxib and nabumetone. | Journal of human hypertension 20020601 |
| [Gynecomastia secondary to rofecoxib]. | Medicina clinica 20020601 |
| Cyclo-oxygenase 2 function is essential for bone fracture healing. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20020601 |
| Effects of SKI 306X, a new herbal agent, on proteoglycan degradation in cartilage explant culture and collagenase-induced rabbit osteoarthritis model. | Osteoarthritis and cartilage 20020601 |
| Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. | Chest 20020601 |
| Coxibs + oral anticoagulants: risk of interaction. | Prescrire international 20020601 |
| Rofecoxib reduces perioperative morphine consumption for abdominal hysterectomy and laparoscopic gastric banding. | Anaesthesia and intensive care 20020601 |
| Right ballpark, wrong base: assessing safety of NSAIDs. | The Journal of family practice 20020601 |
| Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm). | European journal of clinical pharmacology 20020601 |
| Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. | Clinical therapeutics 20020601 |
| Hemicrania continua responds to cyclooxygenase-2 inhibitors. | Headache 20020601 |
| Gateways to Clinical Trials. June 2002. | Methods and findings in experimental and clinical pharmacology 20020601 |
| Differential effects of cyclooxygenase inhibitors on haloperidol-induced catalepsy. | Progress in neuro-psychopharmacology & biological psychiatry 20020601 |
| Evaluation of preoperative administration of the cyclooxygenase-2 inhibitor rofecoxib for the treatment of postoperative pain after lumbar disc surgery. | Neurosurgery 20020501 |
| Cyclooxygenase inhibition: between the devil and the deep blue sea. | Gut 20020501 |
| Selective cyclooxygenase-2 inhibition impairs glomerular capillary healing in experimental glomerulonephritis. | Journal of the American Society of Nephrology : JASN 20020501 |
| Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer. | QJM : monthly journal of the Association of Physicians 20020501 |
| Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use? | Current opinion in rheumatology 20020501 |
| Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. | The Journal of rheumatology 20020501 |
| [Specific inhibitors of cyclooxygenase type 2] ]. | Vnitrni lekarstvi 20020501 |
| Alteration of gastric ulcerogenic and healing responses in rats with adjuvant-induced arthritis. | Japanese journal of pharmacology 20020501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20020501 |
| Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. | Cephalalgia : an international journal of headache 20020501 |
| Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. | The Journal of emergency medicine 20020501 |
| Chronic prostatitis and chronic pelvic pain in men: aetiology, diagnosis and management. | Journal of the European Academy of Dermatology and Venereology : JEADV 20020501 |
| Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? | Expert opinion on drug safety 20020501 |
| Characterization, quantification, and bioactivities of anthocyanins in Cornus species. | Journal of agricultural and food chemistry 20020424 |
| Why do COX-2 inhibitors increase risk of cardiovascular events? | Lancet (London, England) 20020420 |
| Biomedicine. Back to an aspirin a day? | Science (New York, N.Y.) 20020419 |
| Role of prostacyclin in the cardiovascular response to thromboxane A2. | Science (New York, N.Y.) 20020419 |
| Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. | Journal of the National Cancer Institute 20020417 |
| Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. | Circulation 20020416 |
| Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. | JAMA 20020410 |
| Rofecoxib vs celecoxib vs acetaminophen for treatment of osteoarthritis. | JAMA 20020410 |
| Rofecoxib: a possible cause of acute colitis. | Journal of clinical gastroenterology 20020401 |
| Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. | Gastroenterology 20020401 |
| Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. | Cancer research 20020401 |
| Metabolism of human articular chondrocytes cultured in alginate beads. Longterm effects of interleukin 1beta and nonsteroidal antiinflammatory drugs. | The Journal of rheumatology 20020401 |
| Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury. | Alimentary pharmacology & therapeutics 20020401 |
| A possible interaction between lithium and rofecoxib. | British journal of clinical pharmacology 20020401 |
| Which is most effective of osteoarthritis of the knee: rofecoxib, celecoxib, or acetaminophen? | The Journal of family practice 20020401 |
| Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents. | Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20020401 |
| Gastrointestinal safety of coxibs and outcomes studies: what's the verdict? | Journal of pain and symptom management 20020401 |
| Renal effects of cyclooxygyenase-2-selective inhibitors. | Journal of pain and symptom management 20020401 |
| Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. | Journal of pain and symptom management 20020401 |
| Cox-2 inhibitors: today and tomorrow. | The American journal of the medical sciences 20020401 |
| Rofecoxib and cytomegalovirus in acute flare-up of ulcerative colitis: coprecipitants or coincidence? | The American journal of gastroenterology 20020401 |
| Acute pancreatitis associated with rofecoxib. | The American journal of gastroenterology 20020401 |
| Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. | The American journal of gastroenterology 20020401 |
| Considerations for the safe prescribing and use of COX-2-specific inhibitors. | The Medical journal of Australia 20020401 |
| Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial. | Clinical therapeutics 20020401 |
| Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench. | Phytomedicine : international journal of phytotherapy and phytopharmacology 20020401 |
| Clinical experience with cyclooxygenase-2 inhibitors. | Rheumatology (Oxford, England) 20020401 |
| Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib. | Rheumatology (Oxford, England) 20020401 |
| Athletes, nonsteroidal anti-inflammatory drugs, coxibs, and the gastrointestinal tract. | Current sports medicine reports 20020401 |
| [First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs]. | Medicina clinica 20020330 |
| Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models. | Journal of medicinal chemistry 20020328 |
| 4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1). | Journal of medicinal chemistry 20020328 |
| Aseptic meningitis associated with rofecoxib. | Archives of internal medicine 20020325 |
| Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach. | The American journal of cardiology 20020321 |
| An evidence-based evaluation of the gastrointestinal safety of coxibs. | The American journal of cardiology 20020321 |
| Cyclooxygenase-2 inhibition and renal physiology. | The American journal of cardiology 20020321 |
| Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. | The American journal of cardiology 20020321 |
| Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries. | The New England journal of medicine 20020314 |
| Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. | Bioorganic & medicinal chemistry letters 20020311 |
| Improved procedure for the the determination of rofecoxib in human plasma involving 96-well solid-phase extraction and fluorescence detection. | Journal of chromatography. A 20020308 |
| [New indication for selective COX-2 inhibitors. Now also approve for acute pain]. | MMW Fortschritte der Medizin 20020307 |
| Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. | The Journal of pharmacology and experimental therapeutics 20020301 |
| Differential binding mode of diverse cyclooxygenase inhibitors. | Journal of molecular graphics & modelling 20020301 |
| Gastrointestinal bleeds associated with rofecoxib. | Pharmacotherapy 20020301 |
| Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. | The Journal of pharmacy and pharmacology 20020301 |
| Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. | The Journal of rheumatology 20020301 |
| Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. | Biochemical pharmacology 20020301 |
| Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20020301 |
| Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20020301 |
| A comparison of the renal and cardiovascular safety of celecoxib and rofecoxib. | Clinical therapeutics 20020301 |
| Effect of rofecoxib on nociception and the serotonin system in the rat brain. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20020301 |
| Structure-based design of cyclooxygenase-2 selectivity into ketoprofen. | Bioorganic & medicinal chemistry letters 20020225 |
| [Safety of celecoxib and rofecoxib: a critical overview]. | Medicina clinica 20020223 |
| [Rofecoxib-induced upper gastrointestinal bleeding]. | Medicina clinica 20020223 |
| [A critical evaluation of side effect data on COX-2 inhibitors]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20020220 |
| [Improper use of selective COX-2 inhibitor NSAIDs]. | Atencion primaria 20020215 |
| [Effective not only in rheumatism and arthrosis. Rofecoxib fights also acute pain]. | MMW Fortschritte der Medizin 20020214 |
| High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020205 |
| Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. | Biomedical chromatography : BMC 20020201 |
| Absence of nuclear factor kappaB inhibition by NSAIDs in hepatocytes. | Hepatology (Baltimore, Md.) 20020201 |
| Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers. | Journal of clinical pharmacology 20020201 |
| Urticaria and angioedema induced by COX-2 inhibitors. | The Journal of allergy and clinical immunology 20020201 |
| Chronic sinusitis with rofecoxib. | The Journal of allergy and clinical immunology 20020201 |
| Idiopathic paresthesia reaction associated with rofecoxib. | The Annals of pharmacotherapy 20020201 |
| Selective cyclooxygenase-2 inhibitors: after the smoke has cleared. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20020201 |
| [Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions]. | Nihon rinsho. Japanese journal of clinical medicine 20020201 |
| [New nonsteroidal antiinflammatory drugs in rheumatoid arthritis]. | Annales de medecine interne 20020201 |
| COX-2 inhibition and thrombotic tendency. | The Medical journal of Australia 20020121 |
| Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). | The American journal of cardiology 20020115 |
| Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. | JAMA 20020102 |
| The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. | Anesthesia and analgesia 20020101 |
| Current treatment of juvenile rheumatoid arthritis. | Pediatrics 20020101 |
| Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. | The Journal of arthroplasty 20020101 |
| Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction. | Journal of molecular and cellular cardiology 20020101 |
| Rofecoxib-associated upper gastrointestinal bleed: a case report. | The Mount Sinai journal of medicine, New York 20020101 |
| A rapid and sensitive high-performance liquid chromatography assay for rofecoxib in human serum. | Journal of chromatographic science 20020101 |
| Double-blind, placebo-controlled analgesic study of ibuprofen or rofecoxib in combination with paracetamol for tonsillectomy in children. | British journal of anaesthesia 20020101 |
| Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. | American journal of therapeutics 20020101 |
| Preemptive multimodal analgesia for anterior cruciate ligament surgery. | Regional anesthesia and pain medicine 20020101 |
| Anti-inflammatory medications: selective COX-2 inhibitors. | The Journal of the American Academy of Orthopaedic Surgeons 20020101 |
| Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. | Drug safety 20020101 |
| Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol). | Current pharmaceutical design 20020101 |
| Gastrointestinal safety of selective COX-2 inhibitors. | Current pharmaceutical design 20020101 |
| Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey. Current Medical Research and Opinion, 17(2): 81-8, 2001. | Current medical research and opinion 20020101 |
| A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. | Current medical research and opinion 20020101 |
| [Pain management with herbal antirheumatic drugs]. | Wiener medizinische Wochenschrift (1946) 20020101 |
| A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. | BMC family practice 20020101 |
| Sildenafil (Viagra) for male erectile dysfunction: a meta-analysis of clinical trial reports. | BMC urology 20020101 |
| Renal tolerability of three commonly employed non-steroidal anti-inflammatory drugs in elderly patients with osteoarthritis. | Clinical and experimental rheumatology 20020101 |
| Rofecoxib for the treatment of rheumatoid arthritis. | The Cochrane database of systematic reviews 20020101 |
| Erythema multiforme due to rofecoxib. | Dermatology (Basel, Switzerland) 20020101 |
| COX-2-selective inhibitors in the treatment of arthritis. | Cleveland Clinic journal of medicine 20020101 |
| Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. | Cleveland Clinic journal of medicine 20020101 |
| Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. | Cleveland Clinic journal of medicine 20020101 |
| Current perspective on the cardiovascular effects of coxibs. | Cleveland Clinic journal of medicine 20020101 |
| Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. | Cleveland Clinic journal of medicine 20020101 |
| Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. | Cleveland Clinic journal of medicine 20020101 |
| Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. | Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20020101 |
| Rofecoxib, 25 mg/d, was more effective than rofecoxib, 12.5 mg/d, celecoxib, or acetaminophen in osteoarthritis of the knee. | ACP journal club 20020101 |
| Renal failure associated with the use of celecoxib and rofecoxib. | Drug safety 20020101 |
| Be sure to ask your doctor about... | The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha 20020101 |
| Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20020101 |
| Rofecoxib for the treatment of rheumatoid arthritis. | The Cochrane database of systematic reviews 20020101 |
| New use approved for Vioxx. | FDA consumer 20020101 |
| Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. | Current medical research and opinion 20020101 |
| Rofecoxib-induced instant aquagenic wrinkling of the palms. | Pediatric dermatology 20020101 |
| Valdecoxib. | Reviews in gastroenterological disorders 20020101 |
| Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link? | Drug safety 20020101 |
| Valdecoxib. | Drugs 20020101 |
| A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. | Scandinavian journal of rheumatology 20020101 |
| Ibuprofen 400 mg is effective in women, and women are well represented in trials. | BMC anesthesiology 20020101 |
| Attenuation of pro-inflammatory neuropeptide levels produced by a cyclooxygenase-2 inhibitor in an animal model of chronic temporomandibular joint inflammation. | Journal of orofacial pain 20020101 |
| Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? | Journal of nephrology 20020101 |
| Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats. | Digestion 20020101 |
| Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration. | Scandinavian journal of rheumatology 20020101 |
| Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. | Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20020101 |
| [Evaluation model of the effect of Rofecoxib on the co-prescription of gastroprotective agents observed during the treatment of osteoarthritis]. | Reumatismo 20020101 |
| The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. | Current medical research and opinion 20020101 |
| Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections? | The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 20020101 |
| Concerns about COX-2 painkillers. They're easier on the stomach, potentially harder on your heart. | Heart advisor 20020101 |
| Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. | The New England journal of medicine 20011220 |
| Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. | The New England journal of medicine 20011220 |
| Cardiovascular events and COX-2 inhibitors. | JAMA 20011212 |
| [A pop-up menu linked to a computerized drug prescribing system. Prescribing pattern's feedback via a simple and quick method]. | Lakartidningen 20011212 |
| Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. | Circulation 20011211 |
| The coxibs, selective inhibitors of cyclooxygenase-2. | The New England journal of medicine 20011206 |
| Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques. | Drug metabolism and disposition: the biological fate of chemicals 20011201 |
| Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs. | European journal of gastroenterology & hepatology 20011201 |
| COX-2 inhibitors: no pain, no heart gain? | Harvard heart letter : from Harvard Medical School 20011201 |
| Treatment of low back pain with a herbal or synthetic anti-rheumatic: a randomized controlled study. Willow bark extract for low back pain. | Rheumatology (Oxford, England) 20011201 |
| Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints. | The Journal of rheumatology 20011201 |
| Cyclooxygenase-2 inhibitor for pain management in osteoid osteoma. | Clinical orthopaedics and related research 20011201 |
| COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile? | Gastroenterology clinics of North America 20011201 |
| An evidence-based approach to the gastrointestinal safety profile of COX-2-selective anti-inflammatories. | Gastroenterology clinics of North America 20011201 |
| Gastrointestinal safety of COX-2 specific inhibitors. | Gastroenterology clinics of North America 20011201 |
| GI events leading to death in association with celecoxib and rofecoxib. | The American journal of gastroenterology 20011201 |
| The use and effect of analgesics in patients who regularly drink alcohol. | The American journal of managed care 20011201 |
| Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. | The Journal of pharmacy and pharmacology 20011201 |
| [Pharmacology of non-steroidal anti-inflammatory drugs and ENT pathology]. | Presse medicale (Paris, France : 1983) 20011201 |
| [Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine]. | Zeitschrift fur Rheumatologie 20011201 |
| Pharmacological therapies for the treatment of osteoarthritis. | The Medical journal of Australia 20011119 |
| Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. | MedGenMed : Medscape general medicine 20011116 |
| [Cox-2 inhibitors in the focus. Rofecoxib as effective as the 'classics']. | MMW Fortschritte der Medizin 20011115 |
| [Side effects cause enormous costs. Expensive arthritis therapy]. | MMW Fortschritte der Medizin 20011115 |
| Cardiovascular safety of COX-2 inhibitors. | The Medical letter on drugs and therapeutics 20011112 |
| Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. | Circulation 20011106 |
| Cyclo-oxygenase-2 inhibitors to treat gastrointestinal bleeding. | Lancet (London, England) 20011103 |
| LC determination of rofecoxib in bulk and pharmaceutical formulations. | Journal of pharmaceutical and biomedical analysis 20011101 |
| Inhibition of COX-2 counteracts the effects of diuretics in rats. | Kidney international 20011101 |
| Discussion on rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. | Gastroenterology 20011101 |
| Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. | The Journal of rheumatology 20011101 |
| Urticaria and angioedema from cyclooxygenase-2 inhibitors. | The Journal of rheumatology 20011101 |
| Low sodium and furosemide-induced stimulation of the renin system in man is mediated by cyclooxygenase 2. | Clinical pharmacology and therapeutics 20011101 |
| Arthritis. Should you be taking a COX-2 inhibitor? | Harvard health letter 20011101 |
| Pain treatment with NSAIDs, primary focus on ibuprofen. | Clinical rheumatology 20011101 |
| Ginko, Vioxx and excessive bleeding--possible drug-herb interactions: case report. | Hawaii medical journal 20011101 |
| Celecoxib and rofecoxib. | Journal of the American Dental Association (1939) 20011101 |
| COX-2 inhibitors compared and contrasted. | Expert opinion on pharmacotherapy 20011101 |
| Naphthalene derivatives: A new series of selective cyclooxygenase-2 inhibitors. | Bioorganic & medicinal chemistry letters 20011022 |
| [Renal tolerance of selective inhibitors of cyclooxygenase type 2]. | Presse medicale (Paris, France : 1983) 20011020 |
| [COX-2 inhibitor in arthrosis. Discontinuation before operations not necessary]. | MMW Fortschritte der Medizin 20011018 |
| [Gastrointestinal bleeding caused by rofecoxib]. | Medicina clinica 20011013 |
| FDA warns Merck over its promotion of rofecoxib. | BMJ (Clinical research ed.) 20011006 |
| Acute, anuric renal failure associated with two doses of a cyclooxygenase-2 inhibitor. | Nephron 20011001 |
| Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. | Alimentary pharmacology & therapeutics 20011001 |
| COX-1 and COX-2 inhibitors. | Best practice & research. Clinical gastroenterology 20011001 |
| Rofecoxib safe in NSAID hypersensitivity. | Allergy 20011001 |
| Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients. | Journal of clinical pharmacology 20011001 |
| Targeting angiogenic processes by combination rofecoxib and ionizing radiation. | American journal of clinical oncology 20011001 |
| Degradation products of cyanidin glycosides from tart cherries and their bioactivities. | Journal of agricultural and food chemistry 20011001 |
| Clinical implications of drug interactions with coxibs. | Pharmacotherapy 20011001 |
| [Changes in ulcerogenic response to non-steroidal anti-inflammatory drugs (NSAIDs) in adjuvant arthritic rats]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20011001 |
| Nonsteroidal anti-inflammatory drugs for perioperative pain control. | Medicine and health, Rhode Island 20011001 |
| Is concern about cardiovascular events with the new coxib class of drugs justified? | Medscape women's health 20011001 |
| Lipopolysaccharide-mediated immobility in mice: reversal by cyclooxygenase enzyme inhibitors. | Methods and findings in experimental and clinical pharmacology 20011001 |
| Ischemic preconditioning, the most effective gastroprotective intervention: involvement of prostaglandins, nitric oxide, adenosine and sensory nerves. | European journal of pharmacology 20010921 |
| [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)]. | MMW Fortschritte der Medizin 20010906 |
| Pain relief at a price. A blow to the heart? | U.S. news & world report 20010903 |
| Arthritis: what it is, why you get it and how to stop the pain. | Newsweek 20010903 |
| How safe are your prescription pills? | Time 20010903 |
| Nephrotoxicity of selective COX-2 inhibitors. | The Journal of rheumatology 20010901 |
| Tolerability of rofecoxib. | Allergy 20010901 |
| Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20010901 |
| [Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20010901 |
| Rofecoxib: clinical pharmacology and clinical experience. | Clinical therapeutics 20010901 |
| Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. | Clinical therapeutics 20010901 |
| A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. | Clinical therapeutics 20010901 |
| Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug. | Arquivos de neuro-psiquiatria 20010901 |
| [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?]. | Revue medicale de Bruxelles 20010901 |
| Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression. | Pflugers Archiv : European journal of physiology 20010901 |
| [Thinking about the specific cyclooxygenase-2 inhibitors since its recommendation]. | Zhonghua nei ke za zhi 20010901 |
| [Systemic analgesia after peripheral block]. | Minerva anestesiologica 20010901 |
| Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere. | Journal of medicinal chemistry 20010830 |
| Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. | Journal of chromatography. B, Biomedical sciences and applications 20010825 |
| COX-2 inhibition and thrombotic tendency: a need for surveillance. | The Medical journal of Australia 20010820 |
| [Coxibs: cyclooxygenase-2 inhibitors]. | Wiener klinische Wochenschrift 20010816 |
| The coxibs, selective inhibitors of cyclooxygenase-2. | The New England journal of medicine 20010809 |
| [Elderly patient with rheumatoid arthritis. Minimizing the peptic ulcer hemorrhage risk]. | MMW Fortschritte der Medizin 20010809 |
| Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. | Atherosclerosis 20010801 |
| Rofecoxib as an alternative in aspirin hypersensitivity. | Allergy 20010801 |
| Risk of cardiovascular events associated with selective COX-2 inhibitors. | JAMA 20010801 |
| [Safety of specific cyclo-oxygenase 2 inhibitors]. | Nederlands tijdschrift voor geneeskunde 20010728 |
| Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans after the application of cinnamic aldehyde. | Journal of the American Academy of Dermatology 20010701 |
| Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. | Human reproduction (Oxford, England) 20010701 |
| Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. | The Journal of clinical investigation 20010701 |
| Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. | The Journal of allergy and clinical immunology 20010701 |
| Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. | The American journal of medicine 20010701 |
| A new class of COX-2 inhibitors offer an alternative to NSAIDS in pain management after spinal surgery. | Spine 20010701 |
| Stimulated release of arachidonic acid from rat liver cells by celecoxib and indomethacin. | Prostaglandins, leukotrienes, and essential fatty acids 20010701 |
| Cyclooxygenase (COX-2) selective inhibitors. Any better than NSAIDs? | Canadian family physician Medecin de famille canadien 20010701 |
| Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis. | Clinical therapeutics 20010701 |
| [Selective COX-2 inhibitor. Stomach protection--but not always]. | MMW Fortschritte der Medizin 20010621 |
| Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. | Lancet (London, England) 20010616 |
| [Therapy of arthrosis. Life threatening gastrointestinal events can be reduced]. | MMW Fortschritte der Medizin 20010607 |
| [Results of the VIGOR study. Rofecoxib halves the complication rate]. | MMW Fortschritte der Medizin 20010607 |
| Cyclooxygenase-2 inhibition and renal function. | Annals of internal medicine 20010605 |
| [Safety of specific cyclo-oxygenase 2 inhibitors]. | Nederlands tijdschrift voor geneeskunde 20010602 |
| Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. | Microscopy research and technique 20010601 |
| Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. | Neuropharmacology 20010601 |
| Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure. | The American journal of gastroenterology 20010601 |
| Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis. | The American journal of managed care 20010601 |
| Celecoxib-- the debate ranges on. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20010601 |
| [Clinical application of cyclooxygenase-2 inhibitors]. | Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20010601 |
| Adverse effects of rofecoxib (continued). | Prescrire international 20010601 |
| Celecoxib and rofecoxib: a distinction with a difference? | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20010601 |
| COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. | Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20010601 |
| Upper gastrointestinal toxicity of rofecoxib and naproxen. | The New England journal of medicine 20010503 |
| Upper gastrointestinal toxicity of rofecoxib and naproxen. | The New England journal of medicine 20010503 |
| [Prof. Bernd Simon on nonsteroidal anti-inflammatory drugs. Gastrointestinal complications are unpredictable]. | MMW Fortschritte der Medizin 20010503 |
| EULAR recommendations for the management of knee osteoarthritis. | Annals of the rheumatic diseases 20010501 |
| Severe upper gastrointestinal bleeding during treatment with rofecoxib for osteoarthritis. | The American journal of gastroenterology 20010501 |
| Osteoarthritis. A primary care approach for physicians in 2000 and beyond. | Saudi medical journal 20010501 |
| [The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%]. | Zeitschrift fur Gastroenterologie 20010501 |
| Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis. | Hand clinics 20010501 |
| [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents]. | Deutsche medizinische Wochenschrift (1946) 20010406 |
| Rofecoxib (Vioxx): a year in review. | CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010403 |
| COX-2 inhibitors and the gastrointestinal tract. | Gut 20010401 |
| Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge. | British journal of pharmacology 20010401 |
| Cyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve. | British journal of pharmacology 20010401 |
| Selective COX-2 inhibitors. | The American journal of nursing 20010401 |
| Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. | Journal of the American Dental Association (1939) 20010401 |
| Gastrointestinal damage induced by celecoxib and rofecoxib in rats. | Digestive diseases and sciences 20010401 |
| [The coxibs, third generation anti-inflammatories]. | Revue medicale de Bruxelles 20010401 |
| A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. | Aging (Milan, Italy) 20010401 |
| [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?]. | Gastroenterologie clinique et biologique 20010401 |
| Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib. | Prescrire international 20010401 |
| Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. | Molecular interventions 20010401 |
| [Cyclooxygenase inhibitors]. | Presse medicale (Paris, France : 1983) 20010317 |
| Where is the evidence that cyclooxygenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. | Biochemical pharmacology 20010315 |
| Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production. | Gastroenterology 20010301 |
| Is rofecoxib safer than naproxen? | The Journal of family practice 20010301 |
| [Therapy with preferential and specific COX-2 inhibitors]. | Der Internist 20010301 |
| Osteoarthritis management: the role of cyclooxygenase-2-selective inhibitors. | Clinical therapeutics 20010301 |
| Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide. | Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20010301 |
| Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial. | Journal of clinical anesthesia 20010301 |
| Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. | Current drug targets 20010301 |
| Cyclo-oxygenase 2 inhibitors: an important new drug classification. | Pain management nursing : official journal of the American Society of Pain Management Nurses 20010301 |
| Efficacy of cyclooxygenase-2-specific inhibitors. | The American journal of medicine 20010219 |
| Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. | The American journal of medicine 20010219 |
| FDA refuses companies' request to drop ulcer warning. | BMJ (Clinical research ed.) 20010217 |
| Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. | Cancer research 20010215 |
| Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. | The Journal of pharmacology and experimental therapeutics 20010201 |
| The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. | The European journal of neuroscience 20010201 |
| COX-2 inhibitors in rheumatoid arthritis. | Current rheumatology reports 20010201 |
| Safety of a specific COX-2 inhibitor in aspirin-induced asthma. | Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20010201 |
| COX-2 inhibitors: new drugs for the management of pain and inflammation. | Dentistry today 20010201 |
| [Stomach-saving 'Coxibs'. No reason for therapeutic risks]. | MMW Fortschritte der Medizin 20010118 |
| Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. | Alimentary pharmacology & therapeutics 20010101 |
| Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. | Journal of clinical pharmacology 20010101 |
| Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. | American journal of orthopedics (Belle Mead, N.J.) 20010101 |
| Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. | Scandinavian journal of rheumatology 20010101 |
| Renal effects of COX-2-selective inhibitors. | American journal of nephrology 20010101 |
| Cardiovascular and renal effects of COX-2-specific inhibitors: recent insights and evolving clinical implications. | American journal of therapeutics 20010101 |
| Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. | American journal of therapeutics 20010101 |
| Anti-inflammatory drugs, cyclooxygenases and other factors. | Expert opinion on pharmacotherapy 20010101 |
| Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells. | Advances in enzyme regulation 20010101 |
| Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis. | Drugs 20010101 |
| Gastric preconditioning induced by short ischemia: the role of prostaglandins, nitric oxide and adenosine. | Medical science monitor : international medical journal of experimental and clinical research 20010101 |
| Alzheimer's disease, inflammation and non-steroidal anti-inflammatory drugs. | Bratislavske lekarske listy 20010101 |
| Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation. | BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20010101 |
| Celecoxib- and rofecoxib-induced delirium. | The Journal of neuropsychiatry and clinical neurosciences 20010101 |
| Ibuprofen to rofecoxib: what does it all mean and what do I do now? | The American journal of hospice & palliative care 20010101 |
| [Selective cyclooxygenase 2 inhibitors (COX-2)]. | Postepy higieny i medycyny doswiadczalnej 20010101 |
| Cyclooxygenase inhibitors: any reservations? | Internal medicine journal 20010101 |
| [The coxibs, third generation of non-steroidal anti-inflammatory agents]. | Journal de pharmacie de Belgique 20010101 |
| [Clinical use of COX-2 inhibitors]. | Vojnosanitetski pregled 20010101 |
| Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. | Digestion 20010101 |
| Rofecoxib: a new selective COX-2 inhibitor. | Journal of postgraduate medicine 20010101 |
| The ever-emerging anti-inflammatories. Have there been any real advances? | Journal of physiology, Paris 20010101 |
| Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs. | Journal of physiology, Paris 20010101 |
| What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. | Clinical and experimental rheumatology 20010101 |
| NSAIDs and COX-2 inhibitors: what can we learn from large outcomes trials? The gastroenterologist's perspective. | Clinical and experimental rheumatology 20010101 |
| COX-2 inhibitors and the cardiovascular system. | Clinical and experimental rheumatology 20010101 |
| Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. | Clinical and experimental rheumatology 20010101 |
| Effect of nonsteroidal anti-inflammatory drugs on osteogenesis and spinal fusion. | Regional anesthesia and pain medicine 20010101 |
| Clinical case study. | The American journal of hospice & palliative care 20010101 |
| Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective. | PharmacoEconomics 20010101 |
| Fixed drug eruption to rofecoxib with cross-reactivity to sulfonamides. | Dermatology (Basel, Switzerland) 20010101 |
| Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (experience with VIOXX in arthritis) survey. | Current medical research and opinion 20010101 |
| [Rofecoxib]. | Revista de medicina de la Universidad de Navarra 20010101 |
| [VIOXX--a new world without pain]. | Akusherstvo i ginekologiia 20010101 |
| [Specific inhibitors of cyclooxygenase-2 (COX-2): current knowledge and perspectives]. | Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma 20010101 |
| Identification of sulfonamide-like adverse drug reactions to celecoxib in the World Health Organization database. | Current medical research and opinion 20010101 |
| An update on specific COX-2 inhibitors: the COXIBs. | Bulletin on the rheumatic diseases 20010101 |
| Acute renal dysfunction associated with selective COX-2 inhibitor therapy. | International urology and nephrology 20010101 |
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. | The New England journal of medicine 20001123 |
| Rofecoxib. | Expert opinion on pharmacotherapy 20000701 |
| Role of prostaglandins generated by cyclooxygenase-1 and cyclooxygenase-2 in healing of ischemia-reperfusion-induced gastric lesions. | European journal of pharmacology 19991126 |
| Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. | Proceedings of the National Academy of Sciences of the United States of America 19990622 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.